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CLOSE TO THE BONE: INVESTIGATIONS INTO BONE TISSUE 
MINERALISATION AND MECHANOBIOLOGY OF OSTEOPOROSIS 
by Meadhbh Aíne Brennan 
Osteoporosis is a metabolic skeletal disease characterized by low bone mass, depleted 
micro-architecture and reduced strength. The public health costs of osteoporosis relate 
almost entirely to the fractures that are the clinical manifestation of the disease and it 
presents  a  significant  cause  of  morbidity  in  today’s  ageing  population.  Oestrogen 
deficiency during the menopause is  the primary causative factor for postmenopausal 
osteoporosis and although much is known about the pathophysiology of the disease, 
including dysregulated bone cell function whereby more bone is digested than is formed; 
the underlying mechanisms involved have not yet been delineated. Recent studies have 
suggested that although overall strength is decreased following osteoporotic bone loss, 
the remaining bone tissue is stronger and stiffer, suggesting an alteration in bone tissue 
composition. Bisphosphonates are among drug treatments administered to tackle bone 
loss, however the incidence of osteoporotic fractures still remains high. Furthermore, the 
precise effect of drug treatment on bone tissue mineralisation is unknown.  
The global aim of this thesis is to discern the alterations in the quantity and distribution 
of bone mineral during osteoporosis. Specifically, it is sought to test the hypotheses that 
bone mineral distribution is altered at a tissue level following oestrogen deficiency and 
bisphosphonate treatment and that oestrogen depletion alters normal mineralisation and 
mechano-responsiveness of bone cells. Quantitative backscattered imaging (qBEI) on a 
scanning electron microscope was used to examine individual bone trabeculae from the 
proximal  femur  of  ovariectomised  sheep  (oestrogen  deficient  state),  aged  matched 
control sheep and sheep treated with the bisphosphonate Zoledronic acid. It was found 
that  oestrogen  deficiency  caused  significantly  higher  mineral  heterogeneity  within 
trabeculae (site speficic within the femur) and along a common osteoporotic fracture 
line.  Bone  mineralisation  was  diminished  with  prolonged  oestrogen  deficiency  and  
 
conversely  was  higher  in  older  healthy  sheep  compared  to  younger  control  sheep. 
Furthermore, significantly lower mineral heterogeneity was found in OVX sheep treated 
with  Zoledronic  acid  compared  to  untreated  OVX  sheep.  These  results  indicate  that 
changes in bone tissue mineralisation during oestrogen deficiency may be a contributing 
factor  for  reduced  mechanical  strength  during  osteoporosis,  while  drug  induced 
increased  homogeneity  may  contribute  to  the  ability  of  Zoledronic  acid  to  prevent 
fracture occurrence during oestrogen deficiency.  
The next study aimed to delineate the mechanisms responsible for such altered mineral 
distribution.  Osteoblast  and  osteocyte  cells  were  pre-treated  with  oestrogen  and  the 
effects of oestrogen deficiency were evaluated by subsequently withdrawing oestrogen 
from cells, or blocking oestrogen receptors using an oestrogen antagonist, fulvestrant. 
Specifically,  alkaline  phosphatase  expression  was  investigated  using  p-nitrophenyl 
phosphate (pNPP), proliferation by assessing DNA content, calcium production using 
alizarin red assay and apoptosis by measuring for caspase 3/7 activity. Although mineral 
production was significantly increased by oestrogen pre-treatment, a further increase in 
mineral production and apoptosis were observed following oestrogen withdrawal from 
cells. These observations increase our understanding of the mechanisms controlling bone 
formation and bone cell death and may aid in the development of enhanced therapeutics 
for the treatment of osteoporosis. 
The final study of this thesis aimed to determine if the mechano-biological response of 
osteoblasts  is  impaired  during  oestrogen  deficiency  and  whether  changes  in  bone 
mineralisation  may  be  related  to  altered  bone  formation  in  response  to  mechanical 
stimulation. Osteoblasts were pre-treated with oestrogen and subsequently oestrogen was 
withdrawn from cell cultures and their responses under fluid shear stress were evaluated. 
Firstly,  daily  loading  cycles,  using  an  orbital  rotator,  were  applied  to  cells  and 
mineralisation and cell viability (using alamar blue assay) were assessed after 7 and 14 
days.  In  a  separate  experiment,  following  2  and  7  days  of  oestrogen  withdrawal, 
osteoblasts were exposed to 2 hours of shear stress in a custom designed parallel plate 
bioreactor. PGE2 was quantified in cell culture conditioned media using an immunoassay 
kit.  It  was  found  that  orbital  fluid  flow  induced  shear  stress  significantly  increased 
mineral  production  by  bone  cells  and  that  under  an  applied  shear  stress,  mineral 
production  was  decreased  during  oestrogen  withdrawal.  It  was  also  observed  that 
mechanical loading and oestrogen are required in unison to promote mineral production.  
 
PGE2 release was significantly increased with applied laminar flow, but was decreased 
by oestrogen withdrawal.  
Together, these studies provide evidence that bone cells become accustomed to levels of 
circulating  oestrogen  and  that  diminished  oestrogen  causes  osteocyte  apoptosis, 
increased  osteoblast  mineralisation  and  altered  mechano-sensitivity.  These  changes 
might explain the decreased mean concentrations of mineral, together with increased 
mineral heterogeneity, from our earlier in vivo studies. Therefore, the results of the thesis 
provide a unique insight into why the tightly coupled mechanisms of matching bone’s 
structure  and  composition  to  the  loads  it  experiences  are  disrupted  when  levels  of 
circulating oestrogen are depleted.  
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1.  Introduction 
1.1.  Osteoporosis 
Bone  is  a  dynamic,  mineralised  tissue  that  confers  both  mechanical  and  metabolic 
functions to the skeleton. Osteoporosis is a disease of the skeleton characterized by low 
bone  mass,  micro-architectural  deterioration  and  increased  bone  fragility.  It  usually 
presents as clinical fractures which cause severe pain, deformity and in certain cases 
leads to secondary complications or death (Cummings and Melton, 2002; Johnell and 
Kanis, 2006). The most common fracture sites are the proximal femur, vertebrae, wrist 
and pelvis. Hip fractures have, by far, the most impact from a public health perspective 
as they are associated with the greatest bulk of the osteoporosis-related medical costs 
(Cooper et al., 1993). Bone mass decreases with age independent of other risk factors 
(Wendlova and Pacakova, 2007), whereas osteoporotic fracture risk rises dramatically 
with age. It is estimated that one in two women and one in five men will suffer a fracture 
after the age of 50  (Van Staa  et  al.,  2001).  In addition,  approximately nine  million 
osteoporotic fractures occur globally each year (Johnell and Kanis, 2006) and this figure 
is set to increase three fold by 2050 (Gullberg et al., 1997).  
Primary  osteoporosis  refers  to  both  bone  loss  occurring  in  post-menopausal  women 
(type I) and bone loss owing to the normal ageing process (type II). Post-menopausal 
osteoporosis (type I) is the most common form of the disease and is believed to initiate 
when oestrogen production is deficient following the menopause (Riggs et al., 2002; 
Falahati-Nini et al., 2000). This phase lasts for 4-8 years where an imbalance in the bone 
remodelling cycle leads to loss of predominantly trabecular bone. Type II osteoporosis is 
characterised by a slow, steady loss of bone mass in both trabecular and cortical bone. It 
is primarily due to a reduction in bone formation and typically occurs after 70 years of 
age. Men only experience type II osteoporotic bone loss as a result of a reduction in 
testosterone and oestrogen availability (Riggs et al., 2002). Secondary osteoporosis can 
present in old or young individuals and is a secondary effect of medications or diseases 
including  anorexia  nervosa,  cystic  fibrosis,  depression  and  diabetes  mellitus  type  I 
(Lerner, 2006). It is well established that there is a macro-level decrease in mechanical 
properties during osteoporosis (Ederveen et al., 2001; Bourrin et al., 2002; Geusens et 
al., 1996). This can be attributed to a decrease in bone mass since osteoporotic bone is 
characteristically less dense. However, an increase in strength has been demonstrated at 
a  trabecular  level  during  oestrogen  deficiency  (McNamara  et  al.,  2006).  Mineral         
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concentration  and its  distribution  within the bone tissue  is  a key determinant  of the 
mechanical  strength  of  bone  (Currey, 1984b;  Hernandez,  2008;  Jaasma  et  al., 2002; 
Render et al., 2006; Ruffoni et al., 2007), however research performed to discern the 
differences in mineralisation during osteoporosis has produced conflicting observations 
(Bohic et al., 2000; Boyde et al., 1998; Gadeleta et al., 2000; McNamara et al., 2006; 
Rohanizadeh  et  al.,  2000).  In  addition,  studies  have  shown  that  mineral  is  more 
heterogeneously distributed within trabeculae during oestrogen withdrawal (Busse et al., 
2009;  Roschger  et  al.,  2008)  however,  the  exact  trabecular  regions  where  altered 
mineralisation occurs and the precise mechanisms by which such changes might arise, 
have not been distinguished. During oestrogen withdrawal bone removal by  osteoclasts 
is increased (Richelson et al., 1984). This leads to depleted bone architecture, as bone 
trabecular struts are perforated (Mosekilde, 1990) and an overall reduction in bone mass 
and  strength  (Watts  et  al.,  2010).  Currently,  there  is  a  great  deal  of  research  being 
conducted into pharmaceuticals aimed at remedying the disease. Bisphosphonates are 
the most commonly used drug targeted at preventing osteoporotic bone loss and they act 
by inhibiting removal of bone tissue and therefore, retaining bone mass and trabecular 
architecture, however, fracture prevention still only lies at approximately 50-60% (Black 
et al., 1996; McClung et al., 2001).  
   
1.2.  Objectives and Hypotheses 
The aim of this thesis is to discern the alterations in the quantity and distribution of bone 
mineral  during osteoporosis and  to  examine the cellular mechanisms  responsible for 
such  material-level  changes.  Specifically,  mineral  distribution  within  individual 
trabeculae  and  between  distinct  anatomical  locations  will  be  compared  between 
ovariectomised sheep, a group treated with bisphosphonate and a healthy aged matched 
control group. Furthermore, the effects of oestrogen withdrawal on bone cells in terms of 
proliferation,  mineral  production,  cell  death  and  mechano-sensitivity  will  be 
investigated. To address these objectives 5 hypotheses have been defined which will be 
tested in order to provide a better insight into the mechanisms of altered mineralisation 
due to oestrogen deficiency. 
Hypothesis 1: Bone mineral distribution is altered at a tissue level during oestrogen 
deficiency 
Since bone strength is correlated with tissue stiffness (Fyhrie and Schaffler, 1994) and 
the degree of mineralisation (Currey, 1984b; Follet et al., 2004), the increases in strength         
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and stiffness of trabeculae during oestrogen withdrawal (McNamara et al., 2006) suggest 
an increase in mineral concentration may occur within trabeculae during osteoporosis. 
As bone with a high mineral content has diminished impact resistance (Currey, 1969) 
this  may  heighten  the  risk  of  fracture.  Furthermore,  increases  in  remodelling  rates 
brought on by oestrogen deficiency vary considerably according to skeletal site (Baldock 
et al., 1998), suggesting that oestrogen withdrawal may alter the distribution of bone 
tissue mineral between different skeletal locations.   
Hypothesis 2: Mineralisation is altered with prolonged oestrogen depletion  
The discrepancies between studies reporting increases, decreases, or no change in bone 
tissue mineralisation during oestrogen deficiency (Bohic et al., 2000; Boyde et al., 1998; 
Gadeleta et al., 2000; McNamara et al., 2006; Rohanizadeh et al., 2000) may be due to 
variations in the duration of oestrogen deficiency, as it has been shown that there is an 
initial period of significant increase in bone turnover markers, followed by a waning of 
this response (Binkley et al., 1998). In addition, it has been shown that healthy bone 
tissue mineralisation is altered with ageing (Currey et al., 1996; Vajda and Bloebaum, 
1999); however, it has not yet been investigated whether alterations in the degree of 
bone tissue mineralisation reported previously are prolonged with continued oestrogen 
deficiency, or are a transient characteristic caused by the initial diminished oestrogen 
levels.  Together,  these  observations  lead  to  the  hypothesis  that  bone  tissue 
mineralisation is altered over prolonged oestrogen depletion.  
Hypothesis 3: Mineralisation is altered as a result of bisphosphonate treatment 
 It  has  been  observed  that  the  diminutive  increases  in  bone  mineral  density  with 
bisphosphonate treatment cannot account for the large decreases in fracture occurrence 
observed with their administration (Liberman et al., 1995; Riggs and Melton, 2002; Yao 
et  al.,  2007).  Since  tissue  mineralisation  is  dependent  on  functional  remodelling 
(Tsubota et al., 2009) and mineralisation kinetics (Akkus et al., 2003; Ruffoni et al., 
2007)  and  bisphosphonates  alter  bone  remodelling  by  inhibiting  bone  resorption  
(Carano et al., 1990; Fleisch et al., 1969), the distribution of bone tissue mineral may be 
altered by bisphohsphonate treatment.  
Hypothesis 4: Oestrogen deficiency alters the normal bone mineralisation process by 
osteoblasts and osteocytes 
 While there has been extensive research regarding the effects of oestrogen depletion on          
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bone  resorbing  cells,  osteoclasts,  whereby  increased  osteoclastic  resorption  occurs 
during osteoporosis (Heaney et al., 1978; Lerner, 2006) and oestrogen treatment reduces 
bone resorption by osteoclasts (Oursler et al., 1991), there has been much less focus on 
cells responsible for bone formation and mineral deposition; osteoblasts and osteocytes. 
Since both osteoblasts and osteocytes possess receptors for oestrogen (Bellido et al., 
1993) (Bord  et al., 2001; Braidman et al., 2001), oestrogen withdrawal may have a 
direct  impact  on  mineral  production  by  these  bone  cells.  In  addition,  it  has  been 
proposed  that  following  cell  death  by  apoptosis,  mineral  infilling  of  the  remaining 
lacunae,  a  phenomenon  referred  to  as  micropetrosis  (Boyde,  2003;  Frost,  1960; 
Kingsmill and Boyde, 1998) may occur. Interestingly, oestrogen withdrawal in women 
results  in  a higher percentage of dead osteocytes  in  bone  (Tomkinson  et  al., 1997), 
possibly  due  to  increased  apoptosis.  Together,  these  studies  indicate  that  oestrogen 
withdrawal may cause alterations in mineral production by bone cells, which may be 
responsible for the changes that occur at a tissue level during osteoporosis. If validated, 
these experiments may give an important insight into the primary events of the bone loss 
cascade during oestrogen deficiency.  
Hypothesis  5:  The  mechano-responsiveness  of  osteoblasts  is  impaired  during 
oestrogen deficiency 
 In healthy bone, mechanical adaptation ensures efficient load bearing by means of a 
cellular process, which relies on a biological system that senses the applied mechanical 
loading  and  reacts  accordingly.  It  has  been  proposed  that  bone’s  mechano-
responsiveness fails during osteoporosis, but the precise mechanism by which this is 
manifested is not understood. Since mechanical stimulation increases mineral production 
(Chambers  et  al.,  1993;  Robling  et  al.,  2000;  Turner  et  al.,  1996),  it  may  be  that 
oestrogen depletion impairs the detection of mechanical loading, or impairs the normal 
response to the stimulus. Either mechanism may inhibit normal bone formation by bone 
cells in response to loading.   
1.3.  Thesis Structure  
This thesis details the work completed for the duration of the candidates PhD studies. It 
begins  by  presenting  an  extensive  literature  review  of  the  function,  activities, 
characteristics,  and  constituents  of  healthy  and  osteoporotic  bone,  in  addition  to  the 
mechanisms  behind  the  quantitative  backscatter  imaging  (qBEI)  technique  which  is 
employed to quantify tissue mineralisation, in Chapter 2. Chapter 3 details a study which         
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investigates the effects of oestrogen deficiency on tissue mineralisation, thereby testing 
hypothesis  1.  Chapter  4  addresses  hypotheses  2  and  3  by  evaluating  the  effects  of 
prolonged oestrogen deficiency, healthy ageing and bisphosphonate treatment on tissue 
mineralisation. Chapter 5 is concerned with in vitro cell studies which test hypothesis 4 
by investigating mineral production and apoptosis of bone cells undergoing oestrogen 
withdrawal. Chapter 6 examines whether the mechano-responsiveness of bone cells are 
impaired  due  to  oestrogen  withdrawal,  thereby  testing  hypothesis  5  of  the  thesis. 
Chapters  3-6  each  set  out  the  background  and  rationale  for  each  study,  a  detailed 
description of the materials and methods employed, as well as the results and an in-depth 
discussion of the findings.  Finally, chapter 7 outlines the main findings of the thesis, 
together  with  recommendations  for  future  work  based  on  the  subject  of  the  thesis.          
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2.  Literature Review 
2.1.  Bone Function 
Bone is a highly specialised form of connective tissue that plays a vital supportive and 
protective role in the body. It provides an internal structural framework for mechanical 
support in addition to shielding internal organs and bone marrow from potential damage. 
It also presents sites of muscle attachment and levers to transmit forces generated by 
muscles and thereby permit locomotion. This complex living tissue also participates in 
metabolic homeostasis as it is a major source of inorganic ions, particularly calcium and 
phosphate (Murray, 1999). 
2.2.  Bone Morphology 
Anatomically, there are two distinguishable types of bones in the human skeleton; flat 
bones, namely the scapula, mandible and ilium, and long bones which include the femur, 
tibia  and  humerus.  A  typical  long  bone  consists  of  a  central  cylindrical  shaft  or 
diaphysis, an epiphysis at either extremity, as well as an intermediate metaphysis region. 
The growth plate, an expanding region of hyaline cartilage matrix and proliferative cells, 
separates the metaphyses from the epiphysis and represents a region where bone growth 
and elongation occurs  (Murray, 1999).  In a skeletally mature  adult the cartilaginous 
growth plate becomes replaced by cancellous bone and the epiphysis becomes fused to 
the metaphysis. The epiphyses are covered by a layer of hyaline or articular cartilage 
which permits articulation of bones at a joint, thus enabling movement of the skeleton. 
The periosteum, a thin layer of fibrous connective tissue with an inner cellular film of 
undifferentiated cells, covers the outer surface of most bones and plays an important role 
in bone growth and fracture repair. The diaphysis of long bones contains an internal 
marrow cavity which is lined by a thin layer of osteoblastic and bone lining cells, the 
endosteum (Cowin, 2001). The blood supply to the cortex of long bones is primarily 
served by the medullary vessels (Trueta and Caladias, 1964). Haversian canals supply 
cortical  bone  with  blood,  while  nutrients  are  supplied  to  trabecular  bone  through  a 
canalicular system.  
The outer shell (cortex) of all bones and the diaphyses of long bones consists of dense 
and  highly  calcified  tissue,  known  as  cortical  bone,  which  plays  a  supportive  and 
protective role within the body (Buckwalter et al., 1996; Currey, 1984a; Favus, 2006). 
Trabecular bone tissue is encased within the outer cortical cortex and comprises of a 
highly connected system of vertical and horizontal struts, called trabeculae. Intermediate          
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Figure  2.1:  Structure  of  Cortical  and  Cancellous  Bone  (Fawcett,  2011; 
Poole and Compston, 2006; Ritchie et al., 2009) 
 
 
 
spaces between trabeculae are filled with hematopoietic bone marrow. The majority of 
trabeculae are oriented along lines of recurrent mechanical stress (Von Meyer, 1867), 
while the remainder join perpendicularly to adjacent trabeculae in order to strengthen the 
ne2rk (Wolff, 1892). Trabecular bone dissipates internal stresses to the outer cortical 
shell (Lemaire et al., 2004), see Figure 2.1, and also plays a role in vital metabolic 
functions (Murray, 1999). 
              
                    
2.3.  Bone Composition 
Bone is composed of approximately 65% mineral, 35% organic matrix, cells and water. 
The  organic  matrix  is  composed  of  approximately  90%  collagen  and  10%  non-
collagenous  proteins.  The  collagen  in  bone  is  primarily  type  I  collagen,  but  trace 
quantities of type III, IV and VI are also present (Miller, 1969; Miller, 1984). Type I 
collagen serves  as  a scaffold  and is  thought  to be an initiator of mineral  deposition 
(Glimcher,  1989).  Non-collagenous  proteins  such  as  osteocalcin,  osteonectin, 
osteopontin  and  bone  sialoprotein  provide  bonds  between  collagen  fibrils,  facilitate 
mineralisation  and  act  as  chemo-attractant  to  facilitate  the  binding  of  osteoclasts 
(Fantner et al., 2005; Roach, 1994). Bone mineral presents as tiny crystals (in the order 
of  20x40x200Å)  of  impure  carbonated  hydroxyapatite,  Ca10  (PO4)6  (OH)2  and  other 
Trabecular 
Cortical          
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minerals including magnesium,  potassium,  manganese, silica, fluoride, iron, zinc and 
citrate,  which  are  integrated  into  the  crystal  lattice  or  absorbed  onto  the  Ca10 
(PO4)6(OH)2. The mechanical integrity of the skeleton, its load bearing strength and its 
capacity  to  control  the  mineral  ion  homeostasis  are  significantly  influenced  by  the 
quantity of mineral present (Currey and Brear, 1990).  
Collagen fibrils play a highly interactive role with mineral crystals (Landis et al., 1996), 
they have  been indicated as the primary foundation or nucleator for crystal deposition in 
bone tissue (Glimcher, 1959). The importance of collagen as a template for mineral 
deposition  was  demonstrated  by  studies  on  specimens  suffering  from  osteogenesis 
imperfecta which is a set of diseases characterised by a defect in the subject’s collagen. 
One study revealed defects in collagen structure resulted in an altered mineral-to-matrix 
ratio  in  addition  to  mineral  composition  (Camacho  et  al.,  1996).  Cross-linking  of 
collagen also has an effect on mineral deposition. It was shown that blocking the cross-
linking of collagen in cultured osteoblasts reduces in the amount of mineral deposits 
(Gerstenfeld  et  al.,  1993).  Collagen  is  not  however  the  sole  regulator  for  crystal 
deposition, this is evident as other tissues such as tendons, skin, and ligaments contain 
the  same  type  I  collagen  but  do  not  normally  calcify.  Several  other  inducer  and 
inhibitors of bone mineralisation will be discussed in detail in section 2.4.1. 
2.3.1  Hierarchical Structure of Bone 
Bone  is  a  composite  material  with  a  highly  complex  hierarchical  structure.  Its 
components  and their organisation within bone give rise to  an ideal  combination of 
material  properties  bestowing  bone  with  its  high  strength,  fracture  toughness  and 
stiffness, as well as low weight. The structure of bone is illustrated at different structural 
levels in Figure 2.2 and detailed in Table 2.1.          
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Figure 2.2 Hierarchical Structural Organization of Bone (Rho et al., 1998) 
 
Collagen  molecules,  mineral  crystals  and  water  molecules  are  found  at  the  sub-
nanostructure level, where collagen fibrils are composed of collagen molecules arranged 
with  apatite  crystals  distributed  within  the  discrete  spaces  between  the  collagen 
molecules. At the nanostructure level, collagen fibrils are arranged into fibers. At the 
sub-microstructure level in cortical bone, mineralised collagen fibers are arranged into 
concentric parallel rings surrounding a haversian canal which together forms osteons. In 
trabecular bone, tissue lamellae are arranged in a less organized manner into individual 
trabeculae. At the macro-structural level bone type is distinguished as either cortical 
with  densely  packed  osteons,  or  trabecular  bone  with  a  porous  network  of 
interconnecting trabecular struts (Rho et al., 1998). 
Table 2.1: Structural Hierarchy of Bone 
Scale  Size Range  Components 
Sub-nanostructure  <500nm  Apatite crystals, collagen and water molecules 
Nanostructure  500-1000 nm  Mineral matrix and collagen fibrils arranged into 
fibers 
Sub-microstructure  1-10µm  Single lamella, cement lines, canaliculi. 
Microstructure  10-5000µm  Single trabeculae , osteons 
Macrostructure  1-10cm  Cortical and cancellous bone          
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2.4.  Bone Cells 
A variety of cells reside within bone, such as osteoblasts, osteocytes, bone lining cells 
and the precursors of these cells, also referred to as osteoprogenitor cells, as well as 
osteoclasts. Osteoblasts are responsible for the synthesis and secretion of a new bone 
matrix, while osteoclasts resorb or destroy bone tissue. The function and activities of 
osteoclasts and osteoblasts are directly co-ordinated to maintain bone mass and they 
interact during skeletal development and throughout life.  
  
 
Figure 2.3 TEM image of an osteoblast, osteoclast, and osteocyte in situ within bone 
tissue. Arrow indicates the ruffled border of an osteoclast. Reproduced with permission 
from Dr. L.M. McNamara 
 
2.4.1  Osteoblasts and Bone Lining Cells 
Osteoblasts  are  of  mesenchymal  origin,  once  committed  to  the  osteoblastic  lineage 
osteoprogenitor  cells  proliferate  and  differentiate  into  pre-osteoblasts  and  ultimately 
mature osteoblasts (Okazaki et al., 2002). Osteoblasts, who reside on the bone surface 
(see  Figure  2.3)  produce  all  the  components  of  the  bone  matrix  by  secreting  and 
synthesizing an unmineralised bone matrix, the osteoid, and subsequently mineralizing 
this matrix  (Ducy et al., 2000). It takes 5-10 days before the matrix has been 70% 
mineralised and complete mineralisation takes between 3-5 months. Active osteoblasts 
are cuboidal cells (15-30µm thick) and posses a large nucleus, abundant endoplasmic 
reticulum, gap junctions, a large golgi apparatus and secretory vesicles (Cowin, 2001).  
Many substances have been identified that govern the activity of osteoblasts. Alkaline 
phosphatase (ALP) is secreted by osteoblasts and is vital for increasing local phosphate 
concentration and promoting mineralisation by removing nucleation inhibitors (Favus, 
2006).  Animals  with  defective  alkaline  phosphatase  expression  have  been  shown  to          
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develop  the  condition  hypophosphatasia,  which  manifests  as  significant  decreases  in 
mineral deposition (Narisawa et al., 1997). Bone morphogenetic proteins (BMP) are a 
family of cytokines which induce differentiation of mesenchymal stem cells (MSCs) to 
osteoblasts  in  vitro  (Barnes  et  al.,  1999)  and  have  demonstrated  increased  bone 
formation in vivo in rats (Wang et al., 1990). Osteonectin is a glycoprotein that binds to 
collagen, calcium and hydroxyapatite, suggesting it facilitates bone formation by acting 
as a nucleator for  matrix mineralisation (Sikavitsas et al., 2001). Transforming growth 
factor – β (TGF-β) stimulates extracellular matrix production  by promoting collagen 
synthesis and increasing alkaline phosphate production (Barnes et al., 1999). Insulin-like 
growth factor (IGF) stimulates osteoblast proliferation and collagen production in vitro 
(Gillery  et  al.,  1992).  Osteoblast  proliferation  is  also  stimulated  by  platelet-derived 
growth factor (PDGF) and fibroblast growth factors (FGF) (Sikavitsas et al., 2001).  
Conversely,  there  are  several  inhibitors  of  tissue  mineralisation.  Osteopontin,  a 
phosphorylated bone matrix sialoprotein prevents apatite formation and growth due to its 
high  affinity  for  apatite  crystals  (Boskey  et  al.,  1993)  and  inorganic  pyrophosphate 
blocks mineralisation by up-regulating the amount of osteopontin (Addison et al., 2007). 
Osteocalcin, another non-collagenous protein, is thought to inhibit bone mineralisation 
as  it  has  an  affinity  for  calcium  (Sikavitsas  et  al.,  2001).  Furthermore,  parathyroid 
hormone inhibits osteoblast function (Buckwalter et al., 1996).  
2.4.1.1 Mechanotransduction of Osteoblasts  
In  addition  to  responding  to  biochemical  stimuli,  osteoblasts  are  capable  of 
mechanotransduction, which is the conversion of a physical force into a biochemical 
signal (Machwate et al., 1995). Mechanical loading of the skeleton confers mechanical 
strain to bones, which in turn causes increased bone formation in vivo (Chambers et al., 
1993; Robling et al., 2000; Turner et al., 1996) and in vitro (Sittichockechaiwut et al., 
2009). Indeed even after just 96 hours after a mechanical stimulus in vivo, mineralisation 
of newly formed bone matrix has been demonstrated in vivo (Forwood et al., 1996).  
Shear stress induced by fluid flow reflects an indirect effect of applied mechanical strain 
that  may  act  on  osteoblasts  in  vivo  and  has  been  used  extensively  for  in  vitro 
investigations of mechanotransduction in osteoblasts. Intracellular calcium signalling is 
an  immediate  response  to  mechanical  stimuli,  an  elevation  in  intracellular  calcium 
signalling has been observed seconds after mechanical loading in osteoblastic cells (Huo 
et al., 2008). Calcium signalling is required for the expression of bone matrix proteins 
such as osteopontin (You et al., 2001) and for numerous other essential functions such as         
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 proliferation  and  differentiation  (Berridge  et  al.,  2000;  Zayzadoon  et  al.,  2006). 
Osteoblasts can disseminate mechanically induced intercellular calcium signalling via 
two different mechanisms. The first entails activation of plasma membrane receptors, 
generated  by  a  soluble  mediator  (the  extracellular  paracrine  signal  adenosine 
triphosphate –ATP), which causes release of intracellular calcium stores. Alternatively, 
osteoblasts  can  also  propagate  intercellular  calcium  signalling  by  direct  intercellular 
communication using gap junctions, causing the release of intracellular calcium stores 
(Jorgensen et al., 2000). ATP is a high energy molecule that stores energy and is present 
in the cytoplasm and nucleoplasm of every cell. Adenosine monophosphate (AMP) can 
be formed by ATP synthesis by combining  two molecules of adenosine diphosphate 
(ADP), and it has been shown that AMP production by osteoblasts is increased with 
application of shear stress in vitro (Reich et al., 1990).  
Under applied shear stress in vitro, bone cells produce increased quantities of a number 
of other biochemicals in addition to intracellular calcium, including prostaglandin E2 
(PGE2),  nitric  oxide  (NO)  and  osteopontin  (Bakker  et  al.,  2001;  Batra  et  al.,  2005; 
Donahue  et  al.,  2003;  McGarry  et  al.,  2005b;  Smalt  et  al.,  1997).  Mineral  matrix 
production has also been shown to be increased under applied loading (Sikavitsas et al., 
2003; Van den Dolder et al., 2003). It has been demonstrated that prostaglandins induce 
the production of AMP in mesenchymal bone marrow cells (Scutt et al., 1995); therefore 
the up-regulation  of AMP with  shear stress could  occur indirectly  via a mechanism 
involving  increased  prostaglandin  production  with  shear  stress.  Wnt  proteins  are  a 
family of secreted proteins and Wnt/Lrp5 signalling is required for normal proliferation 
and functions of osteoblasts. The down regulation of Wnt inhibitors by osteocytes is 
dependent on mechanical stimulation (see section 2.4.3.1), therefore mechanical loading 
indirectly regulates bone mass by Wnt/Lrp5 signalling (Johnson et al., 2004; Krishnan et 
al., 2006).  
In spite of the extensive evidence that mechanical stimulation of bones in vivo increases 
bone formation (Chambers et al., 1993; Robling et al., 2000; Turner et al., 1996) and 
also that unloading due to disuse or microgravity leads to loss of bone mass (Collet et 
al., 1997; Jee et al., 1983) and mineral content (Le Blanc et al., 1985; Tilton et al., 
1980),  in  vivo  experiments  cannot  distinguish  between  direct  and  indirect  effects  of 
strain. Therefore, several in vitro experiments have investigated the sensing mechanisms 
of mechano-transduction in osteoblasts by comparing direct mechanical strain such as 
tension and compression of the cell attached to a substrate versus indirect effects of          
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strain such as shear stress. When shear stress was compared with unidirectional linear 
strain applied to osteoblasts in vitro, it was found that mechano-responsiveness, in terms 
of NO and PGE2 release, was rapidly increased in cells  exposed to shear stress, however 
cells  subjected  to  linear  strain  showed  no  increase  in  the  production  of  these 
biochemicals (Smalt et al., 1997). However, other studies have shown that when bone 
cells were subjected to cyclic strains on a plastic substrate, PGE2 increased with direct 
strain and the amount of PGE2 released by cells was dependent on the strain magnitude 
(Murray and Rushton, 1990). Interestingly a different study found that although shear 
stress increased NO and PGE2 to a much greater degree than which was found with 
substrate  strain,  collagen  I  production  was  significantly  increased  with  direct  strain, 
whereas shear stress decreased collagen I production  (McGarry et al., 2005b). Other 
studies  have  shown  that  shear  stress  is  the  major  mechanism  of  osteopontin  up-
regulation by osteoblasts compared with direct mechanical strain (Owan et al., 1997).  
Several studies have focused solely on fluid flow and have differentiated between the 
consequential  shear  stress,  streaming  potentials  and  chemo-transport.  Studies  have 
shown that the primary mechanism for mechano-transduction, in terms of NO and PGE2 
release, is shear stress, when compared with chemo-transport or streaming potentials 
(Bakker et al., 2001) (Donahue et al., 2003). This conclusion was made on the basis that 
the up-regulation of these biochemicals due to shear stress, was the same as when the 
viscosity of the media was increased and flow rate was decreased in order to achieve the 
same shear stress (Bakker et al., 2001). Jacobs et al discovered that oscillatory flow was 
a much less potent up-regulator of NO and PGE2 than either steady or pulsatile flow and 
concluded that the underlying cause was the net reduction in fluid flow in oscillatory 
flow,  indicating  that  chemo-transport  does  indeed  play  a  role  in  the  mechano-
responsiveness of cells to fluid flow (Jacobs et al., 1998). Donahue et al investigated the 
role of chemotransport further by keeping the shear stress constant by altering the flow 
rate and viscosity. They found that with constant shear stress, decreasing the flow rate, 
which  deprives  the  cells  of  nutrients,  caused  decreased  NO,  PGE2  and  intracellular 
calcium mobilization (Donahue et al., 2003). This study suggested that although chemo-
transport does not elicit a response alone, it modulates the effect of shear stress on cells, 
which is in contrast to the findings of Bakker et al (Bakker et al., 2001).  
The  mechanisms  by  which  osteoblasts  sense  mechanical  stimuli  are  still  to  be  fully 
elucidated.  There  is  a  growing  body  of  evidence  however  that  cytoskeleton-integrin 
interactions are involved. It was shown in vitro that the increased expression of proteins         
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 linked  to  mechano-transduction  (COX-2  and  c-fos)  by  shear  stress  occurs  by  a 
mechanism whereby the reorganization of actin filaments into contractile stress fibers 
occurs which involves the recruitment of  β1-integrins and α-actinin to focal adhesions 
(Pavalko et al., 1998). Blocking the development of actin stress fibers with cytochalasin 
D  inhibited  the  shear  stress  induced  gene  expression  in  osteoblasts  (Pavalko  et  al., 
1998). Furthermore, it has been demonstrated that the signal transduction mechanism for 
the  mechanical  activation  of  osteopontin  is  dependent  on  microfilaments  of  the 
cytoskeleton  since  cytochalasin  D,  which  disrupts  actin  microfilaments,  inhibited 
mechanical activation of osteopontin expression (Toma et al., 1997). In summary, the 
mechanotransduction  of osteoblasts  involves  a cascade of events  including ATP  and 
calcium signalling, the release of NO and PGE2 and Wnt/Lrp5 signalling, which leads to 
the formation of new bone tissue. As an osteoblast completes their lifespan, which lasts 
approximately  two  months,  they  give  rise  to  both  bone  lining  cells  and  osteocytes 
(Parfitt, 1994).  
The surface of quiescent bone is covered by a layer of elongated bone lining cells lying 
on a 1-2µm layer of un-mineralised collagen matrix (Manolagas, 2000). These cells are 
critical in the bone resorption process, as osteoclasts are unable to attach to the un-
mineralised collagenous layer, it is thought that bone lining cells secrete collagenase that 
digest the matrix to permit osteoclast attachment (Cowin, 2001). In addition, bone lining 
cells  contract  to  permit  osteoclast  access  the  underlying  mineralised  bone  (Murray, 
1999).  
2.4.2  Osteoclasts 
Osteoclasts  are  large  multi-nucleated  cells  whose  primary  role  is  to  digest  the  bone 
matrix in a process known as bone resorption. Osteoclasts cover less than 1% of the 
bone surface in adolescents, hence are comparatively scarce cells, and are temporarily 
found  in  resorption  cavities  or  Howship’s  lacunae  on  the  bone  surface  during  bone 
resorption  (Watanabe  et  al.,  1995).  Osteoclasts  are  derived  from  circulating 
mononuclear  precursors  in  hemopoietic  tissues  (Udagawa  et  al.,  1990).  Briefly,  a 
hematopoietic stem cell (HSC) differentiates through the colony-forming unit (CFU) for 
granulocytes and macrophages to the pre-osteoclast and multinucleated cell and finally a 
mature active resorbing osteoclast is formed (Bar - Shavit, 2007). Mature osteoclasts 
possess up to 50 nuclei and range in diameter from 20 - 100µm (Roodman, 1996). These 
highly motile cells contain multiple cellular adhesions, cytoskeleton proteins, granules, 
vacuoles and an abundance of  mitochondria throughout the cytoplasm (Horne, 1995).          
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Osteoclastogenesis is a diverse physiological pathway dependent on various conditions 
and signalling factors. There are several factors that promote osteoclast differentiation 
and resorption and prevent osteoclast apoptosis. These include the Receptor Activator of 
Nuclear factor-kB Ligand (RANKL) and the macrophage colony-stimulating factor (M-
CSF). Conversely, factors that inhibit osteoclast differentiation and resorption include 
BMP-2, TGF-β, calcitonin and oestrogen (Cowin, 2001; Filvaroff and Derynck, 1998).  
 
Figure 2.4: Scanning electron micrograph of an osteoclast resorbing bone (Poole and 
Compston, 2006) 
 
Several factors are thought to initiate resorption including micro-damage to the bony 
matrix (Lee et al., 2002; Martin, 2002). Following the retraction of bone lining cells 
from the surface of bone, the exposed mineralised matrix acts as a chemo-attractant for 
osteoclast  recruitment  to  the site  (Murray, 1999).  The resorptive cycle  is  a complex 
multi-step process including attachment to the mineralised bone surface, polarization, 
formation of a sealing zone, dissolution of both the mineral and organic components of 
the  matrix,  removal  of  the  degradation  products  and  finally  cell  apoptosis  or  their 
transition into an inactive phase once again (Salo et al., 1997). The ruffled border is the 
most remarkable morphology feature of the osteoclast and is highlighted by the arrow in 
Figure 2.3. It is a region of widespread plasma membrane folding, formed by the fusion 
of  acidic  intracellular  vesicles  (Palokangas  et  al.,  1997),  appearing  only  when  the 
osteoclast has attached to the bone surface. This border is the cells’ resorptive organelle, 
secreting acids and proteolytic enzymes that degrade bone. The sealing zone is rich in 
microfilaments  and devoid  of organelles.  It  completely surrounds  the ruffled border, 
permitting attachment of the osteoclast to the underlying bone matrix and the formation         
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 of  a  cellular  microenvironment  (Teitelbaum,  2000)  in  which  the  pH  is  about  3.5 
(Cowin, 2001; Vaananen and Horton, 1995).  
An image of an osteoclast resorbing bone is presented in Figure 2.4. The dissolution of 
crystalline hydroxyapatite crystals occurs by secretion of hydrochloric acid (HCL) into 
the sealed extracellular microenvironment through the ruffled boarder (Vaananen et al., 
2000). Following solubilisation of the mineral component of the bone matrix several 
proteolytic enzymes digest the collagen and other proteins of the organic bone matrix 
and  the  degradation  products  are  removed  through  vesicles  from  the  ruffled  border 
where they are deposited into the extra-cellular space (Salo et al., 1997). The resorption 
process  releases  calcium,  phosphate  and  other  ions  from  bone  for  homeostasis  and 
instigates the structural remodelling, which adjusts skeletal architecture to mechanical 
loads (Bilezikian et al., 2002). The life cycle of an osteoclast in vivo has yet to be fully 
understood, however their life span is up to six weeks, after which it migrates to the 
marrow space where it undergoes apoptosis (Marks and Seifert, 1985). 
2.4.3   Osteocytes 
Osteocytes are the most abundant cell in mature bone representing more than 90% of the 
total number of bone cells. They reside singularly within the mineralised bone matrix in 
spaces  called  osteocyte  lacunae  (see  Figure  2.3)  and  are  derived  when  osteoblasts 
become embedded in their secreted osteoid. Osteocytes lose much of the organelle of 
their predecessors and acquire elongated dendritic processes, which are extensions of 
their plasma membrane. Osteocytes communicate with other embedded osteocytes, bone 
lining cells and osteoblasts through canaliculi or channels within the bone matrix. They 
also  retain  a  nutrient  supply  and  dispose  of  waste  through  this  lacunar-canalicular 
network (Cowin, 2001). Osteocyte cell processes are connected to one another and to 
cells on the bone surface via gap junctions (Li et al., 2000), which are transmembrane 
channels that connect the cytoplasm of adjacent cells, allowing communication between 
cells (Xia et al., 2010). Gap junction formation is facilitated by a group of proteins 
known as connexins (Goodenough et al., 1996) and in osteocytes, connexin 43 (CX43) 
is found on the membrane of the cell body as well as on the cell processes (Jones et al., 
1993). These highly sensitive and communicative cells have the ability to sense changes 
in the levels of hormones circulating within interstitial fluid (Manolagas, 2000), induce 
signals  of  bone  resorption  by  activating  death  signalling  pathways  during  apoptosis 
(Kogianni  et  al.,  2008)  and  communicate  with  bone  lining  cells  through  their  gap          
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junctions  to  stabilize  bone  mineral  by  maintaining  an  appropriate  local  ionic 
environment (Cowin, 2001).  
2.4.3.1 Mechanotransduction of Osteocytes 
The application of mechanical  strain  during physiological  loading  creates a pressure 
difference that drives fluid flow through the lacunar-canalicular network. In this way, 
mechanical strain translates into flow induced shear stress imposed on cells. Osteocytes 
are mechanosensory cells as they can detect changes in mechanical strains (Bonewald, 
2002)  and  they  relay  this  information  to  osteoblasts  through  biochemical  signalling. 
Several signalling pathways are involved in the osteocyte mechano-responsiveness. The 
dentritic processes of osteocytes are mechano-sensitive and induce the opening of gap 
junctions and hemichannels (Burra et al., 2010) to allow for cell signalling. Osteocytes 
have  been  shown  to  release  intracellular  calcium  as  an  immediate  response  to 
mechanical loading in vitro (Ajubi et al., 1999; Taiji et al., 2009). PGE2 is an anabolic 
agent that regulates bone metabolism and increases bone mass in animals (Harada et al., 
1995). PGE2 release has been shown to be facilitated by the translocation of Connexin 
43 to the membrane surface of osteocytes in response to strain and the formation of 
Connexin 43 hemichannels (Cherian et al., 2005), allowing signalling between cells. The 
opening of such hemichannels in the gap junction has also been shown to be adaptively 
controlled by the magnitudes of mechanical stimulation (Siller-Jackson et al., 2008). It 
has been shown that osteocytes are more sensitive than osteoblasts to flow induced shear 
stress in vitro, with respect to the release of prostaglandin PGE2 (Klein-Nulend et al., 
1995a).  Other  evidence  of  osteocyte  extracellular  signalling  is  the  release  of  NO  in 
response to mechanical strain (Zaman et al., 1999). Interestingly, in a separate study, it 
has  been  shown  that  mechanically  stimulating  a  single  osteocyte  in  vitro,  increased 
production of NO was found, and in particular the production of NO by surrounding 
osteocytes was increased also. This demonstrates that a single osteocyte can dissipate a 
mechanical  stimulus  to  its  surrounding  osteocytes  through  soluble  extracellular 
signalling factors (Vatsa et al., 2007).  
Osteocytes also play a role in the regulation of bone’s response to parathyroid hormone 
(PTH). Targeted deletion of the PTH/PTHrP receptor, a G-protein coupled receptor, in 
mice resulted in the failure of a bone anabolic response to PTH treatment (Barry et al., 
2009)  and  deletion  of  osteocyte  specific  Gsα  resulted  in  osteopenia  and  increased 
osteocyte  density,  highlighting  the  key  role  of  osteocyte  G-protein  signalling  in  the 
regulation  of  bone  mass  (Barry,  2009).  In  addition,  it  has  been  suggested  that  PTH         
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 signalling  also  crosstalks  with  other  signalling  pathways  such  as  Wnt/β-catenin 
signalling pathway (Rhee et al., 2009). Furthermore, sclerostin, an osteocyte-specific 
glycloprotein,  inhibits  bone  formation  by  blocking  Wnt  signalling  through  the  Lrp5 
receptor  that  is  required  to  initiate  bone  formation.  Mechanical  stimulation  in  vivo 
reduces sclerostin levels, thereby indirectly increasing bone formation  by osteoblasts 
(Robling  et  al.,  2008).  Also,  it  has  been  shown  that  when  NO  is  inhibited  during 
application of shear stress, the enhanced expression of Wnt target genes by shear stress 
is suppressed in osteocytes, suggesting that NO plays an important role in shear stress 
induced Wnt production. 
The mechanism by which osteocytes sense fluid flow induced shear stress has not yet 
been  fully  elucidated,  but  it  has  been  proposed  that  flow  induces  a  drag  force  on 
filaments that attach osteocyte cell processes to the canalicular wall (You et al., 2001) 
(You  et  al., 2004), which is  relayed to  the central  actin filament  bundle of the  cell 
process.  It  has  been  proposed  that  the  pericellular  space  is  regularly  interrupted  by 
underlying collagen fibrils that adhere to the cell process membrane through integrin 
attachments  (McNamara et al., 2009; Wang et al., 2007). Integrins are heterodimeric 
transmembrane proteins that bind both to the extracellular matrix outside the cell and 
also to the actin cytoskeleton via the β domain on the inside of the cell. α actinin is a key 
protein responsible for linking actin filaments to integrin cytoplasmic domains (Pavalko 
and Burridge, 1991). Therefore, it is believed that integrins also facilitate considerable 
amplification  of  bone  tissue  strains  at  the  cell  level  and  consequently  lead  to  cell 
signalling (Han et al., 2004; McNamara et al., 2009; Wang et al., 2007; You et al., 2004; 
You et al., 2001).  
The glycocalyx, a pericellular matrix, has also been shown to play an important role in 
osteocyte  mechanoresponsiveness  (Reilly  et  al.,  2003).  PGE2  release  by  osteocytes 
under fluid shear stress was shown to be significantly abrogated following degradation 
of  the  glycocalyx  (Reilly  et  al.,  2003).  Glycocalyx  degradation  had  no  effect  on 
intracellular calcium signalling however, revealing that the calcium and PGE2 responses 
occur  via  different  pathways  (Reilly  et  al.,  2003).  Finally,  primary  cilia,  which  are 
solitary,  microtubule-based  organelles  that  project  from  the  surface  of  cells  into  the 
extracellular milieu, have been shown to act as mechanosensors in both osteoblast and 
osteocyte  cells  (Malone  et  al.,  2007).  In  this  study,  increased  PGE2  production, 
osteopontin mRNA levels and cyclooxygenase 2 (COX2) gene expression was observed 
with applied shear stress, but when primary cilia were abrogated, no increase in any of          
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the aforementioned levels were found (Malone et al., 2007). In summary, osteocytes 
play a pivotal role in sensing mechanical stimuli and responding via various signalling 
mechanisms,  they  play  an  important  role  in  the  controlling  bone  mass  and  anabolic 
responses to hormones, in addition to regulating calcium homeostasis.  
2.5.  Bone Remodelling 
Remodelling is a fundamental property of bone which functions to renew aged, dead and 
hyper-mineralised  bone,  and  restore  bone  following  micro-damage  (Martin,  2002), 
through  the  coupled  activities  of  osteoclast  and  osteoblasts.  Immature  (woven)  or 
primary bone present during infancy is remodelled at 2-3 years and thus replaced by 
secondary bone. Secondary bone in turn is remodelled periodically assuming normal 
bone  turnover;  cortical  bone  is  remodelled  every  20  years  whilst  trabecular  bone  is 
replaced every 1-4 years (Cowin, 2001). Bone is removed from regions of the skeleton 
where mechanical loads are low and conversely bone is deposited and micro-architecture 
is adapted in regions under repeated high mechanical strains. Finally, remodelling grants 
bone  the  capacity  for  mineral  homeostasis  as  it  alters  the  concentration  of  essential 
minerals such as calcium in the interstitial fluid (Cowin, 2001).  
 
Figure 2.5 Bone Remodelling Cycle (Ann Arbor, 2005) 
 
Remodelling of bone occurs in discrete packets within the matrix that are geographically 
and chronologically separate from other remodelling packets. This individual operational 
unit of cells is called a bone multi-cellular unit (BMU), first described by frost in 1973 
(Frost,  1973).  A  BMU  involves  oteoclast  resorption,  (see  Figure  2.4)  followed  by 
osteoblast formation of new bone called a bone structural unit (BSU) (Murray, 1999). 
The life cycle of a BMU consists of six successive steps; resting, activation, resorption,          
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reversal, formation and mineralisation, see Figure 2.5. The life span of a BMU ranges 
from 6-9 months. Approximately 3-4 million new BMU are initiated each year and on 
average 1 million BMU’s are active at any given moment (Weinstein and Manolagas, 
2000).  
2.6.  Apoptosis 
Cells can either die by apoptosis or necrosis. Necrosis is the premature death of cells 
caused by external factors to the tissue, such as poisons, trauma, or infections and is 
characterized by cytoplasm and membrane swelling (Bonfoco et al., 1995). Apoptosis is 
the naturally occurring process of programmed cell death. The term apoptosis was first 
coined to describe the distinctive morphological changes that a cell undergoes during 
cell  death  that  differs  from  necrosis  (Kerr  et  al.,  1972).  These  include  cytoplasmic 
shrinkage, nuclear condensation and changes to the mitochondrial and cell membranes. 
Protrusions  or blebs form  on the cell membrane, referred to  as  membrane blebbing, 
which  detach  from  the  cell,  forming  apoptotic  bodies,  as  depicted  in  Figure  2.6. 
Apoptosis is in stark contrast to that of necrosis, where the internal organelles and cell 
lyse without any formation of apoptotic bodies. Apoptosis is a tightly regulated process, 
genetically controlled, hence the term ‘programmed cell death’ with precise biochemical 
qualities (Hengartner and Horvitz, 1994; Wyllie, 1980). Apoptotic bodies and the dying 
cell are phagocytosed by macrophages. Apoptotic cells do not induce an inflammatory 
response in vivo whereas necrotic cells are phagocytosed by macrophages and cause an 
inflammatory  response  in  vivo.  There  are  also  forms  of  cell  death  intermediate  to 
apoptosis  and  necrosis  which  may  have  characteristics  of  both  types.  In  addition, 
following apoptosis in vitro, secondary necrosis ensues where the apoptotic cells release 
their  cytoplasmic  contents  into  the  cell  culture  media  following  loss  of  membrane 
integrity (Riss and Moravec, 2004).  
In  healthy  bone,  similar  to  the  coupled  resorption  and  formation  processes  of  the 
remodelling cycle, the birth and death of bone cells are inexorably linked. Following 
resorption, osteoclasts either return to the resting stage or undergo apoptosis (Hughes 
and Boyce, 1997). Osteoblasts, on the other hand have three fates, approximately 5% 
become bone lining cells, 30% become osteocytes and 65% die by apoptosis (Jilka et al., 
1998;  Parfitt,  1994;  Weinstein  and Manolagas,  2000). The coupled balance between 
proliferation  and  apoptosis  dictates  the  quantity  and  life  span  of  osteoclasts  and 
osteoblasts and the amount of respective remodelling they perform, thereby regulating 
bone mass and strength.           
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Figure 2.6 Morphological characteristics of apoptosis (Promega, 2011) 
 
Apoptosis is a tightly regulated process with various steps involved; therefore, there are 
multiple experimental methods available to detect and quantify apoptosis. The cysteine 
aspartic acid-specific protease (caspase) family are early markers of apoptosis as they 
play  important  roles  as  effectors  of    apoptosis  of  mammalian  cells  (Nicholson  and 
Thornberry,  1997).  Caspases  can  be  detected  using  luminescent,  fluorescent,  or 
colorimetric techniques and their detection is employed extensively in the measurement 
of apoptosis (Bradford et al., 2010; Plotkin et al., 1999; Tan et al., 2006).  
Apoptosis can also be detected by measuring changes in the cell membrane. Healthy 
cells  have  an  asymmetry  of  phospholipids  on  the  inner  and  outer  side  of  the  cell 
membrane,  however  there  is  a  alteration  in  this  symmetry  during  cell  death. 
Phosphatidylserine (PS) becomes abundant on the outer surface of the membrane and 
this change in phospholipid asymmetry can be detected using Annexin V, which is a 
phospholipid binding protein with a high affinity for PS. Annexin V is then conjugated 
to  fluorescein  isothiocyanate  (FITC)  which  can  be  detected  using  fluorescent 
microscopy or flow cytometry (Claro et al., 2011; Duus et al., 1994). Another common 
means of detecting apoptosis is by fluorometric or colorimetric TUNEL (TdT-mediated 
dUTP  Nick  End  Labeling)  that  detect  DNA  fragmentation,  which  occurs  during 
apoptosis (Plotkin et al., 1999; Sun et al., 2006; Weinstein et al., 1998).     
2.7.  Pathophysiology of Osteoporosis 
According to the American Association of Clinical Endocrinologists, osteoporosis is a 
disorder  which  is  characterized  by  compromised  strength  and  an  increased  risk  of 
fracture (Watts et al., 2010). Bone fracture occurs when the applied load exceeds the 
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load-carrying  behaviour  of  the  bone,  which  in  material  mechanics  encompasses  the 
strength, stiffness, and toughness of the material (Vable, 2002). Bone strength reflects 
bone mass and the quality of the constituent material. Therefore, in order to understand 
why bones break it is necessary to examine changes in bone mass and bone quality, 
which include the composition, the degree of micro-damage and the micro-architecture 
of the tissue material. The quality of the bone tissue and hence the overall strength is 
also affected by the rate of bone renewal (Felsenberg and Boonen, 2005; Robling et al., 
2006).   
As  described  in  section  2.5  normal  bone  turnover  entails  a  balance  between  bone 
resorption and bone formation, by the concerted efforts of osteoclasts and osteoblasts, in 
order to  maintain healthy  bone  with  neither a loss  of bone mass nor an increase in 
damage accumulation. A perturbation of this co-ordinated cellular activity occurs during 
osteoporosis.  Firstly,  the  activation  frequency  of  BMU,  which  is  the  statistical 
probability that bone remodelling will occur on any bone surface at any given moment 
(Riggs and Parfitt, 2005), is increased during osteoporosis. Secondly, bone resorption 
supersedes bone formation. The increased frequency of BMU and the disparity between 
the resorption and formation phases is evident by the increase in calcium and osteocalcin 
levels in the urine of patients with this metabolic disease (Lerner, 2006). This has major 
consequences that manifest as low bone mass and micro-architectural deterioration of 
bone tissue, as demonstrated in Figure 2.7.  
 
 
Figure 2.7 A scanning electron micrograph of (a) normal bone versus (b) osteoporotic 
bone with depletion of interconnecting struts (Ritchie et al., 2009) 
(a)  (b)          
 
23 
 
Diminishing levels of circulating oestrogen following the menopause increases the rate 
of  bone  removal  (Riggs  et  al.,  2002).  This  occurs  because  oestrogen  withdrawal 
prolongs the life-span of osteoclasts and therefore there is a net increase in the number 
of resorption cavities, and an increase in the depth of resorption pits, which together can 
lead  to  a  complete  perforation  of  the  trabecula  (Mosekilde,  1990).  The  resultant 
diminished bone architecture reduces the overall strength of bone which is demonstrated 
in a study that investigated the trabecular architecture of patients with the same bone 
mass, with and without vertebral fractures (Aaron et al., 2000). This study reported that 
those  with  fractures  had  four  times  the  number  of  broken  trabeculae  than  patients 
without  fracture,  in  spite  of  having  the  same  bone  mass.  The  effect  of  oestrogen 
depletion  on  osteoblast  activity  is  less  well  known,  however  the  main  products  of 
osteoblast activity, collagen and mineral, play an important role in determining bone 
strength. The degree of bone mineralisation (Follet et al., 2004) and the distribution of 
this mineral within the bone tissue (Ciarelli et al., 2003), both influence bone strength. 
Oestrogen deficiency is thought to increase (Boyde et al., 1998), decrease, or have no 
impact on mineral concentration, while the distribution of mineral is significantly altered 
as  a  consequence  of  oestrogen  withdrawal.  Human  osteoporotic  bone  also  has 
significantly less collagen cross-links compared to age and gender matched controls, 
highlighting the important role of collagen in the maintenance of healthy tissue. This 
suggests that impaired collagen cross-linking could contribute to reduced strength of 
bone tissue in individuals with osteoporosis (Oxlund et al., 1996).  
Disruption of normal apoptosis has been linked to osteoporosis; experiments on murine 
osteoclasts showed oestrogen treatment increased apoptosis from approximately 0.5% to 
2.7% (Hughes et al., 1996). The larger erosion pits in oestrogen deficient bone could 
therefore be contributed to by the loss of this apoptosis induction effect which would 
lead to a longer lifespan of osteoclasts. Conversely, osteoblasts and osteocyte apoptosis 
increases with age (Almeida et al., 2007) and oestrogen deficiency (Emerton et al. 2010) 
in vivo.  
2.7.1  Epidemiology 
Osteoporosis is a worldwide dilemma whose prevalence in today’s ageing society means 
that is an immense global, economic and social burden. It is estimated that 30-50% of 
women and 15-30% of men will suffer an osteoporotic fracture in their lifetime (Randell 
et al., 1995) and irrespective of the fracture type sustained, fracture sufferers are 50-
100%  more  likely  to  have  another  fracture  of  a  different  type  in  their  lifetime         
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 (Klotzbuecher et al., 2000).  In the year 2000 there were an estimated nine million 
osteoporotic fractures globally, with fracture occurrence more prevalent in Europe than 
in any other continent (Johnell and Kanis, 2006). It is estimated that 179,000 men and 
611,000 women will suffer a hip fracture each year in Europe and that the financial 
impact  of  all  osteoporotic  fractures  is  calculated  provisionally  as  being    €25  billion 
(Melton et al., 2003). Our improved health care and better lifestyles permit longer life 
expectancy  but  means  that  consequently  the  prevalence  of  osteoporosis  is  ever 
increasing. Globally, the 323 million individuals over the age of 65 in 1990 will increase 
to a predicted 1555 million by 2050. Solely, this demographic trend could result in an 
increase in the worldwide incidence of hip fractures from 1.7 million in 1990 to an 
estimated 6.3 million in 2050 (Cooper et al., 1992). In summary, it is clear from the 
statistics presented that osteoporotic fractures are a significant cause of disability and 
morbidity, particularly in developed nations, and an immense economic burden on our 
health systems. Finding adequate interventions to remedy this disease is vital and it is 
imperative  that  an  understanding  of  the  underlying  causative  factors  of  bone  tissue 
changes in osteoporosis is achieved.  
2.7.2  Diagnosis 
Osteoporosis is suspected in most low trauma fractures over the age of 45 and bone 
mineral  density  (BMD)  measurement  by  dual-energy  X-ray  absorptiometry  (DEXA) 
scanning  is  the  clinical  standard  diagnostic  tool.  According  to  the  world  health 
organisation (WHO), when bone mineral density is 2.5 standard deviations below the 
mean for normal Caucasian women, the presence of osteoporosis is diagnosed (WHO, 
1994). Arresting the disease before the occurrence of a fracture results in a significant 
financial  saving  (Brecht  et  al.,  2004),  however  it  has  been  suggested  that  BMD 
diagnostics are underutilized in the majority of European countries as a result of lack of 
availability  of  densitometers,  personnel  trained  to  perform  scans  and  reimbursement 
(IOF, 2001). The rationale for employing BMD as a indicator of osteoporosis are that 
DEXA scans  can be easily performed in  situ and epidemiologic studies  have linked 
decreasing BMD with increased fracture risk (Marshall et al., 1996). However, BMD 
measurements  are by no means  optimal for the detection of patients  at  high risk of 
fracture, as although they have high specificity, they have low sensitivity (WHO, 1994 ). 
The risk of fracture is very high with low BMD values and the risk of fracture doubles 
with each standard deviation reduction in the T-score of the BMD, regardless of the site 
of bone measured in DXA (Marshall et al., 1996). However, a high percent of fractures          
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occur  in  individuals  with  normal  BMD  (Cummings  et  al.,  2002).    Likewise,  BMD 
cannot  fully  characterize  the  efficacy  of  osteoporosis  medications  since  fracture 
reductions of up to 50% have paralleled little or no gain in BMD (Sarkar et al., 2002). 
There are also a plethora of risk factors independent of low bone density including age, 
previous fragility fracture, smoking, alcohol intake ≥ 3 units/day and body mass index 
≤19 (Poole and Compston, 2006). From a mechanical point of view the failings of DXA 
are that although it measures bone mass at the whole bone level, it is not capable of 
ascertaining the strength, stiffness, or toughness of the material which also have a huge 
impact on the fracture risk of bone.  
2.7.3  Pharmacological Interventions 
Due to the major impact osteoporosis has on society, the prevention and management of 
this disease is of paramount importance. As a consequence of extensive investigations 
into osteoporosis, there are currently a wide range of pharmaceuticals available targeted 
at  preventing  bone  loss  and  preventing  further  fractures.  These  include  oestrogens, 
Selective Oestrogen Receptor Modulators (SERMs), calcitonin, parathyroid hormone, 
calcium, vitamin D, anabolic agents and most popularly, biphosphonates (Boivin and 
Meunier, 2003). The administration of oestrogen to female patients, known as Hormone 
Replacement Therapy (HRT), was the most popular osteoporotic treatment in the 1980’s 
as  it significantly reduced skeletal bone loss  (Komulainen  et  al., 1999)  and fracture 
incidence (Turner et al., 1994) by countering the acceleration in bone turnover following 
the  menopause  (Benhamou,  2007).  However  HRT  prescription  for  postmenopausal 
osteoporosis is rapidly declining due to its association with the development of breast 
cancer (Colditz et al., 1995; Lindsay et al., 1996).  Raloxifene was the first SERM to be 
marketed for osteoporosis treatment; it has oestrogenic actions on bone tissue, such as 
prevention of bone loss and increasing bone mass and conversely has anti-oestrogenic 
actions on the uterus and breast. Therefore, Raloxifene is administered for reducing the 
risk  of  breast  cancer  in  postmenopausal  women  with  osteoporosis  and  has  proved 
effective at increasing BMD in the spine and femoral neck and reducing the risk of 
fractures (Ettinger et al., 1999).  
Most  therapeutic  agents  prescribed  for  osteoporosis  are  targeted  at  inhibiting  bone 
resorption, however a few agents have recently been developed that are aimed at bone 
formation. Teriparatide, a portion of human parathyroid hormone (PTH), is a potent 
anabolic  agent  which  enhances  bone  formation,  however  it  is  currently  only 
administered to tackle the most severe postmenopausal cases (Benhamou, 2007). It has          
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demonstrated a 65% reduction in vertebral fractures (Neer et al., 2001) and has achieved 
increased  cortical  thickness,  trabecular  connectivity  and  increased  portion  of  plates 
compared to mechanically weaker rods (Jiang et al., 2003). PTH increases BMD and 
bone mineral content in ovarectomized monkeys (Brommage et al., 1999) and reduces 
fracture risk of osteoporosis patients when administered alone or in combination with 
anti-resorptive medications (Vestgaard et al., 2007). Similarly, strontium ranelate boosts 
bone formation and also inhibits bone resorption (Meunier et al., 2004; Seeman et al., 
2006). 
2.7.3.1 Bisphosphonates 
Biphosphonates  are  the  most  widely  employed  pharmaceutical  for  treatment  and 
prevention  of  osteoporosis  (Bauss  and  Schimmer,  2006).  They  are  highly  effective 
inhibitors of bone resorption, thereby increasing the mass and mechanical resistance of 
bone. The efficacy of this drug cohort has been shown to depend on treatment duration, 
dosage, frequency, animal model and bisphosphonate type. This class of agent includes 
alendronte,  etidronate,  pamidronate,  clodronate,  (Gomez  and  Xiao,  2009)  and 
zoledronate acid.  
Bisphosphonates inhibit bone resorption by selectively adsorbing to mineral surfaces, 
from  where  they  are  subsequently  ingested  by  osteoclasts,  and  thereby  modulate 
osteoclast function. The P-C-P backbone, common to all bisphosphonates, is composed 
of two phosphate groups covalently bonded to a carbon and it is the reason this class of 
drug is called bisphosphonates. The P-C-P moiety, together with the hydroxyl act as a 
‘bone hook’ and thereby allowing rapid attachment of bisphosphonates to bone mineral 
surfaces  (Russell,  2007).  The  internalization  of  bisphosphonates  into  osteoclasts  has 
been  demonstrated  in  vivo  by  fluorescently  labelling  the  drug  and  its  uptake  was 
demonstrated  in  intracellular  vacuoles  (Sato  et  al,  1991).  Bisphosphonates  are 
categorized into two main groups according to whether or not they contain nitrogen. 
Non-nitrogen  containing  biphosphonates  (non-NBP)  cause  osteoclastic  cell  death  by 
apoptosis (Frith et al., 1997). Nitrogen containing biphosphonates (NBP) inhibit bone 
resorption by perturbing the cytoskeleton necessary for maintaining the ruffled border 
that facilitates osteoclastic bone resorption (Murakami et al, 1995; Rodan and Reszka, 
2002). They also interfere with protein prenylation and thus the signalling of critical 
regulatory proteins, thereby affecting cellular activity and survival (Russel, 2007).  
The first generation of biphosphonates, etidronate, a non-NBP, has shown to preserve 
bone mass in post-menopausal women (Herd et al., 1997). Ibandronate, a highly potent         
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 NBP was shown to increase cancellous bone mass and improve bone strength in animals 
(Smith et al., 2003) and post-menopausal women (McClung et al., 2004). Similarly, 
alendronate, a NBP, increases bone density and strength  in  animals  (Spadaro et  al., 
2006) and postmenopausal women (Boivin et al., 2000). Finally, risendronate, a NBP, 
increases bone mass and preserves trabecular micro-architecture in animals (Borah et al., 
2002) and postmenopausal women (Borah et al., 2004).   
Although bisphosphonates are currently the most popular pharmaceuticals administered 
to treat osteoporosis, current drug treatments are by no means a solution to the dilemma 
of  osteoporosis.  Usually,  bisphosphonates  are  administered  orally  however, 
disadvantages  include  low  bioavailability  and  gastrointestinal  intolerability.  It  has 
therefore been suggested, following animal (Smith et al., 2003) and human (Reid et al., 
2002) trials, that bisphosphonates should be administered by intermittent intravenous 
injections    in  order  to  improve  patient  compliance.  An  intravenous  formulation  of 
Ibandronate, administered over 15-30 seconds every three months, is approved in the 
UK  for  postmenopausal  osteoporosis  (Poole  and  Compston,  2006).  Furthermore, 
osteonecrosis  of  the  jaw  is  an  extremely  rare  (64  cases  as  of  2004)  complication 
associated with bisphosphonate treatment (Ruggiero et al., 2004). It is a severe bone 
disease whereby the death of bone cells occurs because of decreased blood flow, and 
leads to severe bone loss and collapse of regions of the maxilla and the mandible bone. 
Its symptoms include pain, loose teeth and exposed bone. The disease is most prevalent 
in bisphosphonate treated patients who have undergone invasive dental procedures. The 
precise cause is unknown; however, it is thought that bisphosphonates might interfere 
with  the  body’s  ability  to  heal  bone  following  dental  procedures  such  as  tooth 
extractions (Reid and Cundy, 2009).  
2.7.3.2 Zoledronic Acid 
Zoledronic  acid  (ZOL),  marketed  under  the  brand  name  Zometa  by  Novartis, 
Switzerland,  is  a  potent,  third  generation  NBP.  In  vivo  animal  trials  analysing  the 
efficacy  of  this  drug  have  produced  promising  findings.  In  the  rat  model  of 
postmenopausal bone loss, ZOL administered as subcutaneous injections for ten days 
decreased bone resorption and produced a dose dependent increase in trabecular bone 
volume and architectural  integrity (Alexander Pataki et  al., 1997).  In  addition,  ZOL 
administration to ovariectomised adult rhesus monkeys increased bone mineral density 
(BMD) of the spine and radius in a dose dependent manner and reduced bone turnover 
(Binkley  et  al.,  1998).  Human  trials  have  revealed  an  increase  in  BMD  of         
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 postmenopausal women treated with this pharmaceutical (Reid et al., 2002), as well as a 
significant reduction in fracture occurrence (Black et al., 2007).  
2.8.  Quantification of Mineral Content in Bone 
Determining the variations of mineral content of trabecular bone on a microscopic scale 
can  yield  important  insights  into  mechanical  strength,  integrity  and  remodelling 
activities.  Bone  mineral  composition  may  be  analysed  by  employing  a  variety  of 
analytical  techniques  such  as  gravimetric  analysis,  energy  dispersive  spectroscopy, 
scanning electron imaging, backscatter electron imaging, x-ray diffraction, as well as 
spectroscopic methods such as infrared, raman, and nuclear magnetic resonance.  
Gravimetric  analysis  can  be  used  to  assess  the  water  content,  mineral  content  and 
carbonate  content  of  bone.  Generally  the  bone  is  crushed  and  the  percentage  water, 
mineral,  and  carbonate  per  weight  is  established.  ‘Ashing’  is  a  gravimetric  analysis 
technique  and  the  residue  or  ash  content  obtained  when  bone  is  heated  to  extreme 
temperatures may be used to quantify the total amount of mineral within a bone sample. 
Heating bone to these temperatures removes all the organic components of bone such as 
matrix  proteins,  water,  and  bone  cells  and  therefore  only  the  inorganic  or  mineral 
components of bone are left in the ash content (Cowin, 2001). A temperature of 550˚C is 
recommended for ashing procedures by the Royal Society of Chemistry (Watson, 1994). 
Ash content analysis has been used extensively to assess the mineral content in bone 
(Aerssens  et  al.,  1997;  Kolosova  et  al.,  2002;  Pointillart  et  al.,  1995;  Thorp  and 
Waddington, 1997). Gravimetric analysis offers reproducible quantitative data, however 
it does not provide information on the quality of the mineral. Another disadvantage is 
the long ashing times required, approximately 10 hours, and the destructive nature of the 
technique, rendering samples useless for further assessment. Moreover, any information 
regarding the location of the mineral distribution is lost during this technique.   
Fourier transform infrared spectroscopy (FTIR) may be utilised to provide qualitative 
and  quantitative  information  regarding  components  in  bone  that  possess  IR  active 
vibrations, therefore it can analyse the mineral phosphate, matrix proteins and lipids. It 
has been used extensively to analyse the mineral content of bone (Boskey et al., 2005; 
Marcott et al., 1998). The advantage of employing this technique for analyzing bone 
mineral is that it can map alterations in mineral properties at a spatial resolution of 20µm 
(Paschalis et al., 1997). However, there are disadvantages associated with FTIR such as 
the requirement of having particles less than 2 m in order to avoid light scattering. 
Secondly,  FTIR  instruments  measure  interferograms,  not  spectra,  therefore  fourier          
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transforms must be performed to produce a spectra and the execution of this can affect 
the results (Vagenas et al., 2003). Raman microprobe spectroscopy has also been used to 
analyse bone minerals  (Carden and Morris, 2000). This IR technique relies on inelastic 
scattering, called Raman scattering of light from a laser in the visible, near ultraviolet, or 
near infrared range. The primary disadvantage of this technique is the interference from 
the fluorescent elements of the organic matrix (Cowin, 2001).  
Quantitative backscatter electron imaging (qBEI) has been demonstrated as an extremely 
effective tool for measuring microscopic mineral content variations in bones as the BE 
image intensity (grey level) has been shown to have a strong positive correlation with 
ash (mineral) content (Crofts et al., 1994). In addition, one can calibrate the grey level 
scale in order to produce comparable results and the grey level can be related to weight 
percentage  calcium  (Roschger  et  al.,  1998).  qBEI  is  therefore  the  chosen  analytical 
technique for mineral content quantification in this thesis and is described in detail in 
section 2.9. 
2.9.  QBEI 
Quantitative Backscatter Electron Imaging (qBEI) is a Scanning Electron Microscope 
(SEM) technique which permits compositional and topographical analysis of specimens. 
A SEM is a high resolution instrument that forms an image by producing a beam of high 
energy electrons and examining the interactions between the incident electrons and the 
specimen of interest. The SEM can achieve a magnification and resolution of 500,000x 
and 0.4nm respectively. It can acquire compositional information by producing images 
whose contrast is based on the constituent elements and compounds of the sample. Also, 
characteristic x-rays produced when the electron beam hits the sample can be used to 
identify  and  image,  specific  elemental  distributions  (from  boron  to  plutonium)  in  a 
specimen (Goldstein et al., 2003). The development of electron backscatter diffraction 
(EBSD)  in  the  SEM  permits  the  attainment  of  crystallographic  information  of  the 
material (Randle, 1995).  
A basic schematic of the principle components of a typical SEM is presented in Figure 
2.8 (a). The SEM generates a beam of electrons in a vacuum using an electron gun 
which  thermionically  (using  a  heated  electronic  conductor)  emits  electrons  from  a 
tungsten or lanthanum hexaboride cathode towards an anode at an energy ranging from 
1keV  to  30  keV.  The  electrons  are  passed  through  a  series  of  apertures  including 
electromagnetic  condenser  lenses  which  collimate  the  beam  and  objective  lens  for          
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focusing, allowing adjustment of the final beam diameter, called the probe diameter or 
spot size.  
When  the  electron  beam  strikes  the  specimen  the  electrons  will  scatter  through  the 
sample  within  a  defined  area  called  the  interaction  volume.  This  electron  beam–
specimen  interaction  causes  the  formation  and  scattering  of  electrons  which  can  be 
classified  as  either  elastic  scattering  or  inelastic  scattering.  Elastic  scattering  occurs 
between the incoming electrons from the electron beam and the nucleus of the target 
atoms. This gives rise to backscattered electrons that are of particular importance in this 
thesis.  Inelastic  scattering  occurs  between  the  incident  beam  and  the  loosely  bound 
electrons of the conduction band, or the tightly bound valence electrons and nucleus. 
This  occurrence  gives  rise  to  secondary  electrons,  x-rays  and  auger  electrons,  as 
illustrated in Figure 2.8 (b) (Goldstein et al., 2003).   
Secondary electrons (SE) are low energy electrons (10-50eV) which are detected by a 
scintillator-photomultiplier  system  know  as  the  Everhart-Thornley  detector.  When 
produced deep within the interaction volume they do not possess adequate energy to 
escape and are absorbed by the specimen. Therefore, only secondary electrons close the 
surface of the specimen will escape the interaction volume. The secondary electrons 
emitted can go in any direction and therefore a Faraday cage surrounds the secondary 
electron  detector  and  exerts  a  positive  pull  on  weakly  negative  secondary  electrons 
towards the detector. As the beam scans the specimen and the interactions are detected, 
an image is sequentially formed presenting the information of interest. 
2.9.1  Backscatter Image Formation 
Backscattered  electrons  (BSE)  arise  due  to  elastic  collisions  between  the  incoming 
electrons  in  the  primary  beam  and  the  nucleus  of  the  target  atoms.  Backscattered 
electrons  are  produced  deep  within  the  sample  however  as  they  have  much  higher 
energies  than  secondary  electrons  they  are  able  to  escape  from  deeper  within  the 
interaction volume, see Figure 2.8 (d). As their generation region is larger than those of 
secondary electrons they give less spatial resolution than SE. However, because they 
have higher energies they are less affected by charge-up and sample damage. Specimen 
charge-up is  when negatively  charged electrons collect  locally on the surface of the 
specimen, which prevents  normal  emission of  SE and causes abnormal  contrast  and 
distorted images.           
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Figure 2.8: (a) Basic components of a SEM  (Iowa State University, 2009). (b) Electron 
beam-specimen  interactions  in  a  SEM.  (c)  Backscattered  electrons  detection  (Corp., 
2009). (d) Interaction volumes of secondary and backscattered electrons (Smith College, 
2009).  
                     
   The  backscatter  detector  is  located  within  the  specimen  chamber  above  the 
specimen in a ‘doughnut’ shape configuration with the incident beam passing through its 
hole or centre, as depicted in Figure 2.8 (a) and (d). The backscattered electron image 
can either provide compositional or topographical sample information. Addition of a 
paired  semiconductor  detector  gives  compositional  information,  while  subtraction 
provides information regarding the specimen topography. This thesis is solely concerned
(d) 
(b) 
(c) 
(a)          
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with compositional information of the mineralised bone specimens. The intensity of the 
backscattered image is related to its mean atomic number (Z). Regions of the material 
that  are  composed  of  larger,  heavier  atoms  will  backscatter  more  electrons  thus 
generating brighter grey tones in the backscatter image. Conversely, lighter atoms will 
produce darker grey tones in the image. In this way, an image grey level (GL) can be 
generated which provides compositional-based information (Goldstein et al., 2003).  
2.9.2  Image Quality    
There are a number of interdependent SEM parameters under operator control that can 
impact the quality of the qBEI obtained. These include the probe current, the spot size, 
the acceleration voltage and the working distance. Once the incident beam current passes 
through the anode, its current decreases drastically and it is referred to as the probe 
current. It affects the smoothness of the image; decreasing the probe current will reduce 
the chance of charge-up and also reduce the spot size (JEOL, 2009). The smaller the spot 
size the higher the magnification and resolution, but the greater the chance of specimen 
damage.  
The accelerating voltage (voltage applied to the filament) employed in SEM imaging 
usually ranges from 5kV to 20kV. Increasing the accelerating voltage decreases the spot 
size and theoretically should increase the resolution of the image as there is a decrease in 
the spherical aberration of the system. Spherical aberration is the failure of the lens 
system to image central and peripheral electrons at the same point, thus creating more 
than one focal point which leads to un-sharp image formation. However, the relationship 
between  accelerating  voltage  and  resolution  depends  on  the  atomic  number  of  the 
specimen  of  interest  because  increasing  the  accelerating  voltage  also  increases  the 
interaction volume due to the higher energy of the electrons in the incident beam; see 
Figure 2.9 (a) and (b). Consequently, the backscattered electrons are emitted from a 
larger area of the specimen and this has the effect of reducing the resolution of the 
image,  much  less  so  in  specimens  of  higher  atomic  number  however.  Therefore, 
increasing  the  accelerating  voltage  increases  the  resolution  in  specimens  with  high 
atomic number and decreases the resolution in specimens with low atomic number, such 
as biological samples. Several disadvantages accompany an increase in the accelerating          
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voltage  which  includes  a  higher  possibility  of  specimen  damage,  lack  of  detail  on 
specimen surface, and increased possibility of charge-up.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 (a) Effect of atomic number on the interaction volume  (b) Effect of the 
acceleration voltage on the interaction volume (Smith College, 2009).  
 
The depth in the sample that appears to be clearly focused is known as the depth of field 
(h). Figure 2.10 (c) illustrates this concept. The working distance (WD) is the distance 
between the specimen of interest and the closest condenser lens. Decreased working 
distance results in a decreased depth of field as the specimen is scanned with a wider
(a) 
(b)          
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cone of electrons. It also has the effect of improving the resolution as the effects of 
spherical aberration are reduced and the spot size is reduced. Depth of field can therefore 
be improved by increasing the working distance, decreasing the objective lens apertures 
and decreasing the magnification of the image (Starink, 2008). 
 
Figure 2.10 Effect of working distance (WD) and objective aperature diameter (A) on 
the depth of field (h). 
 
2.9.3  Quantitative Calibration 
Since different materials are differentiated by different intensities, or grey levels ranging 
from 0-255, in a backscatter image, it is essential to employ a method of calibrating this 
GL  scale  to  ensure  accuracy  and  reproducibility  of  the  quantitative  measurements 
between specimens. Two means of GL scale calibration have been used predominantly 
in qBEI throughout the bone tissue mineral literature. The first employed polymers with 
high  atomic  numbers  synthesized  by  Davy  et  al,  (thermoset  dimethylacrylate  esters 
derived  from  the  reaction  of  halogenated  phthalic  acids  and  glycidyl  methacrylate) 
(Davy, 1994)  to  calibrate the GL scale  (Boyde  et  al., 1995; Boyde et  al., 1999). A 
second technique related the qBEI grey levels to weight percentage calcium content (wt 
% Ca) (Roschger et al., 1998; Roschger et al., 1995). Carbon (Z=6) and aluminium 
(Z=13) standards were imaged and the brightness and contrast were altered to C and AL 
grey levels of 25 and 225 respectively. This produced a calibration line relating atomic 
number to grey level, see Figure 2.11 (a). Secondly, a standardization line of BE grey          
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levels  versus  calcium  concent,  see  Figure  2.11  (b),  was  developed  by  imaging  pure 
osteoid  (0  wt  %  Ca)  and  hydroxyapatite  (39.86  wt  %  Ca)  under  the  calibrated  GL 
conditions  (Roschger  et  al.,  1998;  Roschger  et  al.,  1995).  Energy  Dispersive  X-ray 
Analysis (EDX) and GL analysis were performed at the same positions on the same bone 
samples and a clear linear correlation between GL and wt % Ca was revealed  (Roschger 
et al., 1995). This technique has been employed fruitfully by various research groups in 
bone mineral content investigations (Gupta et al., 2005), (Bloebaum et al., 1997), (Burr 
et al., 2003; Sutton-Smith et al., 2008) and is the calibration method utilised throughout 
the present work.  
 
Figure 2.11 (a) Calibration line (y=5.1352+0.035024*x) of grey levels (GL) into atomic 
numbers (Z) for the calibration of the GL scale. (b) Standarization line (y= -4.332 + 
.1733*x) of BE grey levels and calcium concentrations (wt % Ca)  (Roschger et al., 
1995) 
 
2.10. Summary 
Chapter 2 has presented a detailed overview of the structure, composition and functions 
of bone, with particular focus given to the cellular constituents of bone, during health 
and  osteoporosis.  In  summary,  bone  is  a  dynamic  tissue  that  plays  supportive  and 
metabolic functions and permits movement. Bone tissue is continually being renewed 
throughout life by the coupled activities of bone resorbing osteoclasts and bone forming 
osteoblasts, in order to remove old and damaged bone. Bone is remodelled in accordance 
with the mechanical loads imposed on it and both osteocytes and osteoblasts are capable 
of  sensing  mechanical  stimuli  and  producing  a  biochemical  response.  During 
osteoporosis  increased  bone  remodelling  as  a  consequence  of  oestrogen  withdrawal 
results in depleted bone architecture, low bone mass, reduced strength and increased risk 
of fracture. The mineral content of bone tissue is a governing factor for bone strength          
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and is thought to be altered during osteoporosis, which could contribute to increased 
fracture risk. Osteocyte apoptosis is also thought to increase during osteoporosis, this 
may  lead  to  a  depleted  osteocyte  mechano-sensing  network  and  altered  mineral 
distribution.  Bisphosphonates  are  the  primary  drug  prescribed  in  the  treatment  of 
osteoporosis and although an increase in bone density is achieved by the inhibition of 
bone  resorption,  fracture  risk  still  remains  high.  Experimental  methods  employed  to 
quantitatively assess bone mineral content of ex vivo bone tissue include gravimetric 
analysis, fourier transform infrared spectroscopy (FTIR) and quantitative backscattered 
imaging  (qBEI).  In  the  following  chapters  a  detailed  investigation  of  altered  tissue 
mineralisation during oestrogen is presented. This is followed by in vitro cell culture 
studies during static and applied loading conditions in Chapters 5 and 6, which aim to 
understand  the  cellular  mechanism  which  may  be  responsible  for  such  changes.          
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3.  Site Specific Increase in Bone Mineral 
Heterogeneity during Oestrogen Deficiency 
3.1.  Introduction 
The overall mechanical strength and fracture resistance of bone is determined by both 
the bone mass and the quality of the bone tissue  (Judex et al., 2003). Bone quality 
encompasses many features of the bone tissue, in particular (1) tissue micro-architecture, 
(2) the degree of micro-damage and (3) tissue composition. It is now well established 
that,  during  oestrogen  deficiency,  bone  mass  and  trabecular  micro-architecture  are 
significantly  degraded  by  way  of  trabecular  thinning,  micro-fracture  and  loss  of 
trabecular connectivity (Compston et al., 1989; Lane et al., 1998; Parfitt, 1987). There is 
also evidence that the extent of micro-damage within bone tissue is increased during 
oestrogen deficiency (Dai et al., 2004). It is less clear, however, how tissue composition 
is  affected  by  oestrogen  deficiency.  Bone  is  a  composite  material,  composed  of  an 
inorganic phase (predominantly the mineral calcium phosphate) and an organic phase 
(collagen, non-collagenous proteins and cells). The mechanical behavior of bone tissue 
is  determined  by  the  quantity  and  mechanical  integrity  of  each  of  these  phases.  In 
particular the mineral concentration is a key determinant of the mechanical strength of 
bone (Currey, 1984b; Ruffoni et al., 2007). Previous research to discern differences in 
mineral concentration between oestrogen deficient and normal bone tissue has produced 
many conflicting observations; some studies report a decrease (Gadeleta et al., 2000; 
Loveridge et al., 2004), whilst others reveal an increase (Boyde et al., 1998; Dickenson 
et al., 1981; McNamara et al., 2006), or no change in mineral concentration (Bohic et 
al., 2000; Ciarelli et al., 2003; Rohanizadeh et al., 2000). Variations in experimental 
methods or animal model may explain such discrepancies. Alternatively, the distribution 
of  bone  tissue  mineral  in  oestrogen  deficient  bone  might  vary  depending  on  the 
structural level or the anatomical location from which bone was chosen for analysis. 
Trabecular bone is a hierarchically organised structure, formed by an interconnecting 
network of trabeculae, which are comprised of collagen fibrils organised into parallel 
tissue lamellae. While most studies have assessed the mechanical integrity of volumes of 
trabecular bone, changes at all levels of organisation likely contribute to fracture risk. In 
a  previous  study,  micro  tensile  testing  of  individual  trabeculae  from  the  tibia  of 
ovariectomised rats showed that although the overall bone mass and bone strength was 
reduced, the remaining individual trabeculae were approximately 40–90 % stronger and         
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stiffer than trabeculae from sham operated controls (McNamara et al., 2006; McNamara 
et al., 2005). Preliminary studies suggested that these changes in tissue properties were 
related to  micro structural  changes  in  tissue mineralisation  (McNamara  et  al., 2006; 
McNamara et al., 2005). A recent study corroborated this by reporting increased calcium 
content within individual trabeculae during oestrogen deficiency (Busse et al., 2009). 
Studies  have  shown  that  mineral  is  more  heterogeneously  distributed  in  oestrogen 
deficient trabeculae (Busse et al., 2009; Roschger et al., 2008). However, these studies 
have  not  yet  distinguished  precisely  where  mineralisation  differences  arise  within 
trabeculae,  e.g.  whether  tissue  mineral  content  is  altered  at  superficial  surfaces,  or 
whether  such  changes  are  ubiquitous  throughout  trabeculae.  It  is  known  that  bone 
mineral is heterogeneously distributed across different anatomical regions of the healthy 
skeleton  (Nazarian  et  al.,  2007),  due  to  normal  variations  in  functional  remodelling 
(Tsubota et al., 2009) and tissue mineralisation kinetics (Akkus et al., 2003; Ruffoni et 
al. 2007). Furthermore, remodelling activity is variable across anatomical locations of 
the proximal femur (Tsubota et al., 2009). Although it has been shown that increased 
remodelling activity during oestrogen deficiency (Bell, 1996; Caverzasio et al., 2008) is 
not uniform across sites of the distal femur (Baldock et al., 1998), it is not yet known 
whether such variations alter the normal distribution of bone tissue mineral between 
anatomical locations. In this study, quantitative backscattered electron imaging (qBEI) 
with  scanning  electron  microscopy  (SEM)  was  used  to  test  the  hypothesis  that  the 
distribution  of  bone  tissue  mineral  is  altered  during  osteoporosis.  Specifically,  the 
objective of the study was to discern the difference in mean calcium content and the 
density distribution of calcium at a tissue level between healthy and osteoporotic sheep 
trabecular bone. Furthermore, it was sought to quantify whether changes are ubiquitous 
across all trabecular bone tissue from the proximal femur, or are limited to discrete 
anatomical locations within the proximal femur. This chapter presents an edited version 
of previously published work (Brennan et al., 2011). 
3.2.  Materials and Methods 
3.2.1  Animal Groups and Trabecular Bone Origins 
Animal bone tissue was used in this study in order to obtain statistically relevant samples 
sizes of both osteoporotic models and healthy controls, which would be very difficult to 
obtain from human subjects. Although some non human female primates experience a 
cessation of the reproductive cycles similar to menopause in humans several elements 
inhibit their usefulness for research including expense of purchase, ease of handling and         
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possibility of disease transmission to humans. The link between human menopause and 
oestrogen deficiency is  well established (Butler and Santoro, 2011; Longcope et al., 
1986; Richelson et al.,1984). For this reason, the most common approach to generate an 
animal  model  for  studying  the  menopause  involves  a  surgical  procedure  known  as 
ovariectomy, which involves disruption of normal ovarian function and thereby induces 
oestrogen deficiency systemically. Ovariectomy has been applied in rats, monkeys and 
other mini-pigs as an osteoporotic model (Borah et al., 2002; Gadeleta et al., 2000; 
McNamara et al., 2006; Rohanizadeh et al., 2000). Although small animal models, such 
as  rats,  are  easy  to  maintain,  inexpensive  and  have  an  accelerated  ageing  process 
compared to larger animals, bone from such models differs from human bone in terms of 
cell biology, mechanical properties and hormone production and regulation. Sheep have 
been utilised successfully by other researchers as models for osteoporosis (Chavassieux 
et  al.,  2001;  Turner  et  al.,  1995a;  Turner  et  al.,  1995b).  The  sheep  has  a  bone 
remodelling cycle similar to humans (3-5 months) (Canalis et al., 2007) and experiences 
bone loss during osteoporosis similar to humans (Turner et al., 1995a). Their ease of 
handling, vast availability and lack of variability, introduced through diet and exercise, 
make them an ideal model for human osteoporosis. The ovariectomised sheep has been 
shown to be a valid model for analysing the alterations in trabecular architecture that 
accompany osteoporosis (Newton et al., 2004).  
The bone specimens analysed in this study originated from an ovine osteoporosis model, 
acquired from a collaborative project (Bone for Life) between the Trinity Centre for 
Bioengineering, Trinity College, Dublin and the Department of Anatomy in the Royal 
College of Surgeons in Ireland (RCSI), Dublin, which has been described previously 
(Brennan et al., 2009; Kennedy et al., 2008a; Kennedy et al., 2009a; Kennedy et al., 
2009b; Kennedy et al., 2008b). Bone tissue analysed in this study came from either; (1) 
skeletally mature mixed breed ewes that underwent ovariectomy to induce an oestrogen 
deficient  state  (OVX,  n=7)  or  (2)  an  aged-matched  control  group  (CON,  n=5).  All 
surgery  was  performed  following  ethical  approval  by  the  Ethics  Committee  in  the 
School of Veterinary Science in University College Dublin and under an animal licence 
granted by the Irish Department of Health. The serum estradiol and progesterone levels 
in these sheep for the duration of the 12 month study are presented in Appendix 2, 
illustrating that ovariectomy successfully diminished circulating serum hormone levels. 
Animals were maintained at pasture where no difference in feeding or activity levels 
were  observed  between  groups,  however  this  was  not  directly  monitored  or          
 
40 
 
quantitatively assessed. Animals in the current study were sacrificed at 12 months post-
ovariectomy and bones were harvested and frozen at -20
oC.       
3.2.2   Specimen Preparation 
Bone  tissue  samples,  consisting  of  the  proximal  extremity  of  the  left  femur,  were 
defrosted and thoroughly washed by extracting the marrow and fatty deposits with a 
water jet and were then left to air dry. Five individual trabeculae were excised from three 
regions of the left proximal femora (greater trochanter, lesser trochanter and femoral 
head) of animals  from  each of the  CON and OVX cohorts;  see  Figure 3.1 (a).  The 
sample sizes are presented in Table 3.1. Trabeculae were randomly chosen and excised 
with a scalpel and forceps with the aid of a 3x magnifying glass. Excised samples were 
embedded  into  polymethylmethacrylate  (PMMA)  solution  in  glass  vials  that  was 
polymerised  to  form  a  solid  structure  in  order  to  permit  ease  of  handling  and  to 
guarantee spatial continuity and contiguity for qBEI analysis. Firstly, a polymer base 
was prepared in the 10mm diameter vials to ensure samples did not come into contact 
with the surface of the glass. Under the protection of a fume hood, MMA solution was 
pipetted into the glass vials to an approximate 10mm height. The vials were capped 
securely and placed in an oven at 55˚C for approximately seven hours or until they are 
adequately hardened, but the top surface of the polymer was still tacky to touch with the 
forceps. Heating the MMA causes it to polymerise and harden into PMMA. Trabeculae 
were placed vertically on top of the base of PMMA and the polymer was pipetted into 
each  vial  to  completely  immerse  the  specimens.  Vials  were  placed  in  a  vacuum 
dessicator for two hours to expel air from the medium. The vials were then capped 
tightly and placed in an oven at 50˚C for approximately 18 hours. The vials containing 
the vertically standing specimens embedded in a polymerised resin were placed in a 
freezer at -20˚C to facilitate the subsequent removal of the glass by fracture.  
A precision diamond cutting machine (Minitom, Struers, Denmark) with saw rotation of 
400rpm was used to expose a cross-section through the trabeculae. Samples were ground 
and polished using a polishing wheel (Labopol -21, Stuers, Denmark) fitted with silica 
carbide paper, ensuring constant water irrigation throughout, and then by using diamond 
suspension of decreasing particle size down to 0.25 μm. Extremely smooth surfaces are a 
prerequisite for qBEI as scratches and polishing reliefs could generate a topographical 
contrast  that  would  interfere  with  the  qBEI  material  contrast.  In  order  to  provide  a 
conductive path for electrons for SEM analysis and prevent charge up on the specimen          
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surface of non-conductive specimens, such as biological samples, samples were coated 
with a thin layer, approximately 30nm, of carbon by vacuum evaporation (Edwards 306 
Auto Unit, Crawley, U.K.). 
3.2.3  Scanning Electron Microscopy and qBEI 
In order to ascertain the mineral content of the bone specimens, quantitative backscatter 
images were acquired of the cross section of each trabecula using an SEM (JSM 5910, 
JEOL,  Welwyn  Garden  City,  U.K.),  fitted  with  a  backscattered  detector.  Following 
chamber venting, loading of specimens and chamber evaluation, the incident beam was 
turned  on  for  analysis.  The  following  operating  settings  were  applied:  electron 
acceleration  voltage  of  15kV,  beam  current  of  1.2nA  and  objective  lens  aperature 
diameter of 30µm. The magnification was kept the same for all images (200x), which 
resulted in a pixel resolution of 0.66µm/pixel and images comprising 1280 x 901 pixels.. 
 
 
Figure 3.1 (a) Schematic depicting anatomical regions from which single trabeculae 
were excised from sheep bone; Greater Trochanter (GT), Lesser Trochanter (LT) and 
Femoral Head (H). Note also the inter-trochanteric region which is a primary fracture 
site in osteoporosis is also depicted. (b) qBEI image of trabecular cross section; tissue 
lamellae are clearly evident. Spatial distribution of calcium was analysed in specific 
regions of interest (ROI); Superficial (Boxes 1, 2), intermediate (Boxes 3, 4) and (Box 5) 
deep regions. For each trabecula eight superficial, eight intermediate and eight deep ROI 
were analysed. 
Quantitative backscattered electron images were acquired with the samples at a fixed 
working distance of 12mm; see Figure 3.1 (b). In order to calibrate the grey level scale 
range,  pure  carbon  and  aluminium  standards  (Agar  Scientific,  Stansted,  U.K.)  were 
included in each scan. The standards were imaged in the qBEI mode and the contrast and         
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brightness settings were altered until carbon measured 25 on the grey level (GL) scale 
and aluminium measured 225. Calibrations were checked after every image capture and 
were recalibrated if necessary 
3.2.4   Bone Mineral Density Distribution Analysis 
Each qBEI image was analysed to determine the GL intensities of each pixel using a 
custom  MATLAB  script.  An  image  histogram  of  pixel  count  versus  grey  level  was 
produced (with pixels due to PMMA embedding material threshold out). Pixel count was 
presented as a percentage of total pixel count and therefore expressed as a percentage of 
total  bone  area  (%  bone  area).  A  linear  relationship  between  the  grey  levels  of  the 
backscattered image and the local calcium content was established previously (Roschger 
et al., 1998). This relationship was employed to calculate bone mineral content (wt%Ca) 
from the GL measurements (GL) according to equation 3.1    
                                                                                           
           
This  relationship  was  used  to  determine  the  bone  mineral  content  (wt  %  Ca)  of 
individual  trabeculae  excised  from  three  regions  of  the  proximal  femora  (greater 
trochanter, lesser trochanter and femoral head) of animals from each cohort. A frequency 
distribution  of  the  calcium  content  of  single  trabeculae,  known  as  the  bone  mineral 
density  distribution  (BMDD),  was  used  to  compare  the  distribution  of  bone  tissue 
mineral between normal and osteoporotic bone similar to previous methods (Busse et al., 
2009;  Roschger  et  al.,  1998).  Histograms  of  wt  %  Ca  were  derived  from  the  high-
resolution qBEI images (0.66 µm), which produced histograms with a resolution of 0.17 
wt % Ca. A Gaussian curve-fit was superimposed on the BMDD histograms since the 
data was normally distributed. The mean calcium content of each trabecula,  Ca  , was 
calculated according to equation 3.2 
 
           
     
                        
   
                                 (3.2) 
 
The heterogeneity of calcium within each trabecula was quantified by calculating the full 
width  at  half  maximum  (FWHM)  from  the  BMDD  histogram.  The  FWHM  is  the 
distance between points on the Gaussian curve at which the function reaches half its 
maximum value (Figure 3.2). To assess inter-trabecular variation, the standard deviation, 
 ,  and  coefficient  of  variation  (
Ca
v c 
  )  for  three  anatomical  regions  (greater         
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trochanter, lesser trochanter, femoral head) of every sheep was computed. In order to 
evaluate inter-group comparisons, the percentage differences of Ca  ,   and  v c between 
anatomical regions were calculated. 
 
3.2.5  Spatial Distribution of Calcium within Trabeculae 
BMDD analysis provides important information regarding the mean calcium content and 
heterogeneity  of  bone  tissue  mineral  but  does  not  distinguish  where  precisely 
mineralisation  differences  arise  within  trabeculae.  To  attain  spatial  information  on 
mineral distribution within trabeculae, calcium content was quantified at specific regions 
of interest (ROI) through the cross section of trabeculae. Each qBEI was analysed using 
a custom MATLAB script, which allowed the operator to manually select the surface of 
a trabecula and then automatically analyse mineral content in the superficial region, the 
intermediate region and the deep region within each trabecula, see Figure 3.1 (b). The 
distinction and differentiation of superficial, intermediate and deep regions through the 
cross section of rod-like and plate-like trabeculae can be subjective. Therefore, regions 
of interest (ROI) were automatically generated to avoid operator bias. Two opposite ROI 
on  the  surface  of  a  trabecula  (superficial  region),  two  intermediate  ROI  (midway 
between the trabecular surface and centre) and one core (deep) ROI were automatically 
defined at equidistant locations. These ROI were of the same size (38 x 38 pixels) and 
were defined proportional to the diameter of each cross section, to allow comparison of 
trabeculae with one another regardless of thickness or shape and also remove any bias 
that might be introduced in a manual method. This method generated five ROIs through 
the  cross  section  of  trabeculae  and  this  was  performed  four  times  per  trabecula  to 
generate eight superficial, eight intermediate, and four deep ROIs, in total, per trabecula. 
Histograms of GL were plotted for each ROI, a threshold was applied to remove GL data 
from  PMMA  embedding  material  and  the  pixel  count  (frequency)  was  weighted 
accordingly,  and  since  the  data  was  normally  distributed,  a  Gaussian  curve  fit  was 
superimposed on the histograms (see Figure 3.2). The mean wt % Ca for each level 
(superficial, intermediate, and deep) was calculated. The percentage difference of wt % 
Ca between the deep and superficial regions of trabeculae was computed and compared 
between CON and OVX groups to assess the influence of oestrogen deficiency on the 
spatial distribution of calcium within single trabeculae.           
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Figure 3.2 Histrogram of pixel count versus grey level for a typical region of interest 
(ROI) (pictured inset) in the superficial region of trabeculae, with a Gaussian curve fit 
applied. The peaks on the left represent the PMMA embedding material (black in the 
ROI), which was removed from analysis by applying a threshold to each image.  
 
3.2.6   Statistical Analysis 
General linear model (GLM) ANOVA’s were applied to statistically analyse wt % Ca 
parameters between groups. A p value of ≤0.05 was considered statistically significant. 
The  mean  calcium  content  ( Ca  )  of  normal  and  OVX  bone  within  regions  was 
compared, as well as the pooled mean calcium content between CON and OVX (i.e. 
combined  data  from  all  anatomical  regions).  Next,  mineral  heterogeneity  (FWHM) 
within  trabeculae  was  compared  between  normal  and  OVX  bone  tissue.  The  spatial 
distribution of mineral within trabeculae (% difference between superficial and deep 
regions) was compared between normal and OVX bone tissue. Sheep were defined as 
random factors nested within either CON or OVX groups while femora regions and 
trabecular regions were fixed factors, nested within the sheep from which they arose. 
Therefore, sample size for the purpose of statistically comparing OVX and CON refers 
to sheep numbers. Tukey’s method for pair wise comparisons, with a family error rate of 
0.05,  was  employed  to  determine  statistical  differences  between  distinct  anatomical 
locations within femora and between trabecular regions. Finally, Student’s t-tests were 
employed  to  compare  CON  and  OVX  sheep  by  assessing  the  %  difference  of  the 
standard  deviation  (   )  and  coefficient  of  variation  ( v c )  of  mineralisation  between 
regions. 
3.3.  Results 
The results of this study are presented in detail below. Each section addresses a specific
PMMA  Bone          
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question  related  to  the  global  hypothesis,  which  is  “The  distribution  of  bone  tissue 
mineral is altered during osteoporosis”.  
3.3.1   Does  Oestrogen  Deficiency  Alter  the  Mean  Calcium  Content  of  Bone 
Tissue? 
Pooled mean calcium content data from all trabeculae in all three regions of the proximal 
femur  revealed  no  significant  difference  in  Ca  between  CON  and  OVX  groups. 
Similarly, no difference in  Ca   was found between these two groups within any of the 
specific  femoral  regions,  i.e.  lesser  trochanter,  femoral  head  and  greater  trochanter. 
These data are presented in Table 3.1. 
3.3.2   Does Oestrogen Deficiency Alter the Mineral Heterogeneity of Trabeculae? 
BMDD  analysis  revealed  significantly  higher  FWHM,  a  measure  of  heterogeneity, 
within trabeculae from the greater trochanter of the OVX group compared to CON (3.57 
± 0.68 vs. 3.17 ± 0.36, p<0.04), see Figure 3.3. However, the higher heterogeneity in 
OVX animals compared to CON was site specific, as no significant differences were 
observed  in  the  FWHM  from  trabeculae  of  the  head  and  lesser  trochanter  regions 
between groups. These data are presented in Table 3.1. 
 
Figure 3.3 Bone mineral density distributions (BMDD) through the entire cross section 
of representative CON (n=25) and OVX trabeculae (n= 30) in the greater trochanter of 
proximal femora. A Gaussian curve fit (red) was applied to the data points (blue). The 
mineralisation profiles in superimposition reveal significantly higher (p<0.04) full width 
at half maximum (FHWM) and a non-significant shift towards a higher mineralisation 
range in OVX trabeculae.           
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Table 3.1: Mean weight percentage calcium (wt % Ca), full width at half maximum 
(FWHM) and sample sizes (n) for bone trabeculae from the Greater Trochanter (GT), 
Femoral Head (H) and Lesser Trochanter (LT) regions of control (CON) and OVX bone. 
Data is presented as mean ± standard deviation. * indicates different from CON LT 
(p<0.01), + higher than LT (p<0.01), ++ higher than H (p<0.02), and ** FWHM differs 
between groups. 
 
    Mean  p    FWHM  p    n 
Sheep  Trabeculae 
GT  CON  24.46 ± 1.09 
*  0.65    3.17 ± 0.36  0.04 
** 
  5  25 
OVX  24.71  ±  1.06 
+, 
++ 
  3.57 ±0.68    6  30 
H  CON  23.67 ± 1.26  0.88    3.60 ± 0.31  0.31    4  20 
OVX  23.78 ± 1.48    3.84 ± 0.72    7  35 
LT  CON  23.29 ± 0.95  0.76    3.86 ± 0.61  0.34    5  25 
OVX  23.40 ± 1.68    3.96 ± 0.61    5  25 
Pooled 
data 
 
CON  23.80 ± 1.20   
0.65 
  3.54 ± 0.53   
0.10 
  5  70 
OVX  24.0 ± 1.49    3.78 ± 0.74    7  90 
 
3.3.3  Does Oestrogen Deficiency Alter the Spatial Distribution of Mineral within 
Trabeculae? 
For  both  CON  and  OVX  groups,  the  highest  mineral  content  was  in  the  core  of 
trabeculae with a lower calcium content measured in the outermost surface (superficial 
region), see Figure 3.4. For bone tissue from the lesser trochanter of CON animals, 
calcium content was significantly higher in the deep region of trabeculae compared to 
the superficial region (p=0.01). In the OVX group, calcium content was significantly 
higher in the deep region compared to superficial region for all three femoral regions; 
the greater trochanter (p<0.01), head (p<0.01) and lesser trochanter (p<0.01). In OVX 
animals, calcium content was higher in intermediate ROIs compared to superficial ROIs 
in the head region (p<0.02). These data are presented in Table 3.2. The % difference of 
calcium content between the deep and superficial regions was statistically higher in the 
OVX group compared to CON in the proximal femur when data from all regions were 
pooled  (p<0.04).  When  regions  were  analysed  separately,  these  differences  were 
detected in the head region (p<0.05), but not in the greater or lesser trochanters, see 
Figure 3.5.           
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Figure 3.4 Spatial distribution of calcium between superficial, intermediate and deep 
ROIs, in the greater (GT), head (H) and lesser trochanter (LT) regions of the proximal 
femora of control sheep (CON, n=5) and ovariectomised sheep (OVX=7). * indicates 
statistical significance between trabecular regions under horizontal brackets (p ≤ 0.02).  
 
Table 3.2: Spatial distribution within trabeculae from the greater trochanter (GT), head 
(H) and lesser trochanter (LT) regions of control (CON) and ovariectomized (OVX) 
sheep.  Wt  %  Ca  from  the  superficial  (S),  intermediate  (I)  and  deep  (D)  trabecular 
regions is compared between groups. Data is presented as mean ± standard deviation. * 
indicates significant difference (p<0.05) 
 
    S  I  D  Pairwise 
comparison   
n 
S - D  S - I  Sheep  Trabeculae 
GT  CON  24.56 ± 1.70  24.70 ± 1.65  25.16 ± 1.68  0.07  0.86  5  25 
OVX  24.45 ± 1.47  24.94 ± 0.96  25.35 ± 1.04  0.01*  0.06  6  30 
H  CON  23.50 ± 1.36  23.81 ± 1.32  24.18 ± 1.35  0.16  0.67  4  20 
OVX  23.31 ± 1.64  24.05 ± 1.60  24.51 ± 1.50  0.01*  0.02*  7  35 
LT  CON  22.67 ± 1.36  23.25 ± 1.04  23.47 ±0.99  0.01*  0.09  5  25 
OVX  22.52±2.17  23.32±1.77  23.86 ± 1.75  0.01*  0.13  5  25          
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Figure  3.5  Comparisons  between  CON  (n=5)  and  OVX  (n=7)  groups  for  the  % 
difference between superficial and deep regions of trabeculae in the greater trochanter 
(GT), lesser trochanter  (LT) and head (H) regions  of proximal femora.  Increased % 
difference by the OVX group was significant in the head region (p<0.05). * indicates 
significance between groups.  
 
3.3.4  Does  Oestrogen  Deficiency  Alter  the  Mineral  Distribution  across 
Anatomical Locations?  
Significant differences in  Ca  were found across anatomical regions of the femur in both 
CON and OVX groups. In the CON group,  Ca  was significantly higher in bone tissue 
from the greater trochanter compared to the lesser trochanter (p<0.01). In OVX sheep, 
Ca  in  the  greater  trochanter  region  was  significantly  higher  than  that  of  the  lesser 
trochanter (p<0.01) and head (p<0.02) regions, see Figure 3.6. 
Inter-trabecular  variation:  The  standard  deviation  (σ)  of  mineralisation  between 
trabeculae  of  the  lesser  trochanter  was  significantly  higher  than  that  of  the  greater 
trochanter  in  the  OVX  group  (1.36  ±  1.13  vs.  0.36  ±  0.29,  p<0.05).  Similarly,  the 
coefficient of variation (cv) was higher in the lesser trochanter compared to the greater 
trochanter  (0.06  ±  0.05  vs.  0.01  ±  0.01,  p<  0.05).  No  significant  difference  existed 
between the two regions in the CON group. 
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Inter-group  variation:  The  %  difference  in  mean  mineral  content  ( Ca  )  between 
anatomical regions (greater and lesser trochanter) was not significantly different when 
comparing CON and OVX groups (p<0.42), see Figure 3.7. The % difference in the 
standard  deviation  ( )  of  trabecular  mean  mineral  content  between  the  greater  and 
lesser trochanters was statistically higher for OVX compared to CON (77.11 ± 11.70 vs. 
45.64 ± 23.70, p<0.03). The % difference in coefficient of variation ( v c ) between the 
greater and lesser trochanters was also statistically higher for OVX compared to CON 
(77.77 ± 11.16 vs. 48.16 ± 24.80, p< 0.04).  
 
 
Figure 3.6 Comparison of mean calcium content (wt % Ca) between anatomical regions 
within  the  proximal  femur  of  CON  (n=5)  and  OVX  (n=7)  sheep.*  and  **  signify 
statistical  difference  between  femoral  regions  indicated  by  the  horizontal  brackets, 
(p<0.01, and p≤0.02) respectively. 
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Figure  3.7  Comparisons  between  CON  (n=5)  and  OVX  (n=7)  groups  for  the  % 
difference of trabecular mineralisation between the greater and lesser trochanters. The 
differences  were  significant  (p<0.05)  for  standard  deviation  (σ)  and  coefficient  of 
variation (cυ). The % difference in mean calcium content  Ca   was not significantly 
different. * indicates statistical significance between groups.                                                
                                                                                                                                                   
3.4.  Discussion 
This study provides direct evidence that oestrogen deficiency alters the distribution of 
bone  tissue  mineral  compared  to  healthy  controls,  both  on  the  trabecular  level,  and 
across anatomical locations. Although bone tissue mineral distribution is heterogeneous 
in healthy bone, the current study reveals that this heterogeneity is significantly more 
pronounced in oestrogen deficient animals. Increases in heterogeneity within trabeculae 
were  site  specific,  occurring  in  the  greater  trochanter,  whereas  the  %  difference  in 
mineral content between superficial and deep region was significantly increased in the 
femoral head. Finally, regional differences in the variability ( , v c ) of mineral content 
between the greater and lesser trochanters were significantly more pronounced during 
oestrogen deficiency.  
It should be noted that there were some limitations associated with this study. Firstly, 
ovariectomy, or removal of the ovaries, was used as a model of osteoporosis which 
causes  dramatic  lowering  of  circulating  oestrogen  levels  (see  Appendix  2),  whereas 
during the menopause the cessation of the ovary functions is a more gradual process. 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Mean  SD  COV 
 
%
 
D
i
f
f
e
r
e
n
c
e
 
CON 
OVX 
*  *          
 
51 
 
Plasma  oestrogen  levels  during  the  menstrual  cycle  of  females  of  reproductive  age 
ranges from 50-200 pg/mL (Longcope and Pratt, 1978), levels for females from 42 years 
of age ranges from 60-80 pg/mL (Randolph et al., 2004), and levels for postmenopausal 
women  are  less  than  40  pg/mL  (Randolph  et  al.,  2004).  However,  sheep  plasma 
oestrogen levels for control animals are in the range of 2pg/mL, which are rather less 
than  human  oestrogen  concentrations  prior  to  the  menopause.  Nevertheless,  the 
ovariectomised sheep model has been an accepted means of assessing the effects of 
osteoporosis on bone tissue in many previous studies (Chavassieux et al., 2001; Turner 
et  al.,1995a;  Turner  et  al.,  1995b)  and  has  shown  to  experience  bone  loss  during 
oestrogen deficiency similar to humans (Turner et al., 1995a). Secondly, ewes, unlike 
humans, have twenty oestrous cycles and experience a short period (1-2 months) of 
oestrogen  deficiency  annually  (Newton  et  al.,  2004).  Therefore,  while  comparisons 
between each sheep group can provide an insight into the role of oestrogen deficiency in 
bone mineralisation, the limitations in  the animal  model should be considered  when 
making comparisons with human tissue. It must be noted however that calcium content 
values that were measured in sheep bone tissue (22-26%) are comparable with ranges 
reported from control (18-28%) and osteoporotic human bone tissue (16-26%) (Gupta et 
al., 2005; Roschger et al., 1998; Roschger et al., 2001).  
Five trabeculae from each of the three skeletal sites of each sheep were used for analysis 
and selection may have been biased towards larger trabeculae due to limited availability 
and  the  difficulties  associated  with  excising  them  for  analysis.  Furthermore,  as  the 
preparation  method  is  destructive,  it  was  not  possible  to  track  changes  in  specific 
trabecular  regions  over  the  course  of  time.  Therefore,  the  intermediate  region  of 
trabeculae from OVX bone might not correspond to the intermediate region that existed 
prior to increased surface remodelling characteristic of oestrogen deficiency. However, 
our analysis method enabled selection of equidistant regions relative to the diameter of 
each  trabecula,  rather  than  setting  a  predefined  distance  for  intermediate  and  deep 
regions, ensuring that the chosen region was indeed the intermediate layer of the newly 
remodelled OVX trabeculae. It is expected that differences in tissue heterogeneity would 
be more pronounced with larger sample sizes and in human osteoporotic bone compared 
to healthy subjects that do not experience an oestrogen deficient period. Finally, there 
are important limitations associated with the method to calculate wt % Ca from grey 
level intensities acquired from qBEI images that should be noted. Although carbon and 
aluminium have been employed extensively as calibration standards for qBEI on bone          
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samples (Grabner et al., 2001; Misof et al., 2003; Roschger et al., 1998; Sutton-Smith et 
al., 2008) channelling contrast can occur due to their crystalline nature. Two approaches 
were  used  to  reduce  this  effect;  (i)  the  angle  of  electron  beam  incidence  was  kept 
constant  throughout  all  experiments  and  (ii)  mechanically  polished  carbon  and 
aluminium were used as standards to reduce the contrast channelling effect (Finch, 1936; 
Reimer,  1998).  The  method  to  calculate  wt  %  Ca  from  grey  level  intensities  was 
developed by calibrating backscattered images using quantitative energy dispersive x-
ray (EDX) analysis (Roschger et al., 1998). Although this method has been employed 
extensively to relate grey levels to calcium content of bone tissue (Busse et al., 2009; 
Gupta et al., 2005; Misof et al., 2003; Seitz et al., 2010; Sutton-Smith et al., 2008; 
Vajda, 1996), Monte Carlo simulations of electron trajectories have shown that the 3D 
x-ray  production  volume  for  calcium  greatly  exceeds  the  excitation  volume  of 
backscattered electrons (Howell and Boyde, 2003). Furthermore, there is evidence that 
EDX-standardized BSE images tend to give a lower mineral content value of bone than 
when measured with traditional ash measurements (Vajda et al., 1998). However, an 
identical approach was used to compare both CON and OVX groups and, as such, these 
limitations  are  expected  to  influence  each  group  equally.  Therefore,  the  relative 
differences observed between groups are believed to be an accurate representation of 
tissue level changes as a result of oestrogen deficiency. Alternative analysis techniques 
such as synchrotron µCT could be used in future to assess mineral distribution ex vivo 
within  bone  tissue  in  3D,  overcoming  the  challenges  of  sample  size  and  tissue 
preparation (Nuzzo et al., 2002). 
It is interesting that no differences were detected from the pooled mean mineralisation 
data of all trabeculae from all regions of normal and OVX tissue. This is consistent with 
previous studies, which found no difference in the mineral content of osteoporotic bone 
compared to control (Bohic et al., 2000; Ciarelli et al., 2003; Loveridge et al., 2004; 
Rohanizadeh  et  al.,  2000).  Increased  mineral  heterogeneity  within  trabeculae  during 
oestrogen deficiency is in agreement with other studies (Busse et al., 2009; Roschger et 
al., 2001). Our results reveal, for the first time, that changes in mineral heterogeneity in 
the femur during oestrogen deficiency are dependent on anatomical location. In addition, 
this  study  shows  that  oestrogen  deficiency  results  in  a  higher  variability  of  mineral 
distribution between regions of the proximal femora and also causes specific alterations 
in  the  spatial  distribution  of  mineral  between  trabecular  regions.  These  findings 
corresponded  to  no  changes  in  the  mean  calcium  content  of  trabeculae,  or  the  %          
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difference  of  mean  calcium  content  between  anatomical  locations  during  oestrogen 
deficiency, highlighting that such important effects of oestrogen deficiency on mineral 
distribution may be undetectable by studies focusing solely on mean mineral content of 
bone tissue during oestrogen deficiency (Bohic et al., 2000; Boyde et al., 1998; Ciarelli 
et  al., 2003; Dickenson  et  al.,  1981;  Gadeleta  et  al.,  2000; McNamara  et  al., 2006; 
Rohanizadeh et al., 2000). 
The spatial distribution of mineral within trabeculae from control bone tissue was as 
expected; these trabeculae had a more mineralised core, as this tissue was older and 
secondary mineralisation had persisted for longer (Grynpas, 1993), whereas the surface 
regions are more frequently renewed and would be less mineralised (Ciarelli et al., 2003; 
Gadeleta  et  al.,  2000).  It  is  interesting  that  oestrogen  deficiency  altered  the  spatial 
distribution of calcium within trabeculae in the proximal femur, specifically by means of 
a  greater  difference  in  mineralisation  between  the  superficial  and  deep  regions  of 
trabeculae  from  the  head  region.  This  might  be  attributed  to  increased  surface 
remodelling characteristic of osteoporosis (i.e. higher turnover rates) which results in the 
formation  of  new  superficial  tissue  (Parfitt  et  al.,  1983).  As  such,  increased 
heterogeneity may be a transient characteristic, and the normal heterogeneity might be 
restored by complete mineralisation of new bone over time. In addition, since osteocytes 
possess  oestrogen  receptors  (Batra  et  al.,  2003);  direct  modulation  of  osteocyte 
secondary mineralisation might occur when levels of circulating oestrogen are deficient. 
It  is  known  that  osteocyte  apoptosis  is  up-regulated  during  oestrogen  withdrawal 
(Kousteni et al., 2001; Tomkinson et al., 1997) and, as such, infilling of the remaining 
cavities,  known  as  micropetrosis  (Boyde,  2003;  Frost,  1960;  Kingsmill  and  Boyde, 
1998),  might  occur.  The  studies  outlined  in  Chapter  5  and  6  are  thus  conducted  to 
delineate if these mechanisms contribute to the differences observed in the current study.  
The precise implications of differences in mineralisation between trabecular regions, on 
the  mechanical  properties  of  oestrogen  deficient  bone  are  unknown.  Assuming 
previously published relationships between calcium content and ash fraction (Vajda et 
al., 1998) and between ash fraction and mechanical strength (Hernandez et al., 2001), an 
increase as small as 0.5% (wt % Ca) between trabecular regions would equate to an 
increase in strength of 4.5% between the regions. A greater concentration of calcium in 
the deep regions with a lower concentration of mineral in the superficial regions would 
be beneficial under bending loads, whereby the superficial regions would be capable of 
withstanding  greater  strain  without  fracture,  thereby  protecting  the  whole  trabeculae          
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from fracture. However, it is also likely that there is a critical level for differences in 
mineralisation  between  regions,  and  beyond  such  a  level,  these  differences  become 
detrimental to the mechanical integrity of the trabeculae. Alternatively, these alterations 
in spatial distribution of mineral may be a compensatory mechanism following bone loss 
during oestrogen withdrawal. Further experiments are required to delineate this problem.  
The site specific nature of increased mineral heterogeneity may occur as a result of local 
changes in bone remodelling activity or mechanical loading during oestrogen deficiency. 
While previous studies on the same sheep cohort have reported variations in trabecular 
micro-architecture  between  anatomical  regions  of  the  vertebrae  of  healthy  sheep 
(Kennedy  et  al., 2009c), site-specific changes  in bone remodelling activity or tissue 
micro-architecture  of  OVX  sheep  were  not  identified  (Kennedy,  2007).  However,  a 
previous study has demonstrated site specific variations in bone loss and remodelling 
activity in  ovariectomised rats; while bone loss was  significant  in  the diaphysis and 
metaphysic, the epiphysis appeared to be immune to bone loss and the time course of 
remodelling activity varied considerably between regions (Baldock et al., 1998). One 
other study reported that oestrogen deficiency amplifies the variability of mineralisation 
in  alveolar bone of the jaw, and that this  is likely due to alterations  in  active bone 
remodelling  in  response to  forces  generated during mastication  (Ames  et  al., 2010). 
These observations suggest that the alterations in mineral heterogeneity observed in the 
current study may occur as a result of changes in local factors, such as cellular activity 
and mechanical loading during oestrogen deficiency. The studies outlined in Chapter 5 
and 6 will investigate these factors further. These findings also highlight the fact that it is 
imperative to assess bone tissue from different regions when evaluating the effects of 
oestrogen deficiency on trabecular bone.  
It is well established that low bone mass and micro-architectural deterioration occur 
during oestrogen deficiency and are primarily responsible for the reduced bone strength 
and increased fracture risk, characteristic of osteoporosis. As bone mineral content is a 
determinant of bone strength (Currey, 1984b; Ruffoni et al., 2007), alterations in tissue 
mineral distribution within trabeculae and across anatomical locations, might also be 
indicative of reduced mechanical integrity. Indeed, previous computational studies have 
predicted that increased heterogeneity within trabeculae results in significantly increased 
stiffness  (Van der Linden et al., 2001), and adaptive modelling will likely occur leading 
to trabecular thinning, bone loss and trabecular perforation (Mulvihill et al., 2008; Van 
der Linden et al., 2004). Increased heterogeneity between skeletal sites may indicate          
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zones of the bone that are more affected by oestrogen deficiency and therefore represent 
weak points. In fact, computational studies have predicted that regions of bone that have 
more heterogeneous material properties are at an increased risk of fracture (Hernandez, 
2008; Jaasma et al., 2002; Renders et al., 2008). It is most interesting that significant 
alterations  in  tissue mineral  distribution occurred between the greater trochanter and 
lesser trochanter (% difference   and  v c ), which is coincident with the most common 
osteoporotic fracture site known as the inter-trochanteric fracture line. Taken together 
with our results, it is proposed that alterations in tissue mineral distribution may be a 
contributing factor for weakened bone at increased risk of fracture, at this site during 
osteoporosis.  
3.5.  Conclusion 
This  study  provides  evidence  that  the  distribution  of  tissue-level  mineral  is  altered 
during osteoporosis, which may alter tissue-level mechanics. In particular, our results 
suggest  that  these  changes  are  anatomically  distinct  and  do  not  occur  ubiquitously 
throughout the proximal femur. These findings highlight the fact that methods evaluating 
the mean mineral content of bone tissue are insufficient to detect oestrogens impact on 
tissue mineral distribution and also indicate that local factors might have a significant 
impact on bone tissue during oestrogen depletion. Furthermore, in addition to the well 
established  changes  in  bone  mass  and  architecture  during  oestrogen  deficiency, 
alterations in tissue mineral distribution in ovariectomised animals may be a contributing 
factor  for  reduced  mechanical  strength.  Heterogeneous  regions  may  be  indicative  of 
weakened  zones  at  both  the  trabecular  and  anatomical  levels  that  contribute  to  a 
reduction in  mechanical strength, and render osteoporotic bones more susceptible to 
fracture.  Therefore,  these  findings  are  of  potential  importance  in  understanding  the 
underlying  mechanisms  of  altered  mechanics  during  osteoporosis.  Whether  these 
findings are a transient effect of oestrogen deficiency or whether they are sustained with 
prolonged oestrogen deficiency has not yet been evaluated. In addition, since this study 
indicates  that  altered  mineral  distribution  may  contribute  to  increased  fracture  risk 
during oestrogen deficiency; it is interesting to postulate that the beneficial effects of 
bisphosphonates may lie in the ability of these drugs to normalise the tissue mineral 
distributions back to that of controls. These questions will, therefore, be investigated in 
Chapter 4. In Chapters 5 and 6, whether changes in bone cell activities as a direct effect 
of  oestrogen  withdrawal  are  responsible  for  the  tissue-level  alterations  in  mineral 
concentration that were observed in this Chapter will be examined.           
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4.  Effects of Ageing, Prolonged Oestrogen 
Deficiency and Zoledronate on Bone Tissue 
Mineral Distribution  
4.1.  Introduction 
One of several bone quality characteristics known to govern the mechanical strength of 
bone is  the quantity of  mineral, together with  its  distribution within the  bone tissue 
matrix  (Currey,  1984b;  Follet  et  al.,  2004).  The  degree  of  bone  mineralisation  is 
influenced by the frequency of bone remodelling and mineral deposition rates. Increases 
in the degree of bone tissue mineralisation have been shown to be associated with a 
significant enhancement of overall bone strength (Vose and Kubala, 1959). However, 
beyond approximately 66% mineralisation, further elevations in mineral content lead to 
brittleness and decreased bone mechanical strength (Bonfield and Clark, 1973; Currey, 
1969).  Although  bone  mineral  content  is  generally  believed  to  increase  with  ageing 
(Currey  et  al., 1996;  Reid  and Boyde, 1987;  Vajda and Bloebaum,  1999), there are 
conflicting  observations  of  altered  bone  mineralisation  as  a  consequence  of  ageing. 
Studies  on  healthy  human  bone  which  found  increased  mineralisation  with  ageing 
(Currey et al., 1996; Reid and Boyde, 1987; Vajda and Bloebaum, 1999), indicate a 
material level alteration in tissue properties with ageing, whilst others that demonstrate 
no correlation (Roschger et al., 1998; Roschger et al., 2003) (Bloebaum et al., 2004; 
Boivin and Meunier, 2002), signifying that changes in healthy bone over time are purely 
structural and that the material that constitutes the volume of bone remains relatively 
unchanged. 
Oestrogen deficiency, occurring following the menopause, has been established as the 
primary causative factor in postmenopausal osteoporosis. A marked increase in bone 
turnover rates occurs during osteoporosis (Balena et al., 1993) and leads to low bone 
mass  and  strength,  depleted  bone  architecture,  and  increased  risk  of  fractures 
(Cummings  and  Melton,  2002).  Previous  studies  quantifying  trabecular  bone 
mineralisation  have  found  increases  (Boyde  et  al.,  1998;  McNamara  et  al.,  2006), 
decreases  (Gadeleta  et  al., 2000; Yao  et al., 2006; Yao et al., 2007), or only slight 
alterations in mineral content (Bohic et al., 2000; Brennan et al., 2011; Ciarelli et al., 
2003;  Rohanizadeh  et  al.,  2000)  as  a  consequence  of  oestrogen  deficiency.  These 
discrepancies  may  be  explained  by  the  duration  of  oestrogen  depletion  under 
investigation,  as  it  has  been  shown  that  after  the  onset  of  oestrogen  deficiency,          
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biological and structural alterations occur immediately, but these responses wane over 
time (Binkley et al., 1998; Smith et al., 2003). Bone mass deterioration and increases in 
bone  turnover  markers  have  been  shown  to  stabilize  at  about  nine  months  post 
ovariectomy  in  monkeys  (Binkley  et  al.,  1998).  A  further  study  on  ovariectomised 
monkeys noted a rapid phase of bone loss lasting approximately 8-12 months following 
ovariectomy,  and  by  16  months  post-ovariectomy,  a  trend  toward  normalization  of 
markers and stabilization of bone mass was observed (Smith et al., 2003). However, the 
impact of such time dependent changes in remodelling and bone mass on bone tissue 
mineralisation has not been elucidated. In chapter 3, increased mineral heterogeneity 
within  trabeculae,  as  well  as  alterations  in  mineral  distribution  along  the  inter-
trochanteric  fracture  line  in  the  proximal  femur  of  sheep  following  12  months  of 
oestrogen deficiency was demonstrated. However, whether these changes are sustained 
with prolonged oestrogen deficiency is unknown.  
Presently  biphosphonates  are  the  most  widely  used  pharmaceutical  used  to  treat 
osteoporosis. Bisphosphonates act to inhibit bone resorption by selective absorption to 
bone mineral surfaces and subsequent internalization by osteoclasts, where they interfere 
with osteoclast function. They reduce bone turnover by decreasing activation frequency 
and markers of bone remodelling and thereby prolong the secondary mineralisation of 
bone (Balena et al., 1993). Bisphosphonate treatment has been shown to increase bone 
mineral density (BMD), mechanical strength and reduce the incidence of bone fractures 
(Balena et al., 1993; Black et al., 1996; McClung et al., 2001). Zoledronic acid is a third 
generation,  nitrogen  containing  bisphosphonate  (NBP)  (Green  et  al.,  1994).  NBPs 
perturb  the  cytoskeleton  necessary  for  maintaining  the  ruffled  border  that  facilitates 
osteoclastic  bone  resorption  (Rodan  and  Reszka,  2002).  In  animal  models  of 
osteoporosis, Zoledronic acid has been shown to prevent bone loss and increases bone 
mineral density and trabecular bone volume (Glatt, 2001; Pozzi et al., 2009). Zoledronic 
acid suppresses bone resorption and increases bone mineral density (Leal et al., 2010; 
Reid et al., 2002) and has been shown to inhibit fractures of the vertebrae and the hip in 
clinical trials on postmenopausal women (Black et al., 2007). It has been postulated that 
the small increases in BMD (3-8%) with bisphosphonate treatment (Riggs and Melton, 
2002; Yao et al., 2007), can only explain a small portion of the significant reduction in 
the incidence of bone fractures observed with this drug treatment (Liberman et al., 1995; 
Riggs  and  Melton,  2002).  Therefore,  it  is  likely  that  other  changes  in  the  tissue 
composition  might  also  occur.  Whether  bisphosphonate  treatment  counteracts  the          
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increased mineral heterogeneity occurring during oestrogen deficiency (Brennan et al., 
2011), thus contributing to reduced fracture incidence, has yet to be delineated. In this 
study,  quantitative backscattered imaging (qBEI)  was used to  quantify  bone mineral 
density  distributions  (BMDD)  within  trabeculae  from  proximal  femora  of  an  ovine 
model  of  osteoporosis  that  underwent  oestrogen  deficiency  for  31  months,  an 
ovariectomised  group  administered  with  Zoledronic  acid  and  aged-matched  controls. 
The hypothesis that bone tissue mineralisation is altered during normal ageing and over 
the  course  of  prolonged  oestrogen  deficiency  will  be  tested  by  comparing  BMDD 
parameters  with  previously  reported  data  from  sheep  that  underwent  oestrogen 
deficiency  for  the  shorter  duration  of  12  months  (n=7)  and  their  aged  matched 
counterparts (n=5) (Brennan et al., 2011). Furthermore, the effects of Zoledronic Acid 
treatment  on  BMDD  parameters  and  site  specific  mineral  distribution  within  the 
proximal femur will be assessed.  
4.2.  Materials and Methods 
4.2.1  Bone Samples 
Bone tissue originated from the ovine osteoporosis model described in Chapter 3. Unlike 
the OVX and CON sheep sacrificed after 12 months for the study presented in Chapter 
3, the bone tissue examined in this chapter originated from OVX and age-matched CON 
sheep  that  were  maintained  for  a  further  19  months.  In  addition,  20  months  post-
ovariectomy,  four  OVX  animals  were  randomly  assigned  to  a  Zoledronic  acid 
(NovartisPharma, Switzerland) treated group (ZOL). Each animal received a 5mg dose 
of ZOL in 100 ml of saline infused over 30 minutes via an indwelling jugular catheter 
per  week  for  5  weeks.  Animals  were  sacrificed  at  31  months  post-ovariectomy  and 
bones were harvested and frozen at -20
oC. 15 individual trabeculae (5 from each of the 
three proximal femora regions - greater trochanter, lesser trochanter and femoral head) 
were excised from each animal in the CON (n=5), OVX (n=5) and ZOL (n=4) groups.  
Bone  trabeculae  were  prepared  as  described  in  chapter  3,  by  embedding  in  PMMA 
blocks, surface polishing and finally coating the surface with a thin layer of carbon. 
4.2.2  Quantitative Backscattered Electron Imaging (qBEI) 
The bone mineral density distribution (BMDD) of each trabeculae was determined from 
quantitative  backscattered  images  (qBEI)  of  the  cross  section  through  trabeculae,  as 
published  previously  (Brennan  et  al.,  2011)  and  described  in  Chapter  3.  Briefly,  a 
Scanning Electron Microscope (JSM 5910, JEOL, Welwyn Garden City, U.K.) fitted          
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with a backscattered detector was operated at an electron acceleration voltage of 15kV 
and a beam current of 1.2nA. Backscattered images were acquired with samples at a 
fixed  working  distance  (12mm)  and  magnification  (200x).  Pixel  resolution  was 
0.66µm/pixel and images comprised pixel dimensions of 1280 x 901. The grey level 
scale range was calibrated using pure carbon and aluminium standards (Agar Scientific, 
Stansted, U.K.). Bone mineral density distribution (BMDD) parameters including the 
mean calcium concentration ( Ca  ), the median, the peak height, and the full width at 
half maximum (FWHM), as well as the spatial distribution of the mean wt % Ca in the 
superficial, intermediate, and deep regions of interest (ROI) within trabeculae, and the 
percentage difference in wt % Ca between ROI, were quantified as detailed in Chapter 3 
and were compared between OVX, ZOL and CON groups. 
4.2.3  Statistical Analysis 
General linear model (GLM) ANOVA’s were applied to statistically analyse BMDD and 
spatial  distribution  parameters  between  groups.  A  p  value  of  ≤0.05  was  considered 
statistically  significant.  The  difference  in  BMDD  parameters;  the  mean  calcium 
concentration ( Ca  ), median, FWHM, and peak height, was evaluated between groups 
by comparing pooled measurements (i.e. combined data from all femora regions), in 
addition to comparing data from distinct regions (greater trochanter, head and lesser 
trochanter). To evaluate the effects of  ageing, parameters of  BMDD  were  compared 
between  CON  sheep  cohorts  that  were  sacrificed  12  months  following  experiment 
initiation  (n=5)  with  those  at  31  months  (n=5).  Similarly,  the  effects  of  prolonged 
oestrogen deficiency were assessed by comparing sheep that were oestrogen deficient 
for 12 months (n=7) with sheep that were oestrogen deficient for the longer duration of 
31  months  (n=5).  To  evaluate  the  effects  of  oestrogen  deficiency  and  Zoledronate 
treatment in the 31 month cohort, mineralisation parameters of OVX, ZOL and CON 
groups were compared within femoral regions (intra) and also regions (intra-regional) 
were compared within sheep groups. The spatial distribution of mineral within (intra) 
trabeculae; superficial, intermediate and deep mineral concentration, as well as the % 
difference between superficial and deep regions, was compared between sheep cohorts. 
The  spatial  distribution  between  (inter)  trabeculae  was  also  compared  within  sheep 
groups. In the GLM, age and osteoporosis status (OVX, ZOL, and CON) were fixed 
factors.  Sheep  were  defined  as  random  factors  nested  within  OVX,  ZOL,  or  CON 
groups, while femora regions and trabecular regions were fixed factors, with trabeculae          
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nested  within  the  sheep  from  which  they  arose.  Tukey’s  method  for  pair  wise 
comparisons, with a family error rate of 0.05, was employed to determine statistical 
differences between distinct anatomical locations within femora and between trabecular 
regions.  One-way  ANOVAs  were  used  to  compare  regional  %  differences  between 
sheep groups.  
4.3.  Results 
4.3.1  Effects of Ageing on Bone Mineralization  
When data was pooled from all regions within the proximal femur, see Figure 4.1, the 
peak height of wt % Ca distributions was significantly lower in the 31 month control 
group compared to the 12 month control cohort (4.57 ± 0.64 vs. 4.24 ± 0.65, p<0.04), 
whereas the FWHM was significantly higher (3.54 ± 0.53 vs. 3.84 ± 0.68, p<0.03) with 
ageing.  When  femoral  regions  were analysed separately, in the greater  trochanter of 
control proximal femora, significantly lower peak height of the distributions (5.02 ± 0.56 
vs. 4.26 ± 0.61, p<0.01), together with higher FWHM (3.17 ± 0.36 vs. 3.84 vs. 0.60, 
p<0.01) were found in the 31 month control group compared to the 12 month control 
group. In the lesser trochanter region, significantly higher mean wt % Ca (23.29 ± 0.95 
vs. 24.67 ± 1.20, p<0.01) were observed in the 31 month control group compared to the 
12 month controls, as signified in Figure 4.2. No difference in mean wt % Ca existed 
with ageing in the Head region. 
4.3.2  Effects of Prolonged Oestrogen Deficiency on Bone Mineralization  
When sheep that were oestrogen deficient for 12 months were compared with a group 
that were oestrogen deficient for 31 months, an apparent lower mean wt % Ca was found 
in the 31 month group when data was pooled from all regions within the proximal femur 
(24.02 ± 1.49 vs. 23.26 ± 1.86, p<0.07), as indicated by Figure 4.1, although this was not 
statistically significant.  However, when mineral distributions within discrete regions of 
OVX  femora  were  compared,  the  duration  of  oestrogen  deficiency  significantly 
impacted mineralisation. In the greater trochanter region, significantly lower mean wt % 
Ca was observed in the 31 month group compared to the 12 month group (24.71 ± 1.06 
vs. 22.86 ± 1.03, p<0.01), see Figure 4.2. Furthermore, the peak of the distribution was 
significantly lower (4.76 ± 0.98 vs. 3.84 ±0.38, p<0.01), and conversely the FWHM 
higher (3.57 ± 0.68 vs. 4.29 ± 0.48, p<0.01) in sheep that were oestrogen deficient for 31 
months compared to those that were oestrogen deficient for 12 months, as indicated in          
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Table 4.1. No significant difference in mineral distribution parameters was found in the 
head or lesser trochanter regions.  
 
Figure 4.1 Effect of normal ageing: presented as 12 month CON sheep (n=5) compared 
to 31 month CON sheep (n=5), and prolonged oestrogen deficiency: presented as 12 
month OVX (n=7) compared to 31 month OVX (n=5), on mean mineralisation (wt % 
Ca) when data from all regions of the proximal femur was pooled. * indicates OVX at 31 
months is significantly  lower compared to age matched controls   
 
Figure 4.2  Effect of ageing (CON) and prolonged oestrogen deficiency (OVX) on mean 
mineralisation (wt % Ca) in the greater trochanter (GT), head (H), and lesser trochanter 
(LT) regions of the proximal femur. ^ indicates significant differences between 12 and 
31 months of the same region, * indicates significantly lower than age-matched controls 
in  GT.  See  Table  4.1  for  sample  sizes  with  respective  proximal  femoral  regions 
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4.3.3  Effect of Oestrogen Deficiency on Mineralisation of Femoral Regions   
Intra-regional: Comparing OVX with CON at 31 months,  when  BMMD data from 
trabeculae in all three regions of the proximal femur was pooled, there was significantly 
lower mean wt % Ca (23.26 ± 1.86 vs. 24.43 ± 1.16, p<0.01) in OVX animals compared 
to CON, as indicated in Figure 4.1. When trabeculae were analysed within each region, 
as  depicted in Figure 4.2, significantly lower mean (22.86 ±  1.03 vs.  24.58 ±  1.18, 
p<0.02) and peak (3.84 ± 0.38 vs. 4.26 ± 0.61, p<0.04) values were found in the greater 
trochanter of OVX compared to CON. No significant difference in BMDD parameters 
existed between groups in the Head or Lesser Trochanter regions.  
Inter-regional: In CON sheep, the FHWM of the lesser trochanter was significantly 
lower than that of the head region (3.63 ± 0.58 vs. 4.09 ± 0.79, p<0.03). In the OVX 
group, at 31 months, the peak height of the BMDD histogram was significantly higher in 
the head region compared to the greater trochanter (4.65 ± 0.83 vs. 3.84 ± 0.38, p<0.01), 
and conversely the FWHM was significantly lower in the head region compared to the 
greater trochanter (3.49 ± 0.61 vs. 4.29 ± 0.48, p<0.01), see Table 4.1.  
The  %  difference  in  mean  mineralisation  between  regions  of  the  proximal  femur  is 
presented in Figure 4.3. OVX showed significantly higher mineral variability between 
the greater trochanter and head regions compared to control sheep (8.75 ± 5.18 vs. 3.96 ± 
3.19, p<0.05). Similarly, the % difference between the lesser trochanter and the head 
region was significantly more in OVX compared to CON (13.48 ± 5.94 vs. 4.77 ± 4.23, 
p<0.02).         
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Table 4.1: BMDD parameters of oestrogen deficient (OVX), age-matched controls (CON), and Zoledronate treated sheep (ZOL). Results are presented 
as Mean ± SD. Values sharing a letter are significantly different to each other. p values; a<0.02, b<0.04, c<0.03, d-f <0.01  
  Mean    Median    Peak    FWHM    n 
    Sheep   Trabeculae 
Greater Trochanter                     
    OVX  22.86 ± 1.03  a  23.06 ± 1.15    3.84 ± 0.38  b f  4.29 ± 0.48   d  5    25 
    ZOL  23.46 ± 0.30    23.57 ± 0.48    4.04 ± 0.43    3.96 ± 0.45    4    20 
    CON  24.58 ± 1.18  a  24.80 ± 1.36    4.26 ± 0.61  b  3.84 ± 0.60    5    25 
Head                     
    OVX  23.02 ± 2.31    23.21 ± 2.47    4.65 ± 0.83  f  3.49 ± 0.61  d  5    25 
    ZOL  23.65 ± 1.93    23.84 ± 2.08    4.32 ± 0.70    3.79 ± 0.60      4    20 
    CON  23.92 ± 0.95    24.32 ± 1.07    4.04 ±0.71    4.09 ± 0.79  c  4    20 
Lesser Trochanter                   
    OVX  23.91 ± 2.00    24.20 ± 2.23    4.23 ± 0.89    3.96 ± 0.88    5    25 
    ZOL  23.20 ± 0.78    23.32 ± 0.85    4.19 ± 0.41    3.63 ± 0.44    4    20 
    CON  24.67 ± 1.20    24.90 ± 1.35    4.38 ± 0.63    3.63 ± 0.58  c  5    25 
Pooled regional data                   
    OVX  23.26 ± 1.86  e  23.49 ± 2.03    4.22 ± 0.79    3.94 ± 0.74    5    75 
    ZOL  23.60 ± 1.30    23.80 ± 1.42    4.24 ± 0.54    3.79 ± 0.51    4    60 
    CON  24.43 ± 1.16  e   24.70 ± 1.28    4.24 ± 0.65    3.84 ± 0.68    5    70          
 
64 
 
4.3.4  Zoledronic  Acid  Reduces  the  Variability  of  Mineral  between  Anatomical 
Locations 
Intra-regional: Comparing ZOL with OVX at 31 months, no statistical difference was 
found  when  trabeculae  from  all  regions  were  pooled,  or  evaluated  within  distinct 
femoral  regions.  Similarly,  when  ZOL  and  CON  were  compared,  no  significant 
difference was found.  
Inter-regional:  In  stark  contrast  to  the  significant  differences  in  BMDD  parameters 
between femoral regions found in OVX and CON groups (section 4.3.3), no difference 
existed in any BMDD parameters (mean, median, peak, FWHM) between any region 
(i.e. Greater Trochanter, Head, Lesser Trochanter) of proximal femora, as indicated in 
Table 4.1. 
The  %  difference  in  mean  mineralisation  between  regions  of  the  proximal  femur  is 
presented in Figure 4.3. The mineral variability between the lesser trochanter and head 
(6.97  ±  4.58  vs.  13.48  ±  5.94,  p<0.05)  was  significantly  less  in  ZOL  treated  sheep 
compared to OVX sheep. 
 
 
Figure  4.3  %  difference  of  mean  calcium  concentration  between  regions  (greater 
trochanter,  head  and  lesser  trochanter)  of  CON  (n=5),  OVX  (n=5)  and  ZOL  (n=4) 
groups  (31  month  cohorts).  *  indicates  significantly  higher  compared  to  controls.  ^ 
indicates higher compared to ZOL.  
* 
* 
^ 
0 
5 
10 
15 
20 
25 
GT -H  LT-GT  LT-H 
%
 
d
i
f
f
e
r
e
n
c
e
 
w
t
 
%
 
C
a
 
CON  
OVX 
ZOL          
 
65 
 
4.3.5  Effect of Oestrogen Deficiency on Mineralisation of Trabeculae 
Intra-trabecular:  When  experimental  groups  were  compared  within  trabecular  ROI 
(intra-trabecular)  it  was  found  that  in  the  greater  trochanter,  OVX  was  significantly 
lower than CON in the superficial (22.04 ± 1.30 vs. 23.80 ± 1.41, p<0.04), intermediate 
(22.81 ± 1.26 vs. 24.84 ± 1.40, p<0.02), and deep (23.37 ± 1.13 vs. 25.54 ± 1.18, p<0.01) 
ROI.  
Inter-trabecular: When bone tissue from sheep, that underwent oestrogen deficiency 
for 31 months, and age-matched controls, was analyzed, it was observed that for all 
groups, the highest mineral content was in the core of trabeculae with a lower calcium 
content measured in the superficial region, as illustrated in Figure 4.4. For bone tissue 
from the greater trochanter of CON animals, calcium content was significantly lower in 
the superficial region of trabeculae compared to both the intermediate region (23.80 ± 
1.41 vs. 24.84 ± 1.40, p< 0.01) and the deep region (23.80 ± 1.41 vs. 25.54 ± 1.18, 
p<0.01).  The  mean  mineral  concentration  in  the  intermediate  region  was  also 
significantly lower than the deep region (p=0.02). In the head region of CON animals, 
the superficial region was significantly lower than the intermediate (23.05 ± 1.11 vs. 
23.72 ± 1.3, p<0.04) and the deep region (23.05 ± 1.11 vs. 24.22 ± 1.42, p<0.01). In the 
lesser trochanter of the CON group, calcium concentration was significantly lower in the 
superficial region to that of the intermediate (23.86 ± 1.30 vs. 24.89 ± 1.25, p<0.01) and 
the deep region (23.86 ± 1.30 vs. 25.25 ± 1.20, p<0.01). In the greater trochanter of the 
OVX  group,  the  calcium  concentration  was  significantly  lower  in  the  outermost 
superficial region of trabeculae compared to the intermediate (21.94 ± 1.29 vs. 22.81 ± 
1.26,  p<0.01)  and  to  the  deep  region  (22.54 ±  1.29  vs.  23.37 ±  1.13,  p<0.01).  The 
intermediate  region  was  also  significantly  lower  than  the  deep  region  (p<0.04).  No 
significant  difference  was  seen  between  trabecular  ROI  in  the  head  region  of  OVX 
sheep. In the lesser trochanter of the OVX cohort, the superficial was significantly lower 
than the intermediate region (22.44 ± 2.14 vs. 23.88 ± 1.55, p<0.01) and the deep region 
(22.44 ± 2.14 vs. 24.24 ± 1.51, p<0.01).           
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Figure  4.4  Intra-trabecular  spatial  distribution  of  calcium  (wt  %  Ca)  between 
superficial, intermediate, and deep ROI in the greater trochanter (GT), head (H) and 
lesser trochanter (LT) regions of the proximal femur from the 31 month sheep cohort. * 
indicates  significantly  different  to  deep  ROI  within  the  same  femoral  region  of  the 
indicated group and ^ indicates significantly different to intermediate ROI. + indicates 
significant difference to the same ROI of the CON group. See Table 4.1 for respective 
sample sizes within each ROI.  
 
4.3.6  Zoledronic Acid Alters the Spatial Distribution of Mineral within Oestrogen 
Deficient Trabeculae 
Intra-trabecular:  Comparing  groups  within  trabecular  regions  of  interest  (intra-
trabecular), it was observed that in the greater trochanter, the calcium content in the deep 
ROI of the ZOL group was significantly lower than that of the CON group (23.94 ± 0.98 
vs. 25.54 ± 1.18, p<0.04).    
Inter-trabecular: In contrast to the mineral distribution in OVX sheep, in ZOL sheep 
there was no statistical difference between the superficial and intermediate ROI within 
trabeculae,  in  any  of  the  greater  trochanter,  head,  or  lesser  trochanter  regions,  as 
illustrated in Figure 4.4. In the greater trochanter region, the mean mineral concentration 
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in the deep region was significantly higher compared to the superficial region (23.26 ± 
0.48 vs. 23.94 ± 0.98, p<0.02) and also compared to the intermediate region (23.28 ± 
0.54 vs. 23.94 ± 0.98, p<0.02). The superficial ROI was lower than the deep ROI in the 
head (23.38 ± 2.35 vs. 24.15 ± 1.81, p<0.03) and lesser trochanter (23.40 ± 1.34 vs. 
24.25 ± 1.12, p<0.01) of the ZOL group.  
In  the  lesser  trochanter  the  %  difference  in  mean  mineral  concentration  between 
superficial and deep ROI (S-D) was significantly lower in the ZOL group compared to 
the  OVX  group  (3.97  ±  2.39  vs.  8.25  ±  4.33,  p<0.05),  as  depicted  in  Figure  4.5. 
Likewise, when comparing % difference of mean mineralisation between the superficial 
and intermediate ROI (S-I), ZOL was significantly lower compared to OVX (2.01 ± 1.80 
vs. 6.65 ± 4.27, p<0.03). There was also a significant decrease in ZOL compared to 
CON in the lesser trochanter region (2.01 ± 1.80 vs. 4.36 ±1.99, p<0.01). 
 
Figure 4.5  % difference of mean calcium concentration between the superficial and 
deep (S-D) and between the superficial and intermediate (S-I) trabecular regions of CON 
(n=5),  OVX  (n=5)  and  ZOL  (n=4)  sheep  from  the  31  month  group.  *indicates 
significantly lower than OVX while ^ indicates significant lower than CON.  
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4.4.  Discussion 
This study found significantly higher mineralisation and mineral heterogeneity in the 
proximal  femora of  the 31 month control  group compared to 12 month controls.  In 
contrast, when sheep that were oestrogen deficient for 12 months were compared with 
those oestrogen deficient for 31 months, it was observed that sheep with more prolonged 
oestrogen deficiency had lower mineralisation but higher mineral heterogeneity. BMDD 
parameters (mean, median, peak, FWHM) differed significantly between femora regions 
in CON and to a greater extent OVX. Furthermore, the OVX group had more mineral 
variability  between  anatomical  locations  compared  to  control  sheep.  However  in 
contrast, ZOL treatment of oestrogen deficient sheep significantly lessened the tissue 
mineral variability, both at a trabecular level and between femoral regions, compared to 
the OVX group. Together, these indicate that ZOL treatment acts to reverse the higher 
heterogeneity occurring during oestrogen deficiency  and restore mineralisation levels 
closer to control values.  
A limiting factor of this study which could have contributed to the lower mineral content 
seen at 31 months compared to 12 months post-ovariectomy, could be that the 12 month 
OVX group were sacrificed in November, whereas the 31 month cohort were sacrificed 
in June. Sheep are considerably less active in the winter months, therefore remodelling 
rates would be decreased and bone tissue would likely be older and more mineralised, 
compared  to  the  summer  months.  However,  in  spite  of  the  seasonal  differences, 
significantly  higher  mineralisation  was  observed  in  the  31  month  control  group 
compared to the 12 month controls, therefore the reduction found in OVX animals over 
prolonged oestrogen deficiency (31 months) compared to the 12 month OVX group, 
cannot  be  attributed to  the seasonal  differences at  sacrifice. As stated  in  Chapter 4, 
another  aspect  that  could  affect  differences  in  mineralisation  between  groups  is  the 
automated  method  of  defining  regions  of  interest  within  trabeculae  according  to 
trabecular diameter at analysis and not prior to the increased remodelling characteristic 
of oestrogen deficiency. However, significantly lower mineralisation was found in all 
ROI of OVX trabeculae compared to CON, which would only be expected to reduce 
further if ROI were defined before oestrogen deficiency. Finally, the small sample size 
of ZOL sheep (n=4) could be a limiting factor of this study. However, in spite of this, 
with zoledronate treatment of oestrogen deficient sheep, clear, statistically significant 
alterations in mineral distributions were found, compared to oestrogen deficiency alone.          
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The  finding  of  higher  mineralisation  in  more  aged  healthy  sheep  (31  months  CON 
versus 12 month CON) affirm previous findings in monkey (Grynpas et al., 1993) and 
human subjects (19-96 years)(Kingsmill and Boyde, 1998). This can be attributed to 
increased mean tissue age; since newly formed collagen fibrils accumulate mineral over 
time,  older  bone  will  contain  more  mineral  than  newly  formed  bone.  The  higher 
heterogeneity  with  ageing  in  healthy  bone  tissue  demonstrated  in  the  current  study 
corresponds with studies on healthy human proximal femur (Bloebaum et al., 2004). The 
reduction in mineralisation demonstrated with prolonged oestrogen deficiency (sheep 
sacrificed 12 versus 31 months post-ovariectomy) is interesting and cannot be explained 
by ageing since it follows the opposite pattern to the changes occurring in CON animals. 
Indeed,  after  31  months  of  oestrogen  deficiency,  significantly  less  mineralisation 
compared to age matched controls was found, whereas the previous study, presented in 
Chapter 3, found no differences in mean mineralisation between OVX and CON groups 
after 12 months of oestrogen deficiency (Brennan et al., 2011). These findings therefore 
reveal the importance of duration in assessing the effects of oestrogen deficiency on 
bone  mineralisation and may  explain discrepancies regarding the effect of  oestrogen 
deficiency between previous studies.  
The lower mineralisation observed with 31 months of oestrogen deficiency compared to 
controls is likely due to the reduction in mineralisation in oestrogen deficient animals 
over time, in combination with increasing mineralisation in CON animals as they age. 
Increased rates of bone turnover associated with oestrogen deficiency (Wronski et al., 
1989) could explain this lower mineralisation. Sites of bone with high turnover will 
comprise newer packets of bone that have a low mineral content because there is a 
greater chance of resorption before full mineralisation is achieved. This study concurs 
with others from literature which evaluated the impact of long term oestrogen depletion 
compared to controls (Gadeleta  et al., 2000;  Loveridge et al., 2004). Following two 
years  of  ovariectomy,  FTIR  analysis  revealed  significant  lower  mineralisation  in 
trabecular bone of vertetrae from skeletally mature monkeys  (Gadeleta et al., 2000). 
Similarly,  a  further  study  on  osteoporotic  female  patients  (72-90  years)  affirms  our 
findings of reduced mineralisation with long term oestrogen deficiency (Loveridge et al., 
2004). The calcium content of sheep that were oestrogen deficient for 31 month reported 
in this study range from 22-24 wt % Ca, whereas age-matched controls were higher and 
range from 23-26 wt % Ca. These values are within ranges reported for control (18-
28%) and osteoporotic human bone tissue (16-26%) (Roschger et al., 1998; Roschger et          
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al,  2001;  Gupta  et  al.,  2005).  After 31 months  of oestrogen deficiency, the mineral 
content was significantly lower compared to control age matched control sheep. Several 
studies have reported that increased mineral content correlates with improved strength 
and  stiffness  (Yao  et  al.,  2006;  Currey,  1969;  Follet  et  al.,  2004).  Furthermore,  the 
degree to which the strength and stiffness would be affected by the reductions in mineral 
content as a consequence of OVX was estimated by first relating mineral content to ash 
content (calcium occupies 39.9% of stoichiometric HA by weight) (Vajda et al., 1998) 
and then utilizing published relationships between ash fraction and compressive strength 
(Hernandez  et  al.,  2001).  By  these  means,  it  was  estimated  that  even  decreases  in 
calcium concentration as low as 2% (wt % Ca) observed with oestrogen deficiency can 
reduce  bone  strength  by  19%  and  may  therefore  contribute  to  the  reduced  fracture 
resistance of oestrogen deficient bone tissue.  
ZOL  did  not  differ  significantly  compared  to  OVX  or  CON  in  terms  of  mean 
mineralisation; indeed, this group appeared to be intermediate to both. ZOL treatment 
was  administered  for  11  months  to  sheep  that  had  been  oestrogen  deficient  for  20 
months  previously;  therefore  perhaps  with  longer  treatment  durations  ZOL  would 
continue to increase mineralisation to control levels. Indeed, a study on the effects of 
Alendronate  on  osteoporotic  women  demonstrated  significantly  increased  mean 
mineralisation after 3 years of treatment but no significance was revealed after only two 
years (Roschger et al., 2001).  
The most striking observation of this  study is  that  ZOL  administration to  oestrogen 
deficient sheep reduced calcium heterogeneity that arose during oestrogen deficiency, 
whereby ZOL reduced the % difference of the mean mineralization between anatomical 
locations and also between trabecular regions of OVX sheep. These alterations could 
occur  due  to  the  well  established  reduction  in  remodelling  activity  associated  with 
bisphosphonate  treatment.  In  addition,  altered  mineral  heterogeneity  may  occur  as  a 
direct consequence of modulation of mineralisation by cells, independent of remodelling 
inhibition. Interestingly, recent studies have shown a direct uptake of the bisphosphonate 
risedronate by osteocytes, which was concentrated within newly embedded osteocytes 
(Roelofs  et  al.,  2010).  Thus,  bisphosphonates  may  have  the  ability  to  directly  alter 
osteocyte functions such as secondary mineralisation and thereby contribute to altered 
mineral heterogeneity. Furthermore, a recent study observed that Zoledronic acid has an 
anabolic affect on bone (Gamsjaeger et al., 2011). It showed that Zoledronic acid exerts 
effects  on  matrix  quality,  including  increased  mineralisation  and  mineral          
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maturity/crystallinity, as well as decreased GAG content, independent of decreased bone 
turnover (Gamsjaeger et al., 2011). The increased homogeneity between skeletal sites 
found in the current study may indicate that this drug acts to modulate bone cell activity 
in response to mechanical loading.  
The finding of lower mean mineralisation in OVX sheep compared to controls after 31 
months was confirmed in all trabecular regions. Higher mineral content found towards 
the core of trabeculae was expected and is consistent with findings in human iliac bone 
(Ciarelli  et  al.,  2003).  Lower  trabecular  mineral  heterogeneity  with  bisphosphonate 
treatment concurs with studies that revealed higher homogeneity of mineral distribution 
with Alendronate treatment of osteoporotic females (Boivin et al., 2000; Roschger et al., 
2001) and minipigs (Roschger et al., 1997). Indeed, ZOL also had lower variability of 
mineral within trabeculae compared to control sheep, albeit to a lesser degree than when 
ZOL was compared to the OVX group. However, since ZOL treatment was administered 
to sheep following a period of osestrogen deficiency, overall mineralization of the ZOL 
group  did  not  differ  compared  to  CON,  as  stated  previously.  Interestingly,  since 
mineralisation is positively correlated to tissue stiffness, the results presented in this 
chapter  correlate  with  a  further  study  which  showed  that  Zoledronic  acid  treatment 
reduced heterogeneity of elastic modulus distribution of oestrogen deficient bone tissue 
(Yao et al., 2007). 
The results of this study may suggest that in addition to the overall material properties of 
bone  tissue,  including  the  strength  and  stiffness,  material  property  distribution  and 
therefore the stress concentrations within the constituent tissue, may be an important 
factor  governing  the  fracture  resistance  of  bone.  Regions  of  bone  with  more 
heterogeneous mineralisation have been associated with impaired mechanical integrity 
and increased fracture risk (Ciarelli et al., 2003) and past studies have suggested that 
variations  in  the  mineral  heterogeneity  of  individual  trabeculae  can  impact  on  the 
fracture toughness of the bone (Keaveny and Hayes, 1993). Computational studies have 
predicted that higher mineral heterogeneity within trabeculae causes increased stiffness 
(Van der Linden et al., 2001) and that higher trabecular stiffness leads to bone loss and 
trabecular  perforation  (Mulvihill  et  al.,  2008).  Furthermore,  it  has  been  predicted 
computationally that regions of bone with higher mineral heterogeneity have increased 
risk of fracture (Hernandez, 2008; Jaasma et al., 2002; Renders et al., 2008). That the 
overall effect of ZOL on bone tissue is beneficial is clear from the consistent decreases 
in  fracture  occurrence  detailed  in  the  numerous  clinical  trials  with  ZOL          
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(Black et al., 2007; Lyles et al., 2007; Rizzoli et al., 2009). Therefore, it is postulated 
that  the  ability  of  ZOL  to  homogenize  mineral  distribution  within  trabeculae  and 
between anatomical locations in the compromised trabecular architecture of oestrogen 
deficient bone is a factor attributing to reduced fracture occurrence with this drug.  
In conclusion, in spite of the extensive studies in literature highlighting the importance 
of trabecular bone for the mechanical integrity and fracture resistance of the hip, there is 
a lack of understanding regarding the fundamental changes in mineral concentration and 
its  distribution  during  healthy  ageing,  oestrogen  deficiency,  and  bisphosphonate 
treatment. This study is the first to quantify the effects of the duration of  oestrogen 
deficiency  on  bone  tissue  mineralisation  and  it  has  been  highlighted  that  long  term 
oestrogen deficiency reduces the calcium concentration of ovine bone tissue whereas 
mineralisation  is  higher  in  older  healthy  sheep.  The  possible  cellular  mechanisms 
responsible for altered tissue mineralisation will be investigated in Chapters 5 and 6. In 
particular, in Chapter 6 the effects of oestrogen withdrawal for different durations on the 
mechano-responsiveness  of  osteoblasts  will  be  investigated.  This  will  determine  if 
altered mechano-sensitivity could be responsible for the decreases in mineralisation with 
increasing  durations  of  oestrogen  deficiency  found  in  the  current  chapter.  Most 
interestingly, it has been demonstrated that ZOL treatment reversed the effects of OVX 
on mineral heterogeneity and led to a homogeneous calcium distribution both within 
trabeculae and between femoral regions. It is proposed that these changes in mineral 
distribution may contribute to the ability of Zoledronic acid treatment to prevent fracture 
occurrence during oestrogen deficiency.           
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5.  Mineralisation and Apoptosis of Bone Cells 
following Oestrogen Withdrawal 
5.1.  Introduction 
Over 70 years ago, oestrogen deficiency during the menopause was established as the 
primary contributing factor for postmenopausal osteoporotic bone loss, and it was found 
that  oestrogen  treatment  improved  the  calcium  balance  in  postmenopausal  women 
(Albright et al., 1941). Since then, it has been shown extensively that bone loss and 
fractures in postmenopausal women can be prevented by oestrogen treatment (Ettinger et 
al., 1985; Lindsay et al., 1976; Lufkin et al., 1992). During normal physiology, bone 
tissue is continually being renewed by the concerted efforts of osteoclast and osteoblast 
cells (Hill, 1998). A perturbation of the normal bone renewal processes, where excessive 
resorption,  without  adequate  new  bone  formation,  occurs  at  the  onset  of  oestrogen 
deficiency (Balena et al., 1993; Richelson et al., 1984). Such cellular changes lead to 
increased  bone  turnover  that  manifests  in  osteoporotic  bone  as  reduced  bone  mass, 
deterioration  of  bone’s  micro-architecture  and  an  overall  reduction  in  bone  strength 
(Compston  et  al.,  1989;  Lane  et  al.,  1998;  Parfitt,  1987).  These  structural  and 
biomechanical alterations during oestrogen withdrawal impair the ability of the skeleton 
to  perform  fundamental  mechanical  functions  and  lead  to  increased  fracture  risk 
(Cummings and Melton, 2002).  
As discussed in chapter 3, higher strength, stiffness (McNamara et al., 2006; McNamara 
et al., 2005), and mineral concentration (Busse et al., 2009) have been observed in bone 
tissue trabeculae during the initial stages of oestrogen withdrawal compared to control 
groups. However, other studies have reported no change (Bohic et al., 2000; Ciarelli et 
al., 2003) or lower mineralisation (Gadeleta et al., 2000) as a consequence of oestrogen 
deficiency.  Higher  mineral  heterogeneity  following  oestrogen  withdrawal  was 
demonstrated  (Chapter  3)  and  it  has  also  been  shown  that  prolonged  oestrogen 
deficiency  causes  significantly  reduced  tissue  mineralisation  (Chapter  4).  Bone 
mineralisation  contributes  to  bone  strength  (Ruffoni  et  al.,  2007)  and  it  has  been 
predicted that increased mineral  heterogeneity is  a governing factor for fracture risk 
(Mulvihill et al., 2008; Van der Linden et al., 2001), however the cellular mechanisms 
responsible for such bone tissue level changes during oestrogen withdrawal have not yet 
been distinguished.           
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During the normal bone formation process osteoblasts secrete and synthesize the un-
mineralised bone matrix, the osteoid, and subsequently mineralise this osteoid matrix 
(Ducy et al., 2000). They play a seminal role in bone regeneration after removal of aged 
or damaged tissue, which is essential for the maintenance of the structural integrity and 
metabolic capacity of the skeleton. Osteocytes reside in lacunae and are derived from 
osteoblasts that become embedded in their secreted mineralised matrix (Cowin, 2001). 
They are believed to have the ability to modify the mineral content of their surrounding 
matrix, by either dissolving matrix and mineral from their perilacunar regions  (Baud, 
1962;  Bélanger,  1963)  or  by  producing  new  mineralised  tissue,  which  is  known  as 
secondary  mineralisation  (Baud,  1968;  Baylink,  1971).  Osteoblasts  and  osteocytes 
possess receptors for oestrogen (Bellido et al., 1993; Bord et al., 2001; Braidman et al., 
2001), hence their function, in particular tissue mineralisation, may be affected when 
oestrogen production is deficient during postmenopausal osteoporosis (Hoyland et al., 
1999).  
The beneficial effects of oestrogen (Ettinger et al., 1985; Lindsay et al., 1976; Lufkin et 
al., 1992) and the detrimental effects of oestrogen withdrawal (Cummings and Melton, 
2002)  on  bone  strength  and  fracture  resistance  are  evident,  however,  the  cellular 
mechanisms controlling such altered tissue alterations are less clear. It is known that 
oestrogen  causes  reduced  osteoclastic  resorption  (Oursler  et  al.,  1991),  by  both 
inhibiting osteoclast attachment and by inducing apoptosis, a form of programmed cell 
death (Hughes et al., 1996; Saintier et al., 2006). Oestrogen deficiency, on the other 
hand,  increases  the  number  of  osteoclasts,  prevents  apoptosis,  and  enhances  their 
resorbing activities (Jilka et al., 1992; Pacifici, 1996). However, the effects of oestrogen 
and oestrogen deficiency on osteoblasts and bone formation have yielded conflicting 
results: studies show that oestrogen decreases osteoblast proliferation (Robinson et al., 
1997), whereas oestrogen deficiency increases osteoblast proliferation (Modrowski et 
al.,  1993).  Conversely,  other  studies  demonstrate  significantly  increased  cell 
proliferation with oestrogen treatment (Chen et al., 2002; Rao et al., 2003). Furthermore, 
previous  studies  have  revealed  that  expression  of  alkaline  phosphatase  (ALP),  a 
glycoprotein  found  on  the  surface  of  osteoblasts,  and  osteocalcin  (OC),  a  protein 
secreted by osteoblasts that regulates calcium ion homeostasis, are stimulated, inhibited, 
or unresponsive to oestrogen (Chen et al., 2002; Harris, 1996; Robinson et al., 1997). It 
has also been demonstrated in vitro that continuous oestrogen treatment enhances (Patlas 
et al., 2005), or has no effect (Rao et al., 2003) on mineral production by osteoblasts.           
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Recent evidence suggests that alterations in osteoblast activity may be the first event that 
occurs  following  oestrogen  withdrawal  and  that  altered  osteoclast  activity  and 
consequential increased bone resorption may be later events in the osteoporotic bone 
loss cascade (Jilka et al., 1996; Krum et al., 2008; Manolagas et al., 2002). Based on 
these studies and the observed increases in strength, stiffness and mineral content in the 
initial  stages  following  oestrogen  withdrawal  (Busse  et  al.,  2009;  McNamara  et  al., 
2006; McNamara et al., 2005), it is hypothesized that the loss of oestrogen stimulates 
osteoblastic mineral production activity.  
Osteoblasts have an average life span of approximately 3 months, after which they either 
differentiate into osteocytes  or bone lining cells,  or die by  apoptosis  (Parfitt,  1994). 
Osteocytes  also  die  by  apoptosis  and  it  has  been  demonstrated  that  an  increase  in 
osteocyte  apoptosis  occurs  in  hip  fracture  patients  compared  to  healthy  controls 
(Delgado-Calle et al., 2011), following drug induced oestrogen withdrawal in women 
(Tomkinson et al., 1997) and also in the ovariectomised mouse model (Kousteni et al., 
2001). Furthermore, it has been shown that there are more empty lacunae in hip fracture 
patients (Delgado-Calle et al., 2011) and in a sheep model of osteoporosis, compared to 
healthy controls (Zarrinkalam et al., 2011). Such increases in osteocyte cell death may 
result  in  an  indirect  alteration  in  bone  mineralisation  as  mineral  infilling  of  empty 
osteocyte lacunae, a phenomenon referred to as micropetrosis has been demonstrated 
(Frost,  1960).  The  exact  mechanisms  involved  in  micropetrosis  are  not  understood, 
however it has been postulated that osteocytes may hyper-mineralize their surrounding 
matrix  during  death  by  apoptosis  (Boyde,  2003;  Frost,  1960;  Kingsmill  and  Boyde, 
1998).  Although  it  has  been  shown  that  oestrogen  treatment  prevents  drug  induced 
osteoblast and osteocyte apoptosis in vitro (Kousteni et al., 2001; Pantschenko et al., 
2005), whether apoptosis occurs as a direct consequence of oestrogen withdrawal in 
vitro has not yet been investigated.  
The objective of this study is to elucidate how alterations in mineral distribution are 
initiated  during  oestrogen  depletion.  Specifically,  two  separate  hypotheses  by  which 
oestrogen  deficiency  might  alter  bone  tissue  mineralisation  are  tested;  (1)  oestrogen 
deficiency directly alters mineral production by bone cells and (2) oestrogen deficiency 
increases bone cell apoptosis and thereby leads to a micropetrosis type response wherein 
osteocytes  hyper-mineralise  their  surrounding  matrix.  Using  in  vitro  cell  culture, 
osteoblast - like cells (MC3T3-E1) and osteocyte-like cells (MLO-Y4) were pre-treated 
with  oestrogen  for  varying  durations.  Cellular  proliferation,  alkaline  phosphatase          
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activity, mineralisation and apoptosis  were evaluated in these cells when exposed to 
either  oestrogen  withdrawal  or  an  oestrogen  antagonist,  Fulvestrant,  which  blocks 
oestrogen receptors.  
5.2.  Materials and Methods 
5.2.1  Cell Culture 
Two bone cell lines, MC3T3-E1 osteoblast-like cells and MLO-Y4 osteocyte-like cells, 
were used in this study. MC3T3-E1 osteoblast-like cells are a good model for osteoblast 
studies as they express high amounts of alkaline phosphatase, produce mineral and have 
the ability to differentiate into osteocytes (Sudo et al., 1983). MC3T3-E1 osteoblast-like 
cells were maintained in α-MEM supplemented with 10% fetal bovine serum (FBS), 2 
mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin.  
Murine derived MLO-Y4 cells (a gift from Prof. Lynda Bonewald, San Antonio) possess 
many similar characteristics with primary osteocytes such as low expression of alkaline 
phosphatase and production of numerous dendritic processes (Kato et al., 1997). MLO-
Y4  cell  cultures  were  maintained  in  α-MEM  supplemented  with  2.5%  foetal  bovine 
serum (FBS) and 2.5% calf serum (CS), 2 mM L-glutamine, 100 U/ml penicillin/ 100 
μg/ml streptomycin in culture flasks coated with 0.15mg/ml collagen (type I from rat 
tail, C3867 Sigma Aldrich), according to standard methods for maintaining MLO-Y4 
cells. 
5.2.1.1 Oestrogen Pre-treatment 
Estradiol  is  the  primary  type  of  oestrogen  produced  by  the  ovaries  before  the 
menopause.  Therefore, in the present study, in vitro administration of 17β-estradiol, a 
naturally occurring oestrogen derived from cholesterol, was used to simulate normal 
conditions when circulating oestrogen is available to bone cells. In vitro addition of 17β-
estradiol at a concentration of 1x10
-8 M  was used in the studies outlined below, both as 
a  pre-treatment  and  an  experimental  treatment,  at  a  concentration  that  has  been 
employed previously in studies on the effects of oestrogen on bone cell biology (Chen et 
al., 2002; Rao et al., 2003). MC3T3-E1 and MLO-Y4 cells were cultured at 37 °C in a 
humidified 5% CO2 environment  under  three separate conditions  (A)  untreated  cells 
maintained in aforementioned appropriate media without addition of estradiol, (B) cells 
pre-treated for 2 days with 17β-estradiol (1x10
-8 M) and (C) cells pre-treated for 14 days 
with  17β-estradiol  (1x10
-8  M).  Cells  were  passaged  as  required  and  media  was 
replenished every 3-4 days.          
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5.2.1.2 Oestrogen Deficiency Experiments 
The effects of oestrogen deficiency on MC3T3-E1 and MLO-Y4 cells were evaluated by 
either (1) withholding oestrogen from oestrogen pre-treated cells (oestrogen withdrawal) 
or (2) by blocking oestrogen receptors with Fulvestrant (ICI 182,780). Fulvestrant is an 
oestrogen  receptor  (ER)  antagonist  used  to  treat  postmenopausal  women  who  are 
suffering  from  oestrogen  receptor-positive  metastatic  breast  cancer.  Fulvestrant 
competes with endogenous oestrogen for binding to the oestrogen receptor (Curran and 
Wiseman, 2001) with a binding affinity that is 89% that of 17-β estradiol (Wakeling and 
Bowler, 1987), and thereby inhibits oestrogen signalling through the oestrogen receptor 
(Kansra et al., 2005; Wakeling, 1993; Wakeling, 2000). This compound has been used 
previously  to  mimic  oestrogen  deficiency  in  human  osteoblasts  in  vitro  (Foo  et  al., 
2007).  
MC3T3-E1 were plated in triplicate at a density of 3×10
4 cells/ml in 24 well plates in 
osteogenic  media  supplemented  with  50μg/ml  ascorbic  acid,  10mM/L  β-
glycerophosphate and 10nM/L dexomethasome. For MLO-Y4 cultures, 24 well plates 
were  coated  with  0.15mg/ml  collagen  (type  I  from  rat  tail,  C3867  Sigma  Aldrich), 
dissolved in 0.02M acetic acid. Cells were plated in triplicate at a density of 1.5 x 10
4 
cells/ml, in collagen coated tissue culture plates with appropriate media. Both MC3T3-
E1  and  MLO-Y4  cells  were  subsequently  cultured  under  separate  experimental 
conditions;  (1)  Sustained  oestrogen  exposure  (E2):  cells  were  cultured  in  their 
appropriate  media  (osteoblast  osteogenic  media  or  osteocyte  appropriate  media 
respectively)  with  the  addition  of  17β-estradiol  (1x10
-8  M),  (2)  Reduced  oestrogen 
exposure (E1): cells were cultured in their appropriate media with the addition of 1x10
-
10 M 17β-estradiol, this concentration of oestrogen has also been used extensively to 
evaluate the effects of oestrogen (Rao et al., 2003; Robinson et al., 1997), as it is within 
normal physiological ranges for normal serum levels of females (Stricker et al., 2006), 
(3) Oestrogen withdrawal (E-): cells were cultured in their appropriate media without 
the addition of oestrogen, (4) Oestrogen inhibition (F): cells were cultured in their 
appropriate media with the addition of 1x10
-7 M Fulvestrant, (5) Oestrogen inhibition 
with  reduced  oestrogen  exposure  (E1+F):  cells  were  cultured  in  their  appropriate 
media  with  the  addition  of  1x10
-10  M  17β-estradiol  and  1x10
-7  M  Fulvestrant,  (6) 
Oestrogen inhibition with sustained oestrogen exposure (E2+F): cells were cultured 
in their appropriate media with the addition of 1x10
-8 M 17β-estradiol and 1x10
-7 M 
Fulvestrant.  This  concentration  has  been  used  previously  to  block  the  effects  of         
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 oestrogen on bone cells (Robinson et al., 1997). All cells were maintained at 37 °C in a 
humidified 5% CO2 environment and were cultured for 1, 4, 7 and 14 days. Mediums 
were replenished every 3-4 days. Experimental groups are presented in Table 5.1. 
5.2.1.3 Osteocyte Apoptosis Experiments 
To evaluate the effects  of oestrogen deficiency on cell death   and more specifically 
osteocyte apoptosis, MLO-Y4 cells that were pre-treated with 17β-estradiol for 14 days 
were plated in 96 well plates at a density of 4 x 10
4 cells/ml on collagen (type I, rat tail) 
coated tissue culture plates in appropriate media. Cells were subsequently cultured under 
the following conditions for 24 hours; (1) Sustained oestrogen exposure (E2): cells 
cultured  in  their  appropriate  media  with  the  addition  of  1x10
-8  M  17β-estradiol,  (2) 
Reduced oestrogen exposure (E1): cells were cultured in osteocyte appropriate media 
with  the  addition  of      1x10
-10  M  17β-estradiol  (3)  Oestrogen  withdrawal  (E-): 
Osteocyte  appropriate  media  without  the  addition  of  oestrogen,  (4)  Oestrogen 
inhibition (F): cells cultured in their appropriate media with the addition of 1x10
-7 M 
Fulvestrant,  (5)  Oestrogen  inhibition  with  sustained  oestrogen  exposure  (E2+F): 
cells cultured in their appropriate media with the addition of 1x10
-8 M 17β-estradiol and 
1x10
-7 M fulvestrant, see Table 5.1. The E1+F group was eliminated in order to facilitate 
reduction of test groups, required due to constraints imposed on sample numbers by the 
apoptosis  protocol.  It  was  chosen  instead  of  E2+F  since  it  matched  the  pre-treated 
oestrogen concentration. 
After 24 hours of culture, each group was divided in two and half of the cell cultures 
were  treated  with  Etoposide,  to  promote  apoptosis.  This  drug  was  employed  to 
determine  if  oestrogen  deficient  cells  are  more  susceptible  to  induced  apoptosis 
compared  with  cells  exposed  to  oestrogen.  Etoposide  is  a  potent  and  widely  used 
chemotherapeutic agent, which acts by inhibiting the enzyme topoisomerase II and aids 
in re-ligation of the DNA strands. It therefore promotes DNA strand breakage and errors 
in  DNA synthesis  and  consequently induces  apoptosis.  Etoposide was prepared as  a 
stock solution (1mM) in dimethylsulphoxide (DMSO). Final concentration when added 
to culture media was 50µM. All compounds were purchased from Sigma Aldrich, St. 
Louis, MO, USA unless otherwise stated.  
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Table 5.1 Pre-treatments, experimental conditions and assays performed in this study
  Cell lines    Pre-
treatment 
  Experimental conditions    Experimental Assays   
Study 1: 
Mineralisation 
MC3T3-E1 
osteoblast 
  14 days 
oestrogen 
  E- (osteogenic media)    Cells assayed at 1, 4, 7 and 14 days for:   
  MLO-Y4 
osteocyte 
  2 days 
oestrogen 
  E1 (1x10
-10 M 17β-Estradiol)    Proliferation (DNA hoechst) 
 
ALP activity (ρNPP) 
 
Mineralisation   (Alizarin red) 
 
 
       
E2 (1x10
-8 M 17β-Estradiol) 
   
         
F (1x10
-7 M Fulvestrant) 
   
   
 
  Untreated    E1+F     
      E2+F     
Study 2: Osteocyte 
Apoptosis  
MLO-Y4 
osteocyte 
  14 days 
oestrogen 
 
  E- (osteogenic media) 
 
With 
Etoposide 
 
Cells assayed after 4, 12, 24, 30, 48 and 72 
hours for: 
 
      E1 (1x10
-10 M 17β-Estradiol)     
         
E2 (1x10
-8 M 17β-Estradiol) 
   
           
F (1x10
-7 M Fulvestrant) 
Without 
Etoposide 
Apoptosis 
(Caspase 3/7 ) 
 
Cytotoxicity 
 
 
       
E2+F 
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5.2.2  Cellular  Assays 
5.2.2.1 Hoechst 33258 for DNA Quantification 
In  order  to  assess  the  effects  of  oestrogen  deficiency  on  cellular  proliferation, 
measurements of DNA content were performed after 1, 4, 7 and 14 days of culture. Cells 
were washed in sterile PBS and lysed in their plates in 500 µL molecular grade water by 
three freeze/ thaw cycles (-80˚C, 25˚C). The lysate was assayed for DNA content using a 
fluorescent dye Hoechst 33258.  A standard curve was generated using 0 to 500ng DNA 
of calf thymus DNA with 0.1 µg/mL of Hoechst dye (Sigma Aldrich), see Appendix 3. 
Fluorescent assay buffer (100 mM Tris HCl, pH 7.4, with 10 mM EDTA and 2 M NaCl) 
was added to each well of a 96-well plate at 50 µL/well. Standards (50µL) and samples 
were  added  to  each  well  in  triplicate.  Finally  100µL  Hoechst  33258  dye  solution 
(0.1µg/mL) was added to each well. The plate was incubated for 10 minutes in the dark 
at room temperature, and then fluorescence (Ex360 nm / Em 460 nm) was read on a 
Microplate Reader (Wallac 1420 VICTOR 2 TM, Perkin-Elmer, Boston,MA,USA).  
5.2.2.2 Alkaline Phosphatase Expression 
Both  the  nucleus  and  cytoplasm  of  osteoblasts  contain  the  glycoprotein  alkaline 
phosphatase  (ALP),  which  is  expressed  by  active  osteoblasts  and  can  therefore  be 
employed  as  a  marker  for  osteoblast  activity.  ALP  facilitates  mineralisation  by 
producing vesicles that act as sites for nucleation (Cowin, 2001) and by hydrolyzing 
inhibitors of mineral deposition (Favus, 2006). ALP activity was quantified using an 
ALP  Colorimetric  Assay  Kit  (Abcam).  ALP  enzyme  converts  the  p-nitrophenyl 
phosphate  (pNPP)  substrate  to  an  equal  amount  of  coloured  p-Nitrophenol  (pNP). 
Colorimetric absorbance was measured at 405 nm using a micro-plate reader. Relative 
colorimetric readings were converted to ALP activity by creating a standard ALP curve, 
as depicted in Appendix 3.  
5.2.2.3 Alizarin Red S Staining for Mineralisation 
Mineralisation was quantified after 7 and 14 days of culture. Cells were washed with 
sterile PBS solution and fixed with 10% formalin for 10 minutes. Cells were thoroughly 
washed with distilled water and stained with 40mM Alizarin Red-S in deionized water 
(pH 4.2) for 15 minutes at room temperature on an orbital rotator. Alizarin red stain 
binds to mineral nodules present. Cultures were rinsed three times with distilled water to 
remove  any  unbound  stain.  Cells  were  subsequently  de-stained  using  100nM 
cethylpyridium  chloride  in  deionized  water  for  20  minutes  on  an  orbital  rotator  to          
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solubilise  bound  dye.  The  absorbance  of  the  extracted  stain  was  measured  at  a 
wavelength  of  550  nm.  Relative  photometry  units  were  converted  to  µmole/well  of 
alizarin  red  by  creating  a  standard  curve,  as  illustrated  in  Appendix  3.  Alizarin  red 
measurements were expressed as µmole/well of calcium since one mole of alizarin red 
bind  to  two  moles  of  calcium  (Norgaard  et  al.,  2006).  Mineral  production  was 
subsequently normalized to quantity of DNA (µmole Ca/ng DNA).  
5.2.2.4 Apoptosis Quantification 
Cultures were assessed for apoptosis after 4, 12, 24, 30 and 48 and 72 hours of culture, 
with/without Etoposide administration using the ApoTox- Glo Triplex Assay (Promega). 
Apoptosis  was  quantified  by  measuring  caspase  3/7  activity.  These  members  of  the 
cysteine aspartic acid-specific protease (Caspase) family are early markers of apoptosis 
as they play important roles as effectors of  apoptosis of mammalian cells (Nicholson 
and Thornberry, 1997). 50µL of the caspase 3/7 reagent was added to each test well and 
briefly mixed by orbital shaking for 30 seconds. Wells were incubated for 60 minutes at 
room  temperature.  The  reagent  causes  cell  lysis  and  following  caspase  cleavage,  a 
substrate for luciferase (aminoleciferin) is released which causes the production of light. 
Luminescence, which is directly proportional to apoptosis induction, was measured on a 
micro-plate reader.  
5.2.3  Statistical Analysis 
Experiments were conducted in triplicate and repeated giving n=6 per group. Data were 
expressed as a mean ± standard deviation. Statistical differences between groups were 
determined using an ANOVA  crossed factor model, defined using the general linear 
model ANOVA function. Comparison between treatments and pre-treatments were made 
using  the  Tukeys-Kramer  multiple  comparison  test  (Minitab  16).  Statistically 
significance was defined as p≤ 0.05. 
5.3.  Results: 
5.3.1  Does Oestrogen Deficiency alter Osteoblast DNA Content in vitro? 
5.3.1.1 Day 1 and Day 4 DNA Results 
No  significant  difference  in  DNA  content  was  found  between  treatment  groups  and 
controls (E2), in previously untreated cells, or those pre-treated for 14 days, either at day 
1 or day 4, as depicted in Figure 5.1. In cultures pre-treated for two days however, 
significantly higher DNA content was found with reduced oestrogen deficiency (E1) and          
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oestrogen withdrawal (E-), compared to continued oestrogen treatment (E2), at day 4 
(1371 ± 257 vs. 769 ± 130, p<0.01) and (1385 ± 359 vs. 769 ± 130, p<0.01) respectively, 
as depicted in Figure 5.1.  
Effect of Oestrogen Pre-treatment on DNA Content: At day 4, in the E-, F, and 
E2+F groups, DNA content was significantly lower in cultures that were pre-treated for 
14 days compared with untreated cells (590 ± 361 vs. 1375 ± 242, p<0.01), (841 ± 363 
vs. 1503 ± 574, p<0.01), and (643 ± 389 vs. 1405 ± 690, p<0.01) respectively. Also at 
day 4, in the E2+F group, DNA content was significantly lower in cultures pre-treated 
for two days compared to untreated cultures (583 ± 155 vs. 1405 ± 690, p<0.04). In the 
E- group, cells pre-treated for 14 days had significantly lower DNA content compared to 
cells pre-treated for two days (590 ± 361 vs. 1385 ± 359, p<0.03). 
 
 
Figure 5.1 Comparison of DNA, quantified using Hoechst 33258, between continued 
oestrogen  treatment  (E2),  reduced  oestrogen  concentration  (E1)  and  oestrogen 
deficiency  by  withdrawal  of  oestrogen  (E-),  or  by  blocking  oestrogen  receptors 
(F),(E1+F) and (E2+F) at day 1 and day 4, n=6 per group, at each time point. Groups 
that share a letter are significantly different to each other, p values for a and b<0.01. * 
indicates  significantly  different  to  previously  untreated  cultures,  while  ^  indicates 
significantly different to two days E2 pre-treatment, within the same treatments and time 
points. 
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5.3.1.2 Day 7 and Day 14 DNA Results 
When DNA content was compared between treatment groups and controls (E2) at day 7 
and day 14, no significant difference was found, in previously untreated cells, or those 
with either 2 or 14 days of oestrogen pre-treatment, as indicated by Figure 5.2.   
Effect of Oestrogen Pre-treatment on DNA Content: At day 7, cultures pre-treated 
with  oestrogen  for  two  days  had  significantly  higher  DNA  content  compared  to 
untreated cultures in the E1 and E1+F groups (4485 ± 1067 vs. 1408 ± 161, p<0.05 ) and 
(4815 ± 541 vs. 1453 ± 393, p<0.04) respectively, as illustrated in Figure 5.2. Also at 
day  7,  in  the  E-  group,  cells  pre-treated  for  14  days  had  significantly  lower  DNA 
content, compared to cells pre-treated for 2 days (1288 ± 679 vs. 4644 ± 698, p<0.05). 
No significant effect of pre-treatment on DNA content was found at day 14. 
 
 
Figure 5.2 Comparison of DNA, quantified using Hoechst 33258, between continued 
oestrogen  treatment  (E2),  reduced  oestrogen  concentration  (E1)  and  oestrogen 
deficiency  by  withdrawal  of  oestrogen  (E-),  or  by  blocking  oestrogen  receptors 
(F),(E1+F)  and  (E2+F)  at  day  7  and  day  14.  n=6  per  group,  at  each  time  point.  * 
indicates  significantly  different  to  previously  untreated  cultures,  while  ^  indicates 
significantly different to two days E2 pre-treatment, within the same treatments and time 
points. 
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5.3.2  Does Oestrogen Deficiency alter Osteoblast ALP Expression in vitro? 
5.3.2.1 Day 1 and Day 4 ALP Results 
No  difference  in  ALP  production,  between  treatment  groups  (E1,  E-,  F,  E1+F  and 
E2+F) compared to oestrogen treatment controls (E2), were observed at day 1 or day 4 
in either previously untreated cultures or cultures pre-treated with oestrogen  for two 
days. However, in cultures that were pre-treated for 14 days, significantly higher ALP 
production was observed when oestrogen was withdrawn from cells (E-), compared to 
continued oestrogen treatment (E2) at day 4 (0.82 ± 0.26 vs. 0.39 ± 0.19, p<0.01), as 
indicated in Figure 5.3. 
Effect of Oestrogen Pre-treatment on ALP Production by Osteoblasts: At day 1, in 
all treatment groups (E2, E1, E-, F, E1+F and E2+F), 14 days pre-treatment and 2 days 
pre-treatment  were  significantly  higher  compared  to  previously  untreated  cultures  (p 
values  <0.01).  Furthermore,  in  all  treatment  groups,  cultures  pre-treated  for  2  days 
produced significantly more ALP compared to cultures pre-treated for 14 days (p values 
<0.01). By day 4, cultures pre-treated with oestrogen for 14 days were significantly 
higher compared to untreated cultures in all groups (p values<0.05), except in E1. In 
addition, culture pre-treated for 14 days were significantly higher compared to cultures 
pre-treated for only 2 days in all treatment groups (p values <0.04).           
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Figure 5.3 Comparison of ALP expression by osteoblasts between continued oestrogen 
treatment  (E2),  reduced  oestrogen  concentration  (E1)  and  oestrogen  deficiency  by 
withdrawal  of  oestrogen  (E-),  or  by  blocking  oestrogen  receptors  (F),(E1+F)  and 
(E2+F) at day 1 and day 4. n=6 per group, at each time point. Groups that share a letter 
(a) are significantly different to each other, p<0.01) * indicates significantly different to 
previously untreated cultures, while ^ indicates significantly different to two days E2 
pre-treatment, within the same treatments and time points. 
 
5.3.2.2 Day 7 and Day 14 ALP Results 
In untreated cells, significantly lower ALP activity was found in the oestrogen blocker 
group (E2+F) compared to the oestrogen treatment controls (E2) at day 7 (0.06 ± 0.01 
vs. 0.60 ± 0.18, p<0.04), as indicated in Figure 5.4. At day 14, significantly higher ALP 
production was found in the F group compared to controls (E2) (1.21 ± 0.07 vs. 0.56 ± 
0.12, p<0.03).  
In cultures pre-treated for two days, ALP production in the oestrogen withdrawal group 
(E-), was significantly higher compared to continued oestrogen treatment (E-) at day 7 
(0.59 ± 0.13 vs. 0.13 ± 0.06, p<0.04). In cultures pre-treated for 14 days, no difference 
between  any  group  and  controls  was  observed  at  day  7,  but  at  day  14,  oestrogen 
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withdrawal from cells (E-) resulted in significantly higher ALP activity, compared to 
continued oestrogen treatment (E2) (2.92 ± 0.70 vs. 1.12 ± 0.38, p<0.01).  
Effect of Oestrogen Pre-treatment on ALP Production by Osteoblasts: At day 7, 
there is no significant effect of pre-treatment on ALP activity. At day 14, in (E2, E-, F, 
E1+F and E2+F) treatment groups, ALP activity was significantly higher in cultures 
pre-treated for 14 days, compared to those with 2 days of pre-treatment (p values <0.01). 
Furthermore, in the E- and E2+F groups, ALP activity was significantly higher in cells 
pre-treated  for  14  days,  compared  with  previously  untreated  cells  (p  values  <0.04). 
Finally, in the F and E2+F groups, ALP was significantly lower in cells pre-treated for 
two days compared with untreated cells (p<0.01).   
 
Figure 5.4 Comparison of ALP expression by osteoblasts between continued oestrogen 
treatment  (E2),  reduced  oestrogen  concentration  (E1)  and  oestrogen  deficiency  by 
withdrawal  of  oestrogen  (E-),  or  by  blocking  oestrogen  receptors  (F),(E1+F)  and 
(E2+F) at day 7 and day 14. n=6 per group, at each time point. Groups sharing the same 
letters  are  significantly  different  to  each  other,  a<0.04,  b<0.03,  c<0.04,  d<0.01.* 
indicates  significantly  different  to  previously  untreated  cultures,  while  ^  indicates 
significantly different to two days E2 pre-treatment, within the same treatments and time 
points
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5.3.3  Does Oestrogen Deficiency alter Osteoblast Mineralisation in vitro?  
Osteoblast mineralisation results at day 7 and day 14 from cultures without oestrogen 
pre-treatment, with 2 days pre-treatment and with 14 days pre-treatment are presented in 
detail in Figure 5.5. When treatment  groups were compared, in previously untreated 
cultures and those pre-treated for two days with oestrogen, no significant differences 
compared to continued oestrogen treatment (E2) were found. In cultures that were pre-
treated for 14 days with oestrogen, withdrawal of oestrogen (E-) resulted in significantly 
higher mineral production compared to continued oestrogen treatment (E2) at day 14 
(459.12  ±  170.56  vs.  247.69  ±  164.28,  p<0.01).  Conversely,  blocking  oestrogen 
receptors  with  (F)  and  (E2+F)  treatments,  caused  significantly  lower  mineralisation, 
compared with continued oestrogen (E2) at day 14 (52.40 ± 39.71 vs. 247.69 ± 164.28, 
p<0.03) and (64.40 ± 32.63 vs. 247.69 ± 164.28, p<0.05) respectively. 
Effect  of  Oestrogen  Pre-treatment  on  Mineral  Production  by  Osteoblasts:  The 
effect of pre-treatment on subsequent mineral production by MC3T3-E1 cells is also 
presented in Figure 5.5. At day 7, in the oestrogen withdrawal group (E-), cultures pre-
treatment for 14 days had significantly higher mineral production compared to untreated 
cultures and those with 2 days pre-treatment (109.95 ± 67.83 vs. 22.89 ± 13.88, p<0.02) 
and (109.95 ± 67.83 vs. 17.08 ± 5.40, p<0.03) respectively. In the oestrogen blocker 
group  (E2+F),  cultures  pre-treatment  for  14  days  also  had  higher  mineralization 
compared to untreated cultures (86.58 ± 62.44 vs. 9.52 ± 1.22, p<0.05).  
At day 14,  in the continued oestrogen group (E2), reduced oestrogen group (E1) and 
oestrogen  withdrawal  group  (E-),  pre-treatment  for  14  days  caused  higher  mineral 
production compared to untreated cultures (247.69 ± 164.28 vs. 23.96 ± 9.57 , p<0.04), 
(269.69 ± 172.25 vs. 36.26 ± 11.36, p<0.04) and (459.12 ± 170.56 vs. 25.84 ± 8.34, 
p<0.01) respectively. Furthermore, in the oestrogen withdrawal group (E-), cultures pre-
treated for 14 days also had higher mineralization compared to 2 days of oestrogen pre-
treatment (459.12 ± 170.56 vs. 94.31 ± 71.89, p<0.01). Interestingly, blocking oestrogen 
receptors  with  fulvestrant  (F,  E1+F,  and  E2+F)  abrogated  the  enhanced  mineral 
production due to oestrogen pre-treatment, as no significant difference was found in any 
of these groups when comparing pre-treatments.           
 
88 
 
Figure 5.5 Mineral production by osteoblasts, after 7 and 14 days, either without prior 
oestrogen pre-treatment, or with 2, or 14 days of oestrogen pre-treatment. Continued 
oestrogen  treatment  control  (E2)  is compared  with  lowering  oestrogen concentration 
(E1), oestrogen withdrawal (E-), and blocking oestrogen receptors (F, E1+F, E2+F). 
n=6 per group, at each time point. Groups sharing the same letters are significantly 
different  to  each  other,  a<0.01,  b<0.03,  c<0.05.  *  indicates  significantly  different  to 
previously untreated cultures, while ^ signifies significantly different to cells with two 
days of pre-treatment, of the same subsequent treatment group and time point.  
 
5.3.4  Does Oestrogen Deficiency alter Osteocyte DNA Content in vitro? 
5.3.4.1 Day 1 and Day 4 DNA Results 
In  cells  that  were  previously  untreated,  or  those  with  two  days  of  oestrogen  pre-
treatment, no significant difference was found between treatment groups and oestrogen 
treated controls (E2) at either day 1 or day 4, as depicted in Figure 5.6. In cells that were 
pre-treated for 14 days with oestrogen, significantly less DNA content was found in the 
oestrogen blocker group (E2+F) compared with controls (E2), at day 4 (819.60 ± 380.71 
vs. 1315.25 ± 53.64, p<0.01).  
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Effect of Oestrogen Pre-treatment on DNA Content by Osteocytes: No significant 
effect of pre-treatment on DNA content was found in any of the subsequent treatment 
groups at day 1, or day 4. 
 
Figure 5.6 Comparison of DNA content by osteocytes, quantified using Hoechst 33258, 
between continued oestrogen treatment (E2), reduced oestrogen concentration (E1) and 
oestrogen  deficiency  by  withdrawal  of  oestrogen  (E-),  or  by  blocking  oestrogen 
receptors (F),(E1+F) and (E2+F) at day 1 and day 4. n=6 per group, at each time point. 
Groups that share a letter (a) are significantly different to each other, p<0.01.    
 
5.3.4.2 Day 7 and Day 14 DNA Results 
When  treatment  groups  were  compared  with  oestrogen  treated  controls  (E2),  no 
significant difference was found in either previously untreated cells, or those with 2 or 
14 days pre-treatment.  
Effect of Oestrogen Pre-treatment on DNA Content by Osteocytes: In all treatment 
groups, significantly less DNA content was found in cells that were pre-treated for 14 
days,  compared  with  those  pre-treated  for  two  days  (p  values  <0.05)  at  day  7,  as 
indicated in Figure 5.7. Furthermore, in (E2, E1, E-, F, E2+F) groups, significantly 
a 
 a 
0 
200 
400 
600 
800 
1000 
1200 
1400 
1600 
1800 
2000 
E2  E1  E-  F  E1+F  E2+F  E2  E1  E-  F  E1+F  E2+F 
Day 1  Day 4 
n
g
 
D
N
A
/
w
e
l
l
 
Untreated MLO-Y4 
2 day E2 pre-treatment MLO-Y4 
14 days E2 pre-treatment MLO-Y4          
 
90 
 
more DNA content was found in cells pre-treated with oestrogen for two days, compared 
with previously untreated cells (p values <0.01). At day 14, in the E2 control group, 
cells with two days pre-treatment had significantly more DNA content than previously 
untreated cells (p<0.01).    
 
 
Figure 5.7 Comparison of DNA content in osteocyte cultures, quantified using Hoechst 
33258, between continued oestrogen treatment (E2), reduced oestrogen concentration 
(E1)  and  oestrogen  deficiency  by  withdrawal  of  oestrogen  (E-),  or  by  blocking 
oestrogen receptors (F),(E1+F) and (E2+F) at day 7 and day14. n=6 per group, at each 
time point. * indicates significantly different to previously untreated cultures, while ^ 
indicates significantly different to two days E2 pre-treatment, within the same treatments 
and time points.  
 
5.3.5  Does Oestrogen Deficiency alter Osteocyte ALP Expression in vitro? 
5.3.5.1 Day 1 and Day 4 ALP Results 
In  untreated  cultures,  ALP  expression  was  significantly  lower  in  the  oestrogen 
withdrawal (E-) group compared to cells treated with oestrogen (E2) at day 1 (0.033 ± 
0.003 vs. 0.046 ± 0.003, p<0.01), as depicted in Figure 5.8. Conversely, cells treated 
with the oestrogen blocker (F) showed significantly higher ALP expression compared to 
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controls (E2) (0.06 ± 0.01 vs. 0.05 ± 0.01, p<0.01). Similar to day 1, the oestrogen 
withdrawal (E-)  group had significantly less ALP production compared to  oestrogen 
treatment (E2) (0.04 ± 0.01 vs. 0.04 ± 0.01, p<0.04).  
In cultures that received two days of oestrogen pre-treatment, by day 4, cells treated with 
the oestrogen blocker (F) and (E1+F) had significantly more ALP production compared 
to continued oestrogen treatment (E2) (0.05 ± 0.01 vs. 0.04 ± 0.01, p<0.01) and (0.05 ± 
0.01 vs. 0.04 ± 0.01 p<0.04) respectively. In cultures that were pre-treated for 14 days 
with oestrogen, by day 4, cultures treated with the oestrogen blocker (E2+F) showed 
significantly higher ALP production compared to continued oestrogen treatment (E2) 
(0.06 ± 0.01 vs. 0.04 ± 0.01, p<0.01).  
Effect of Oestrogen Pre-treatment on ALP Production by Osteocytes: At day 1, in 
the continued oestrogen group (E2), reduced oestrogen group (E1), oestrogen deficiency 
group (E-) and the oestrogen blocker groups (F) and (E1+F), cells pre-treated for 14 
days produced significantly less ALP (p values <0.01) compared to previously untreated 
cultures. In the E1, E-, F, E1+F and E2+F groups, cultures pre-treated with oestrogen 
for two days produced significantly less ALP at day 1 compared to untreated cultures (p 
values <0.01). In the E1+F and E2+F groups, 14 days pre-treatment was significantly 
higher than 2 days pre-treatment (p<0.01) and (p<0.01) respectively. At day 4, in the 
E2+F group, ALP production was significantly higher cultures that were pre-treated for 
14  days  compared  with  both,  cells  pre-treated  for  2  days  and  untreated  cells.           
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Figure 5.8 Comparison of ALP expression by osteocytes, between continued oestrogen 
treatment  (E2),  reduced  oestrogen  concentration  (E1)  and  oestrogen  deficiency  by 
withdrawal  of  oestrogen  (E-),  or  by  blocking  oestrogen  receptors  (F),(E1+F)  and 
(E2+F) at day 1 and day 4. n=6 per group, at each time point. Groups that share a letter 
are significantly different to each other, p values are; a<0.01, b<0.01, c<0.04, d<0.01, 
e<0.04, f<0.01* indicates significantly different to previously untreated cultures, while ^ 
indicates significantly different to two days E2 pre-treatment, within the same treatments 
and time points. 
 
5.3.5.2 Day 7 and Day 14 ALP Results 
In untreated cultures, no difference between any groups compared to controls (E2) was 
observed at day 7. However, at day 14, ALP production was significantly lower in the 
oestrogen blocker groups (F) and (E2+F), compared to controls (E2) (0.04 ± 0.01 vs. 
0.07 ± 0.01, p<0.01) and (0.04 ± 0.03 vs. 0.07 ± 0.01, p<0.05), as depicted in Figure 5.9. 
In cultures pre-treated for two days with oestrogen, no significant difference was found 
between groups compared to controls at either day 7, or day 14. In cultures pre-treated 
for  14  days,  significantly  more  ALP  production  was  observed  in  oestrogen  blocker 
groups (F) and (E2+F), compared to continued oestrogen treatment (E2), at day 7 (0.14 
± 0.01 vs. 0.07 ± 0.02, p<0.01) and (0.14 ± 0.01 vs. 0.07 ± 0.02, p<0.01) respectively. No 
difference compared to controls was found at day 14.  
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Effect of oestrogen pre-treatment on ALP production by osteocytes: At day 7, in all 
treatment groups, (E2, E1, E-, F, E1+F and E2+F), ALP was higher in cultures that 
were pre-treated for 14 days compared to both untreated cultures (p values <0.01) and 
those pre-treated for only 2 days (p<0.01). Similarly at day 14, cultures pre-treated with 
oestrogen  significantly increased  ALP production of all subsequent  treatment  groups 
(E2, E1, E-, F, E1+F, E2+F), compared to both untreated (p<0.01) and 2 days pre-
treated (p<0.01) groups.  
 
Figure 5.9 Comparison of ALP expression by osteocytes between continued oestrogen 
treatment  (E2),  reduced  oestrogen  concentration  (E1)  and  oestrogen  deficiency  by 
withdrawal  of  oestrogen  (E-),  or  by  blocking  oestrogen  receptors  (F),(E1+F)  and 
(E2+F) at day 7 and day 14. n=6 per group, at each time point. Groups that share a letter 
are significantly different to each other, p values are; a<0.04, b<0.05, c<0.01, d<0.01. * 
indicates  significantly  different  to  previously  untreated  cultures,  while  ^  indicates 
significantly different to two days E2 pre-treatment, within the same treatments and time 
points. 
 
5.3.6  Does Oestrogen Deficiency alter Osteocyte Mineralisation in vitro?  
Osteocyte mineralisation results at day 7 and day 14 from cultures without oestrogen 
pre-treatment, with 2 days pre-treatment, and with 14 days pre-treatment are presented in 
detail  in  Figure  5.10.  No  difference  in  mineral  production  was  found  between  any 
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subsequent treatment groups (E1, E-, F, E1+F and E2+F) compared with continued 
oestrogen treatment (E2), at either day 7, or day 14 in either untreated cells, or those 
with 2, or 14 days of pre-treatment. However, at day 14, cultures without oestrogen (E-), 
had  significantly  higher  mineral  production  compared  to  reduced  oestrogen 
concentration (E1), in previously untreated cultures and cells that were pre-treated for 2 
days (68.16 ± 23.85 vs. 35.16 ± 18.58, p<0.05) and (24.50 ± 5.51 vs. 17.70 ± 4.75, 
p<0.01) respectively.  
Effect of Oestrogen Pre-treatment on Mineral Production by Osteocytes: At day 7, 
in the oestrogen withdrawal group (E-) and the oestrogen blocker groups (E1+F) and 
(E2+F),  mineral  content  was  significantly  higher  in  previously  untreated  cultures 
compared to cultures pre-treated for two days (32.88 ± 15.55 vs. 7.04 ± 2.96, p<0.05), 
(37.05± 13.41 vs. 9.85 ± 4.11, p<0.4) and (37.77 ± 12.46 vs. 7.22 ± 1.85, p<0.04), as 
depicted  in  Figure  5.10.  At  day  7,  in  the  reduced  oestrogen  concentration  (E1), 
oestrogen  withdrawal  (E-)  and  oestrogen  blockers  (E1+F)  and  (E2+F)  group, 
significantly more mineral production was observed in cultures that were pre-treated for 
14 days compared to those pre-treatment for 2 days (40.68 ± 27.93 vs. 7.17 ± 2.94, 
p<0.04), (53.83 ± 6.04 vs. 7.04 ± 2.96, p<0.01), (79.55 ± 41.64 vs. 9.85 ± 4.11, p<0.01) 
and (65.43 ± 42.40 vs. 7.22 ± 1.85, p<0.01) respectively.  
At day 14, in the oestrogen withdrawal group (E-), mineral production by previously 
untreated  cultures  was  significantly  higher  compared  to  two  days  of  oestrogen  pre-
treatment (68.16 ± 25.85 vs. 24.50 ± 5.51, p<0.01). In the continued oestrogen (E2), 
reduced  oestrogen  (E1),  oestrogen  withdrawal  (E-)  and  oestrogen  blocker  groups 
(E1+F) and (E2+F), mineralisation was significantly higher in cultures pre-treated with 
oestrogen for 14 days compared to 2 days (67.65 ± 28.29 vs. 17.70 ± 4.75, p<0.01), 
(77.40 ± 50.76 vs. 16.88 ± 5.40, p<0.01), (105.66 ± 50.20 vs. 24.50 ± 5.51, p<0.01), 
(69.75 ± 41.49 vs. 19.18 ± 4.84, p<0.02) and (70.70 ± 33.18 vs. 21.17 ± 3.65, p<0.02).          
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Figure 5.10 Mineral production by osteocytes without prior oestrogen pre-treatment, or 
with 2, or 14 days of oestrogen pre-treatment after 7 and 14 days. Continued oestrogen 
treatment  control  (E2)  is  compared  with  lowering  oestrogen  concentration  (E1), 
oestrogen withdrawal (E-), and blocking oestrogen receptors (F, E1+F, E2+F). n=6 per 
group, at each time point. Groups sharing the same letters are significantly different to 
each other. Respective p-values are; a<0.05, b<0.01. * indicates significantly different to 
previously untreated cultures,  while  ^ signifies  significantly different  to two days  of 
oestrogen pre-treatment, of the same subsequent treatment group and time point. 
 
5.3.7  Does Oestrogen Deficiency alter Apoptosis by Osteocytes in vitro? 
The effects of decreased oestrogen concentration (E1), oestrogen withdrawal (E-), or 
blocking  oestrogen  receptors  (F),  (E1+F),  (E2+F),  on    osteocyte  apoptosis,  and 
apoptosis  induced  using  an  apoptotic  agent,  Etoposide,  as  measured  by  caspase  3/7 
activity, is presented in Figure 5.11. A significantly higher incidence of apoptosis was 
observed by 24 hours, when oestrogen was withdrawn (E-) from osteocytes, compared 
to  continued  oestrogen  administration  (E2)  (110.5  ±  6.42  vs.  100,  p<0.05).  When 
apoptosis was further enhanced  at 24 hours using etoposide this caused significantly 
more  apoptosis,  compared  to  cells  not  treated  with  Etoposide,  in  the  oestrogen 
withdrawal group (E-) by the 30 hour time point (122.91 ± 24.13 vs. 98.46 ± 12.24, 
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p<0.02). Conversely, there was no significant difference with etoposide treatment after 
just six hours with any other treatment group.  
By 24 hours of Etoposide treatment (48 hour time point) it was found that cells treated 
with Etoposide showed significantly more apoptosis in all treatment groups (p<0.01). 48 
hours after Etoposide administration (72 hours experimental time point), significantly 
less apoptosis was observed in the Etoposide treated cultures in all groups (p<0.01), 
except  for  the  oestrogen  withdrawal  (E-)  group,  compared  to  untreated  cultures.  In 
addition, apoptosis in cultures without Etopside treatment was significantly lower in the 
oestrogen  withdrawal  group  (E-)  compared  to  continued  oestrogen  treatment  (E2) 
(p<0.01).          
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Figure  5.11  Apoptosis,  measured  by  caspase  3/7  activity,  of  oestrogen  pre-treated 
osteocytes during decreased oestrogen concentration (E1), oestrogen withdrawal (E-), 
and  blocking  oestrogen  receptors  (F,  E2+F),  compared  to  %  control  (continued 
oestrogen administration: E2). n=6 per group, at each time point. Groups sharing letters 
are  significantly  different  to  one  another,  p-values  are  as  follows;  a<0.05,  b<0.02, 
c<0.01 * indicates significantly different to cultures without etoposide. 
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5.4.  Discussion 
This study provides direct evidence that oestrogen deficiency alters bone cell biology in 
vitro. Specifically, it was observed that changes in cell number, mineral production and 
apoptosis of osteoblast and osteocyte cells occur when oestrogen is withdrawn following 
a period where cells become accustomed to oestrogen. Oestrogen pre-treatment of both 
osteoblasts  and  osteocytes  caused  significantly  higher  ALP  and  mineral  production 
compared to previously untreated cultures. Our studies also reveal that the duration of 
exposure to oestrogen plays an important role in proliferation and cell matrix production; 
while oestrogen pre-treatment for 14 days resulted in higher ALP activity and tissue 
mineralisation compared to untreated cells, such an effect was not observed in cells pre-
treated  for  only  2  days.  Most  interestingly,  oestrogen  withdrawal  from  osteoblasts 
caused significantly more mineralisation compared with cells that continued to receive 
oestrogen.  In  addition,  the  current  study  shows  that  oestrogen  withdrawal  from 
osteocyte-like cells causes a significantly higher rate of apoptosis, both spontaneously 
and when apoptosis was artificially induced by administering Etoposide. Together, these 
findings  highlight  the  impact  of  duration  of  oestrogen  administration  on  bone  cell 
function,  and  suggest  that  osteoblastic  cells  responded  to  oestrogen  withdrawal  by 
increasing apoptosis and mineral production. 
It must be noted that there are a number of limitations associated with the current study. 
Firstly, MC3T3-E1 and MLO-Y4 cells are both cell lines, therefore, a primary culture of 
osteoblasts and osteocytes may be more appropriate for studying the effects of oestrogen 
deficiency on bone cells. The MC3T3-E1 cell line has been used previously in many 
osteoblastic bone cell studies however (Fatokun et al., 2008; Yamamoto et al., 1995). In 
addition, it is extremely difficult to attain osteocytes from human tissue due to their 
locations in the body. MLO-Y4 cells have been shown to display many characteristics of 
primary  osteocytes  and  have  been  employed  extensively  in  bone  cell  investigations 
(Cherian et al., 2005; Kato et al., 1997; Xia et al., 2010). Furthermore, 2D monolayer 
cultures are suboptimal since cells in vivo reside in 3D matrices and interact with various 
other cell types. In spite of these limitations, important findings regarding oestrogen 
deficiency  on  the  apoptosis  of  osteocytes  and  the  bone  formation  capabilities  of 
osteoblasts and osteocytes in vitro were observed. 
The higher ALP activity and mineral production that was observed in both osteoblasts 
and  osteocytes  when  pre-treated  with  oestrogen,  compared  to  untreated  cells,  is  in 
agreement with studies that show the enhanced effect of oestrogen on ALP production          
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and  mineral  production  (Patlas  et  al.,  2005).  It  has  been  demonstrated  in  vivo  that 
oestrogen retains bone mass, not only by acting on osteoclasts, but also by stimulating 
bone formation by osteoblasts (Chow et al., 1992; Edwards et al., 1992). Indeed, it has 
been suggested that alterations in osteoblast activity may be the first event that occurs 
following oestrogen withdrawal and that altered osteoclast activity and consequential 
increased bone resorption may be later events  in  the osteoporotic bone loss cascade 
(Manolagas  et  al.,  2002).  This  idea  is  in  contrast  to  the  widespread  opinion  that 
osteoporosis  occurs  primarily  as  a  consequence  of  altered  osteoclast  activity  due  to 
oestrogen  withdrawal.  There are several  lines  of evidence to  support this  alternative 
concept. Firstly, Krum et al have showed in vitro that oestrogen’s action on osteoclast 
apoptosis  is  mediated  by  Fas  ligand  production  by  osteoblasts  (Krum  et  al.,  2008).  
Furthermore, it was shown in an osteopenia mice model with altered osteoblastogenesis 
that  altered  osteoclast  activity  was  secondary  to  impaired  osteoblast  function,  as 
osteoclast activity in ex vivo was restored to normal following addition of osteoblast 
cells from normal mice (Jilka et al., 1996). If this theory is substantiated, the alterations 
in  osteoblast  activity  observed  in  the  current  study  as  a  direct  result  of  oestrogen 
withdrawal could have an important impact on the initiation of altered bone remodelling 
in osteoporosis.   
The  increased  ALP  activity  and  mineral  production  that  was  found  with  oestrogen 
withdrawal  is  in  agreement  with  in  vivo studies. One study shows mineralised bone 
formation was significantly higher in OVX rats compared to sham operated rats and 
OVX  rats  treated  with  oestrogen  (Yokose  et  al.,  1996).  In  addition,  a  study  on 
osteoporotic females  showed significantly higher  mineralisation in  osteoporotic bone 
compared to controls (Dickenson et al., 1981) and drug induced oestrogen suppression 
caused significantly increased mineralisation in young female patients  (Boyde  et al., 
1998). Our findings are also in agreement with a study that showed that osteoblasts from 
OVX rats produced more ALP activity and mineralised bone nodules compared to cells 
from sham operated rats (Yokose et al., 1996). However, the direct effects of oestrogen 
withdrawal in vitro, on osteoblast mineral production, as evaluated in the current study, 
have not before been investigated. It is revealed for the first time that silencing oestrogen 
receptors with fulvestrant significantly reduces mineralisation by osteoblasts compared 
to controls in pre-treated cells for 14 days after 7 and 14 days of culture. This highlights 
the role of oestrogen receptors and the importance of oestrogen pre-treatment duration, 
in  regulating  osteoblast  mineralisation.  Moreover,  this  study  reveals  that  blocking          
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oestrogen  receptors  affects  mineral  production  differently  than  simply  withdrawing 
oestrogen from cultures. 
The current study shows that oestrogen withdrawal from osteocyte-like cells induces 
apoptosis. This finding is in agreement with previous studies, where it was reported that 
oestrogen deficiency is associated with higher apoptosis rates and depleted osteocyte 
number, in female patients (Boyde et al., 1998; Tomkinson et al., 1997) and also in 
ovariectomized animals (Kousteni et al., 2001; Zarrinkalam et al., 2011). The current 
study showed that oestrogen treatment reduced the amount of apoptosis when cells were 
treated  with  an  apoptotic  inducing  agent  (Etoposide)  compared  to  cells  without 
oestrogen treatment. This is in agreement with other in vitro studies (Bradford et al., 
2010; Kousteni et al., 2001). The current study is the first to investigate the direct effect 
of oestrogen withdrawal on apoptosis in vitro however.  
Since empty osteocyte lacunae are known to lead to tissue hyper-mineralisation in vivo 
(Frost, 1960), it is intriguing to speculate that oestrogen deficiency induced apoptosis 
also leads to a local increase in mineral content. Unlike osteoblasts, which lie on the 
bone surface, the debris from osteocyte apoptosis is not accessible to phagocytic cells 
and may therefore be mineralised instead. Since osteocyte apoptosis is not ubiquitous 
(Zarrinkalam et al., 2011), these changes might explain mineral heterogeneity during 
oestrogen deficiency that was seen in previous studies in Chapter 3 (Brennan et al., 
2011). Although it was shown in this study that higher apoptosis occurrence and mineral 
production both occur as a result of oestrogen withdrawal, a direct link has not been 
established.  However,  a  previous  study  showed  that  in  ex  vivo  cultures,  higher  cell 
apoptosis occurs with increasing mineral nodule formation (Pantschenko et al., 2005). It 
has also been demonstrated that apoptosis occurs during osteoblast mineral production in 
vitro (Lynch et al., 1998). Furthermore, IL-6 inhibits osteoblast apoptosis (Jilka et al., 
1998) and oestrogen inhibits IL-6 production by mice and human osteoblasts (Girasole 
et al., 1992), therefore oestrogen may protect osteocyte cells from apoptosis by the same 
mechanism.  
Bone adapts its mass and structure according to the mechanical loading regimes placed 
upon it (Lanyon et al., 1982). Osteocytes are mechanosensitive cells, which can detect 
mechanical signals in bone and convert these into chemical signals which are conveyed 
to  other  bone  cell  types  (Klein-Nulend  et  al.,  1995a;  Klein-Nulend  et  al.,  1995b). 
Therefore,  increased  apoptosis  may  impair  bone’s  ability  to  adaptively  respond  to         
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mechanical  loading  and  to  repair  micro-damage.  Osteocytes  physically  contact  bone 
lining cells which in turn signal for osteoclast recruitment (Parfitt et al., 1996) and an 
important  role  for  osteocyte  apoptosis  in  bone  remodelling  has  been  suggested 
previously  (Bronckers  et  al., 1996;  Noble et  al., 1997). Although the withdrawal  of 
oestrogen in the current study is much more abrupt than diminished oestrogen levels 
prior  to  the  menopause  in  females,  the  oestrogen  levels  used  are  similar  to  normal 
physiological ranges for serum levels of females (Stricker et al., 2006). Therefore, the 
changes in osteocyte apoptosis during oestrogen deficiency observed in this study might 
provide an insight into the increase in bone turnover characteristic of osteoporosis.   
5.5.  Conclusion 
In  conclusion,  the  current  study  reveals  the  important  implications  of  oestrogen 
administration and oestrogen withdrawal on bone cell mineralisation. In addition, the 
apoptosis induction effect of oestrogen withdrawal from osteocytes and the preventative 
effects of oestrogen administration on osteocyte apoptosis, induced by apoptotic stimuli 
(Etoposide) have been shown. Dysregulated apoptosis of both osteoblasts and osteocytes 
may disrupt normal bone mineralisation and play a direct role in stimulating osteoclast 
resorption  and  bone  loss  during  oestrogen  deficiency.  This  may  have  important 
implications  for  osteoporotic  patients  as  increased  apoptosis  may  compromise  the 
osteocyte network, leading to bone resorption and increased fragility. Higher mineral 
production with oestrogen withdrawal may explain the higher heterogeneity observed in 
Chapter 3 of this thesis. Recognizing the underlying mechanisms regulating bone cell 
mineral production and apoptosis during oestrogen withdrawal and their consequences is 
necessary  to  further  our  knowledge  of  bone  biology  and  aid  in  the  formulation  of 
enhanced pharmaceuticals to remedy osteoporosis. In particular, the osteogenic activity 
and  mineral  production  of  osteoblasts  in  response  to  mechanical  loading  will  be 
investigated  in  Chapter  6  to  determine  whether  the  mechano-responsiveness  of 
osteoblasts is impaired during oestrogen deficiency.          
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6.  Mechanobiology of Osteoblasts during 
Oestrogen Deficiency 
6.1.  Introduction 
Bone is a dynamic tissue that adapts its structure and material properties in response to 
the mechanical stresses it experiences. It is believed that this adaptive nature serves to 
provide  a  structure  capable  of  withstanding  everyday  loads,  while  also  achieving  a 
minimal weight for efficient movement, a concept commonly referred to as Wolff’s Law 
(Wolff,  1892).  It  has  been  shown  that  mechanical  strain  imposed  by  physiological 
loading causes increased bone formation in vivo (Chambers et al., 1993; Robling et al., 
2000; Turner et al., 1996; Forwood et al., 1996). An obvious example of this is in tennis 
players, where the racquet arm has significantly greater mass and size than the non-
playing arm (Bass et al., 2002). Conversely, unloading of bones causes significant loss 
of bone mass and mineral content, as observed in astronauts experiencing weightlessness 
in microgravity (Holick, 1998; Schneider et al., 1995) and patients under strict bed rest 
(Baecker et al., 2003; Leblanc et al., 1990).  
Mechano-sensitive bone cells, such as osteocytes and osteoblasts, are capable of sensing 
their mechanical environment and in response to changes in applied mechanical loads, 
they  produce  biochemical  signals,  by  means  of  a  process  known  as  mechano-
transduction (Machwate et al., 1995). This mechanism activates cells to alter bone mass 
and architecture (Huang and Ogawa). Several biophysical forces are believed to act as 
the in vivo mechanical stimulus to bone cells in their native environment. In particular, it 
is thought that physiological loading results in direct tensile and compressive strains on 
osteoblasts  at  the  bone  surface  (Carter  et  al.,  1998;  Claes  and  Heigele,  1999).  In 
addition, shear stress (Bakker et al., 2001) and streaming potentials (Pienkowski and 
Pollack, 1983) have been proposed to occur as a secondary effects of applied mechanical 
strain,  when  the  interstitial  fluid  within  bone  matrix  is  perturbed.  Increased 
chemotransport due to mechanical loading, has been shown to modulate the effects of 
shear  stress  on  bone  cells  (Donahue  et  al.,  2003).  Shear  stress  is  the  principal 
biophysical  stimulus  that  has  been  studied  in  vitro  to  understand  mechano-
responsiveness by bone cells. Parallel plate flow chambers of various configurations 
have  been  employed  extensively  to  impart  a  constant,  controlled  stimulus  to  a 
homogeneous population of cells and investigate the biochemical response of osteoblasts 
and osteocytes to fluid shear stress (Frangos et al., 1988; Jacobs et al., 1998;           
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Reilly et al., 2003; Sakai et al., 1999; Sterck et al., 1998).    
The mechanotransduction of osteoblasts involves a cascade of signalling events. Under 
imposed mechanical stimuli, intracellular calcium mobilization is increased (Donahue et 
al., 2003) by the activation of plasma membrane receptors generated by ATP release, or 
by direct intercellular communication through gap junctions (Jorgensen et al., 2000). 
Other biochemical signalling molecules are produced including prostaglandin E2 (PGE2), 
nitric oxide (NO), osteopontin (OP) and extracellular signal-regulated kinase (ERK1/2) 
(Bakker et al., 2001; Batra et al., 2005; McGarry et al., 2005a; Papachristou et al., 2009; 
Reilly et al., 2003; You et al., 2001). Wnt protein expression is increased (Santos et al., 
2009), facilitated by down regulation of Wnt inhibitors (Sclerostin) by osteocytes (Van 
Bezooijen  et  al.,  2004)  under  applied  loading  (Moustafa  et  al.,  2012).  PGE2  is  an 
important regulator of bone remodelling (Norrdin et al., 1990; Suda et al., 1996) and 
plays a pivotal role in skeletal mechano-responsiveness (Weinreb et al., 1989). PGE 
receptors  are  present  in  MC3T3-E1  osteoblast-like  cells  and  facilitate  increased  cell 
growth and differentiation in the presense of PGE2 (Suda et al., 1996). Shear stress has 
been shown in vitro to stimulate mechano-transduction by bone cells to a greater degree 
compared to direct mechanical strain, in terms of NO, PGE2, and OP expression (Owan 
et  al.,  1997;  Smalt  et  al.,  1997).  Fluid  flow  engendered  shear  stress  also  leads  to 
increases in mineral matrix production in vitro (Sikavitsas et al., 2003; Van den Dolder 
et al., 2003).  
Post-menopausal  osteoporosis  in  females  is  associated  with  diminished  levels  of 
circulating serum oestrogen levels (Riggs et al., 2002). It is well known that osteoporotic 
bone has compromised strength due to bone loss (Bourrin et al., 2002; Ederveen et al., 
2001)  and  depleted  micro-architecture  (Aaron  et  al.,  2000).  In  addition,  a  marked 
increase in bone remodelling occurs at a cellular and tissue level, with bone resorption 
rates  superseding  bone  formation  rates  (Balena  et  al.,  1993).  In  Chapter  3  it  was 
observed that mineral heterogeneity is significantly altered during oestrogen deficiency 
(Brennan et al., 2011). In addition, bone loss following ovariectomy is remarkably site 
specific within the distal femur of rats (Baldock et al., 1998). Therefore, the synergistic 
effects  of  systemic  oestrogen  deficiency  and  local  differences  in  mechanical  forces 
within bones (Bergmann et al., 2001; Bergmann et al., 1993), might be responsible for 
heterogeneous  alterations  in  tissue  composition  and  structure  during  oestrogen 
deficiency. It has been shown that oestrogen levels affect cortical bone formation rates in 
response to mechanical loading in vivo (Devlin and Lieberman, 2007) and that blocking         
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oestrogen receptors substantially reduces cell proliferation stimulated by strain in vitro 
(Damien et al., 1998). Osteoblasts from osteoporotic donors differ in their response to 
cyclic  strain,  as  measured  by  cell  proliferation  and  release  of  transforming  growth 
factor-β (Neidlinger-Wilke et al., 1995) and show a long-term impaired response to flow 
induced shear stress, measured by PGE2 release (Sterck et al., 1998). It has been shown 
that combined exposure to oestrogen and shear stress increased biochemical signalling 
(PGE2  and NO release) in  an additive manner  (Bakker et  al., 2005).  In addition,  in 
Chapter 4 it has been shown that mineral concentration is significantly reduced, with 
increasing duration of  oestrogen  deficiency.  This  study demonstrated that  sheep that 
were oestrogen deficient for 31 months had significantly less bone tissue mineralisation, 
compared to sheep that were oestrogen deficient for 12 months. Normal ageing was 
ruled out as a cause of this diminished mineralisation. However, whether such local 
changes in tissue mineralisation arise due to an altered mechano-biological response by 
oestrogen deficient bone cells has not yet been studied.  
The aim of this study is to determine if the mechano-biological response of osteoblasts 
in  response  to  mechanical  stimulation  is  impaired  during  oestrogen  deficiency. 
Specifically, it was sought to understand whether changes in the production of PGE2 and 
bone tissue mineral occur in response to mechanical loading in the absence of oestrogen. 
To  address  this  objective,  an  osteoblast  cell  line  (MC3T3-E1)  was  pre-treated  with 
oestrogen to investigate the effect of subsequent oestrogen withdrawal on cell mechano-
sensitivity. Fluid shear stress was applied using an orbital rotator, or a parallel plate flow 
chamber and cell viability (alamar blue), mineralisation (alizarin red staining), and PGE2 
production (iummunoassay) were monitored.  
 
6.2.  Materials and Methods 
In this study, fluid shear stress was applied to in vitro cell cultures using either an orbital 
rotator or a parallel plate flow chamber. The governing equations to estimate the amount 
of mechanical stimulation imparted by each of these loading scenarios is outlined below.  
6.2.1  Orbital Rotation Shear Stress 
An estimate of the applied shear stress at the bottom of the culture dishes in an orbital 
rotator can be calculated according to equation 6.1,  
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Well of a 24 well plate, 
Ø=.8cm 
Shear  stress  =1.16  Pa 
on cell monolayer 
290 rpm  Orbital shaker (Stuart 
Microtitre SSM5) 
where R is the radius of orbital rotation, ρ is the density of the culture media, µ is the 
viscosity of the culture media, and f is the frequency of rotation (Kraiss et al., 2000; Ley 
et  al., 1989;  Pearce et  al.,  1996).  This  equation has  been shown to  be a reasonable 
estimation, when tested experimentally using a flow probe that uses optical velocimetry 
to measure shear stress within 166µm of its surface (Dardik et al., 2005a; Dardik et al., 
2005b).  The radius of orbital rotation for cells cultured in a 24 well plate is 0.8cm 
(calculated from the diameter of the 24 well plate wells), the viscosity of cell culture 
media is assumed to be 7.5 x 10
-4 Pa.s (Pearce et al., 1996), and the shaking frequency 
for experiments outlined below was 290 rpm (4.83 rps). As seen below, the estimated 
shear  stress  was  1.16  Pa  (11.6  dynes/cm
2),  which  is  within  predicted  physiological 
ranges of 6-30 dynes/cm
2 (Weinbaum et al., 1994). Figure 6.1 presents a schematic of 
the orbital rotation set-up for the current study. 
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Figure 6.1 Schematic of the orbital rotation set-up. An estimated shear stress of 1.16Pa 
was applied to the cell monolayer of each well within a 24 well plate using an orbital 
rotator at a speed of 290 rpm.         
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6.2.2  Design of Parallel Plate Chamber 
The  experimental  protocol  employed  in  this  instance  entails  culturing  cells  for 
significant  periods  (up  to  eight  days).  When  osteoblasts  are  cultured  in  vitro  they 
proliferate  and  produce  an  extracellular  matrix  that  they  subsequently  mineralise. 
Therefore, at high cell densities and significant culture periods, they begin to form 3D 
colonies and multilayer, even on flat tissue culture slides and also produce a surrounding 
extracellular matrix. This presents problems when using traditional parallel plate flow 
chambers whose height are in the range of 220-300µm (Bakker et al., 2001; Frangos et 
al., 1988; Jacobs et al., 1998; Nauman et al., 1999). It is necessary to have a sufficiently 
high chamber to ensure laminar flow conditions over the cell layer attached to the base 
of  the  chamber,  because  if  the  height  of  the  cell  layer  is  significant  relative  to  the 
chamber height, the steady flow assumption of Poiseuille pressure driven flow through 
parallel plates are no longer valid (Nauman et al., 2001). To overcome this problem a 
custom flow perfusion parallel plate configuration was designed, to confer shear stress to 
cell monolayers. The design of this flow chamber is outlined in detail below and detailed 
design drawings can be viewed in Appendix 1.  
The most significant parameters in the design of a parallel plate flow chamber are, the 
shear stress imposed on the cells, the Reynolds number of the flow and the entrance 
length (Nauman et al., 1999). Flow through a parallel plate configuration, known as 
Poiseuille flow in fluid mechanics, imparts a wall shear stress on the surface of the 
parallel plates of the flow chamber, i.e. on the cell monolayer attached to the surface. 
This can be expressed using the momentum balance for a Newtonian fluid (Equation 
6.2), assuming a parallel plate geometry; 
 
   
   
                                                                                                                 
where   is the resultant shear stress, ω is the width of the flow field,   is the gap between 
the plates,   is the volumetric flow rate and   is the viscosity of the perfusion medium 
(Frangos et al., 1988). Dimensions of the flow chamber in a parallel flow device are 
critical to ensure the cells are subjected to laminar flow conditions. A Reynolds number 
below 2000 is generally accepted to lie in the laminar region, however, transition from 
smooth or laminar flow to turbulent flow has been shown to occur at Reynolds numbers 
between 1000 and 8000 (Panton, 1996). Therefore, to ensure laminar flow through the          
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flow chamber Re was confined <1000. The Reynolds number of the flow profile through 
the parallel plate chamber is expressed by equation 6.3. 
    
   
 
 
  
  
                                                                                             
where   is the average flow velocity, h is the height of the chamber,   is the density of 
the perfusion medium,   is the viscosity,   is the flow rate and   is the width of the 
chamber. Combining equations 6.2 and 6.3 gives equation 6.4. An estimate of the entry 
length for plane Poiseuille flow to develop is expressed by equation 6.5 (Schlichting, 
1968) . 
    
    
                                                                                                            
                                          (6.5) 
The height of the constructed chamber is 0.40mm. The width of the chamber was chosen 
as 50mm in order to attain a height/width ratio of 0.008, which is within the ranges of 
literature (0.005-0.028) (Frangos et al., 1988; Jacobs et al., 1998; Nauman et al., 1999). 
A minimal height/width ratio is required for the flow to adhere to the assumption of 
being within an infinite parallel plates, which is necessary to apply equations 6.2-6.5 
(Massey and Ward-Smith, 1998). Performing a simple ‘solver’ analysis in Microsoft 
excel ensured dimensional optimisation was achieved, which conformed to constraints 
applied to equations 6.2-6.5 as well as those attained from computational analysis.   
 
  
Figure 6.2 Picture (A) and drawing (B) of parallel plate flow device, designed and 
manufactured in house
(A)  (B)          
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The  flow  chamber  consists  of  a  machined  and  polished  polycarbonate  top  plate,  a 
polyamide  machined  base  plate  and  an  intermediate  self  adhesive  backed  silicone 
sponge sheet to form a watertight seal (RH Nuttall, Birmingham, U.K.). The assembly 
was held in position by threaded screws along the periphery of the plates, see Figure 6.2. 
Unlike most parallel plate designs, where the intermediate gaskets govern the height of 
the chamber, here the channel height was precision machined out of the bottom plate, 
ensuring an accurate and consistent height along the length of the channel. In addition to 
the parallel plate chamber, the flow apparatus consisted of a Masterflex multichannel 
peristaltic pump and Masterflex L/S 17 precision platinum cured silicone tubing (Cole 
Parmer  Instruments  Inc,  London,  UK),  and  a  media  reservoir,  see  Figure  6.3.  A 
schematic of the flow system is also presented in Figure 6.4. The flow rate applied 
through cell chambers in the flow perfusion bioreactor is important, because it governs 
the shear stress on the cells. Flow rate and shear stress have a linear relationship in a 
channel of fixed dimensions (Smalt et al., 1997). This relationship was confirmed for the 
designed chamber with height 0.4mm and width 50mm (depicted in Appendix 2).   
 
Figure 6.3 Pulsatile fluid flow (PFF) pumping configuration including peristaltic pump, 
media reservoir, tubing, flow probe and parallel plate device operating in a CO2 
incubator at 37˚C and 5% CO2.         
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Figure 6.4 Schematic of closed loop pulsatile fluid flow system 
 
6.2.3  Cell Culture: Oestrogen Pre-treatment  
Prior to all mechanical loading experiments,  MC3T3-E1 murine calvarial osteoblasts 
were maintained in α-modified MEM supplemented with 10% fetal bovine serum (FBS), 
2mM L-glutamine, 100U/ml penicillin and 100 µg/ml streptomycin with the addition of 
commercially available 17β-estradiol (1x10
-8M, Sigma Aldrich) for fourteen days. Cell 
culture media were replenished every 3-4 days and cells were maintained at 37 °C in a 
humidified  5%  CO2  environment.  This  allowed  the  cells  to  become  accustomed  to 
oestrogen before subsequent withdrawal.  
6.2.4  Mechanical Loading Experiments 
Shear stress was conferred to MC3T3-E1 osteoblast-like cells by the use of an orbital 
rotator as described in section 6.2.4.1 and also by using a parallel plate configuration as 
described in section 6.2.4.2.  
6.2.4.1 Orbital Shear Stress and Experimental Conditions 
Cells with or without oestrogen pre-treatment were plated at a density of 3×10
4 cells per 
ml in 24-well plates and cultured overnight in osteogenic culture media supplemented 
with 50µg/ml ascorbic acid, 10mM/L β-glycerophosphate and 10nM/L dexamethasome.           
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Cells  were  then  cultured  under  separate  osteogenic  conditions  for  14  days;  (1) 
Osteogenic media with continued oestrogen treatment (1x10
-8M 17β-estradiol): E2, (2) 
osteogenic media without oestrogen: E-, (3) osteogenic media with oestrogen antagonist 
Fulvestrant (1x10
-7M, ICI 182780, Sigma Aldrich): F, and (4) osteogenic media with  
continued oestrogen treatment and the addition of the oestrogen antagonist: E2 + F. All 
cell  cultures  were  exposed  daily  to  40  minutes  of  intermittent  loading  (fluid  flow 
induced shear stress of 1.16 Pa) induced through an orbital shaker (Stuart Microtitre 
SSM5), similar to previous studies (Dardik et al., 2005b; Haga et al., 2003; Pearce et al., 
1996; Yun et al., 2002). The rationale for one loading cycle per day was based on in 
vitro (Batra et al., 2005; Robling et al., 2000) and in vivo studies (Umemura et al., 1997) 
which have demonstrated that mechanical loading elicits more of an osteogenic response 
when applied in discrete loading bouts, compared to continuous loading without rest 
periods.  All  cell  culture  media  were  replenished  every  3-4  days  and  cells  were 
maintained at 37 °C in a humidified 5% CO2 environment. Non-loaded cultures under 
aforementioned conditions 1-4 and under the same temperature and gaseous conditions 
served as static controls.  
6.2.4.2 Laminar Shear Stress and Experimental Conditions 
In order to evaluate the biochemical response of cells to shear stress, a parallel plate flow 
chamber, as described in section 6.2.2, was used to confer pulsatile fluid flow (PFF) to 
monolayer  cultures.  Although  orbital  shear  stress  provides  a  very  useful  means  of 
evaluating  applied  loading  to  cells  and  has  been  used  extensively  for  this  purpose 
(Dardik et al., 2005a; Dardik et al., 2005b; Kraiss et al., 2000; Ley et al., 1989; Pearce 
et al., 1996), a parallel plate design was used instead of orbital rotation as it confers a 
more controlled, constant, laminar flow throughout the test chamber, Therefore, it would 
be expected to give a more accurate evaluation of the effects of shear stress on oestrogen 
deficiency cells for the analysis of biochemical production.  
Cells  that  were  pre-treated  for  14  days  with  oestrogen,  as  described  in  6.2.3,  were 
trypsinized and plated  at  a density of 18.48 ×10
4/cm
2    onto  25 x 75mm  rectangular 
polystyrene culture slides (Nunc Brand, Biosciences, Dublin, Ireland) in 1 mL of media, 
confined within silicone gaskets attached to the slides using ‘press to seal’ technology 
(Biosciences). Slides were contained within slide plates, four slides per plate, and were 
pre-incubated  overnight  in  osteogenic  culture  media  supplemented  with  50µg/ml 
ascorbic acid, 10mM/L β-glycerophosphate, 10nM/L dexamethasome and 17β-estradiol 
(1x10
-8M,  Sigma  Aldrich).  Cells  were  then  either  cultured  up  to  seven  days  in          
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osteogenic  media  without  oestrogen:  E-,  or  with  continued  oestrogen  supplemented 
osteogenic media: E2. Media (13 mL) was replenished every 3-4 days. Half of the slides 
from each media pre-treatment condition were then randomly assigned to either undergo 
applied  loading  group  or  serve  as  non-loaded  controls.  Bioreactor  components  were 
steam sterilized prior to use and were assembled under a laminar flow hood in sterile 
conditions. The slides were placed into the grooves in the base of the parallel plates and 
the pump with six rollers was operated at 48rpm which resulted in pulsatile fluid flow 
with a speed of 137ml/min at 4.8 Hz. The flow apparatus was kept in a 37˚C incubator 
with 5% CO2 for the duration of the fluid flow experiment, see Figure 6.3. Flow was 
applied for two hours, exposing cells to an estimated average shear stress of 1.25 Pa 
(calculated using equation 6.2). The flow rate of perfusion media through the system 
was measured using a Ts410 transit time tubing flow meter and flow probe (Transonic 
Systems  Inc,  Maastricht,  The  Netherlands).  Control  slides  were  placed  beside  the 
bioreactor and were cultured under the same temperature and gaseous conditions, but 
remained non-loaded in the slide plates in 13 mL of culture media, serving as non-
loaded static controls.  Both loaded and non-loaded cell seeded slides were subsequently 
post-incubated in 6 mL of culture media for one hour in the absence of PFF. 
 
6.2.5  Cellular Assays 
6.2.5.1 Cell Viability Assay 
Cell metabolic activity was assessed in orbital shear stress experiments using Alamar 
Blue cell viability reagent (Invitrogen). This assay is designed to quantitatively measure 
the proliferation and viability of cells. Alamar blue is a redox indicator that yields a 
colorimetric  and  fluorometric  response  to  metabolically  active  cells.  It  uses  a  blue 
indicator dye resazurin, which is converted to its fluorescent pink form, resorufin, by 
enzymes produced by metabolically active cells. Non-viable cells have lower metabolic 
activity  and  therefore  produce  proportionally  less  signal.  To  perform  the  assay,  cell 
culture  media  was  removed  from  wells  and  cells  were  washed  with  heated  (37˚C) 
phosphate buffered saline (PBS). Alamar blue dye was diluted 1:10 in PBS and 350 µl 
was added to each well. Cells were incubated at 37 ˚C for 60 minutes, after which 100µl 
of  cell  conditioned  alamar  blue  reagent  was  added  in  triplicate  to  a  96  well  plate. 
Absorbance was measured at 550 and 595nm using a microplate reader (Wallac 1420, 
Victor)  and  viability  was  expressed  as  %  reduction  between  the  two  wavelengths.          
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6.2.5.2 Mineralisation Assay 
Mineral production was quantified in orbital shear stress experiments using Alizarin Red 
S staining, as described in detail in chapter 5. Briefly, cells were stained with 40mM 
Alizarin  Red-S  (Sigma  Aldrich)  and  subsequently  de-stained  using  100nM 
cethylpyridium  chloride (Sigma Aldrich). The  absorbance of the extracted stain  was 
measured at 550 nm on a microplate reader (Wallac 1420, Victor). Relative photometry 
units were converted to µmole/cm
2 of calcium, since one mole of alizarin red binds to 
two moles of calcium (Norgaard et al., 2006).  
6.2.5.3 PGE2 Measurement 
In  parallel  plate  flow  experiments,  PGE2  release  in  the  conditioned  medium  was 
measured by an enzyme immunoassay (EIA) system (KO18-HX1, Arbor Assays, Ann 
Arbor, MI, USA). This assay is based on the competition between PGE2 present in the 
test samples and a PGE2 acetylcholinesterase (AChE) conjugate, which can both bind to 
a limited quantity of PGE2 monoclonal antibody. In this way, the amount of PGE2 AChE 
conjugate that binds to the PGE2 antibody is inversely proportional to the quantity of 
PGE2 present in the test samples. The PGE2–antibody arrangement then binds to a goat 
polyclonal anti-mouse IgG that is attached to the bottom of the wells of the microtitre 
plate. After unbound PGE2 is removed and a substrate to AChE is added, the enzymatic 
reaction results in a colour change in the wells, the intensity of which is directly related 
to the amount of PGE2 present in the sample.  
To perform the PGE2 assay, 100µl samples from each of the experimental groups were 
added to the wells of the PGE2 enzyme immunoassay. Next, 125 µl was added to the 
non-specific binding wells (since the PGE2 monoclonal antibody will not be added to 
these  wells).  Then,  100  µl  of  assay  buffer  was  added  to  wells  acting  as  maximum 
binding wells. Next, 25 µl of the PGE2 conjugate was added to each well, followed by 
25µl of the PGE2 monoclonal antibody to all wells apart from the non-specific binding 
wells. The plate was then placed on a rocker for 15 min at 300 rpm and incubated at 4˚C 
for 16 hours, after which any unbound PGE2 conjugate was removed by washing the 
well with wash buffer diluted in distilled water. The substrate to AChE was then added 
to each well and after 30 minutes incubation at room temperature and the enzymatic 
reaction resulted in a colour change to the well. The reaction was stopped by addition of 
1M solution of hydrochloric acid (HCL) and the intensity of the colour change was read 
at a wavelength of 420nm on a microplate reader (Wallac Victor ,1420). A standard          
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curve was created from serial dilutions of a precise quantity of PGE2 supplied and was 
used to determine the PGE2 concentration of the experimental samples, after correction 
for the dilution factor of the sample is made.  
6.2.6  Statistics 
Data is expressed as a mean ± standard deviation. The general linear model ANOVA 
procedure  was  used  to  analyse  statistical  differences  between  groups.  Pre-treatment 
(with/without  oestrogen  pre-treatment),  loading  status  (shear  stress  or  static),  and 
treatment group (E2, E-, F, E2+F) were crossed, fixed factors, i.e. each level of one 
factor occurred in combination with each level of the other factor and their effect on the 
response variable was determined. % reduction was the response variable for the alamar 
blue experiment and µmole Ca/cm
2
 for alizarin red assay. Fixed, crossed factors for the 
PGE2 experiment were a) duration of oestrogen deficiency prior to loading, b) loading 
status (with/without PFF) and c) treatment. The response variable was pg PGE2/mL. 
There was a sample size of n=3 per group and each experiment was repeated to give n=6 
per group. Factor effects were determined using the ANOVA F test and group means 
were compared using Tukeys-Kramer pair-wise multiple comparison test (Minitab 16). 
Statistical significance was defined as p≤ 0.05.  
6.3.  Results 
6.3.1  Cell Viability 
Cells without oestrogen pre-treatment: At day 7, when data from all treatment groups 
was pooled, there was significantly lower cell viability in cultures with applied loading 
(orbital shear stress), compared to static cultures (10.49 ± 1.01 vs. 12.44 ± 3.81, p<0.03). 
Following pair-wise analysis between treatment groups, it was found that cell viability 
was significantly lower with F compared to E2 (6.85 ± 3.44 vs. 13.88 ± 3.62, p<0.01), 
see Figure 6.5. In the E2 and E2+F groups at day 7, cell viability was lower with orbital 
shear stress compared to static conditions (9.07 ± 3.12 vs. 3.12 vs. 13.88 ± 3.62, p<0.05) 
and (10.47 ± 1.37 vs. 15.41 ± 3.01, p<0.05) respectively.   
At day 14, when all data was pooled from all treatment groups, there was no significant 
evidence of a loading status affecting cell viability. Similarly, when data was compared 
between treatment groups, no significant difference between group means was found at 
day  14.           
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Figure 6.5 Cell viability was quantified using alamar blue viability assay in cell cultures 
without oestrogen pre-treatment. ^ indicates significantly lower compared to E2, n=6 per 
group, per loading status, at each time point. * indicates significantly lower compared to 
static conditions.  
 
Oestrogen pre-treated cells: At day 7, exposure to fluid shear stress (orbital) had no 
effect  on  cell  viability  compared  to  non-loaded  cultures,  either  when  data  from  all 
treatments  was  pooled,  or  within  each  treatment  group,  as  depicted  in  Figure  6.6. 
Likewise, at day 14, cell viability from cultures with applied orbital shear stress did not 
differ from static cultures, either when data from all treatments was pooled, or when 
means were compared between groups. Furthermore, no significant difference was found 
when treatments were compared to continued oestrogen controls (E2), either at day 7 or 
day 14.  Finally,  cell viability was  not  altered in  cultures  pre-treated with  oestrogen, 
compared previously untreated cultures.   
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Figure 6.6 Cell viability in cell cultures with oestrogen pre-treatment. There was no 
significant difference between treatment groups compared to controls (E2), or between 
non-loaded and loaded conditions. n=6 per group, per loading status, at each time point. 
 
6.3.2  Mineral production 
Cells without oestrogen pre-treatment: At day 7, when data from all treatments was 
pooled, significantly higher mineralisation was found in cultures with exposure to fluid 
shear stress compared to static conditions (0.23 ± 0.16 vs. 0.09 ± 0.08, p<0.01). As 
depicted in Figure 6.7, by day 7, mineral production was significantly higher with orbital 
shear stress compared to static conditions in the E- group (0.39 ± 0.31 vs. 0.09 ± 0.04, 
p<0.01). With applied shear stress, mineral production was higher in oestrogen deficient 
controls (E-) compared to E2 controls (0.39 ± 0.31 vs. 0.06 ± 0.03, p<0.03).  
After 14 days of culture, when data from all treatments was pooled, similarly to day 7, 
mineralisation was higher with applied shear stress compared to static conditions (0.81 ± 
0.23  vs.  0.45  ±  0.05,  p=0.001).  Within  treatment  groups,  it  was  observed  that 
mineralisation was higher with applied shear stress compared to static conditions in the 
E- group (1.12 ± 0.19 vs. 0.47 ± 0.24, p<0.05). Similar to day 7, with applied shear 
stress, E- was significantly more mineralised compared to the E2 control group (1.12 ± 
0.19 vs. 0.55 ± 0.19, p<0.03).   
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Figure  6.7  Mineralisation  after  7  and  14  days  under  static  or  orbital  shear  stress 
conditions,  in  cultures  without  oestrogen  pre-treatment,  n=6  per  group,  per  loading 
status, at each time point. * indicates significantly higher compared to static conditions 
of the same treatment group.  ^ signifies statistically higher compared to E2 controls, 
with applied shear stress, at the same time point.   
Oestrogen  pre-treated  cells:  At  day  7,  when  data  from  all  treatments  was  pooled, 
higher mineralisation was found with exposure to fluid shear stress compared to static 
conditions (0.50 ± 0.10 vs. 0.20 ± 0.06, p<0.01). As depicted in Figure 6.8, at day 7, 
mineral  production  was  higher  in  cultures  with  exposure  to  intermittent  shear  stress 
compared to static controls in the E2 and E- groups (0.56 ± 0.14 vs. 0.27 ± 0.15, p<0.05) 
and (0.63 ± 0.17 vs. 0.26 ± 0.04, p<0.01).  
After 14 days, when data from all treatments was pooled, higher mineralisation was 
found in cultures with exposure to fluid shear stress compared to static conditions (0.75 
± 0.30 vs. 0.38 ± 0.16, p<0.01). Higher mineral production was found with applied shear 
stress compared to static conditions in the E2 (1.18 ± 0.11 vs. 0.29 ± 0.11, p<0.01) 
group. With applied shear stress, the mineral in each of the oestrogen deficiency groups 
was significantly less; E- (0.76 ± 0.08, p<0.04), F (0.53 ± 0.16, p<0.01) and E2+F (0.52 
±  0.10,  p<0.01)  compared  to  the  mineral  concentration  with  continued  oestrogen 
treatment  controls,  E2  (1.18  ±  0.11).  Under  static  conditions,  E-  resulted  in  more 
mineral production compared to E2 (0.62 ± 0.08 vs. 0.29 ± 0.11, p<0.04).  
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Figure  6.8  Mineralisation  after  7  and  14  days  under  static  or  orbital  shear  stress 
conditions, in cultures that were pre-treated with oestrogen. n=6 per group, per loading 
status, at each time point. * indicates significantly higher compared to static conditions 
of the same treatment group. ** indicates significantly lower than E2, with applied shear 
stress,  at  the  same  time  point,  +  indicates  significantly  higher  than  E2  under  static 
conditions, at the same time point.  
Effect of oestrogen pre-treatment on cell  mineralisation: When the effect of pre-
treatment  on  subsequent  mineral  production  was  evaluated,  at  day  7,  higher 
mineralisation  was  observed  with  oestrogen  pre-treatment,  compared  to  previously 
untreated cells in the E2 group, under applied shear stress (0.55 ± 0.11 vs. 0.06 ± 0.03, 
p<0.02) and in static conditions (0.27 ± 0.16 vs. 0.03 ± 0.02, p<0.02). Finally, after 14 
days it was observed that pre-treatment with oestrogen caused significantly increased 
mineralisation compared to untreated cultures in the E2 group with applied shear stress 
(1.18 ± 0.11 vs. 0.55 ± 0.19, p<0.03).   
6.3.3  PGE2 release    
Effect of Pulsatile Fluid Flow on PGE2 Release 
As depicted in Figure 6.9, when pulsatile fluid flow (+PFF) was compared with static 
cultures (-PFF) at day 2, +PFF caused significantly higher PGE2 release compared to 
static cultures. This was found both with continued oestrogen controls, E2 (679.03 ± 
212.62 vs. 50.94 ± 25.65, p<0.01) and with oestrogen deficiency, E- (547.05 ± 223.45 
vs.  96.02  ±  32.68,  p<0.01).  Similarly,  at  day  7,  there  was  significantly  more  PGE2 
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release  in  +PFF  compared  to  static  cultures  with  continued  oestrogen  treatment,  E2 
(738.50 ± 158.42 vs. 23.17 ± 13.15, p<0.01) and in the oestrogen deficient group, E- 
(367.19 ± 306.27 vs. 37.84 ± 27.03, p<0.04).  
Effect of Oestrogen Withdrawal on PGE2 Release 
Comparing  oestrogen  deficient  cultures  with  continued  oestrogen  treatment,  it  was 
observed that in static cultures, there was no statistical difference between groups after 
either two or seven days. When cultures were subjected to PFF, there was no significant 
difference  after  two  days  of  oestrogen  withdrawal  compared  to  continued  oestrogen 
treatment, however, by seven days of oestrogen depletion there was significantly lower 
PGE2  release  in  the  oestrogen  deficient  group  compared  to  continued  oestrogen 
treatment, E2 (367.19 ± 306.27 vs. 738.50 ± 1.58.42, p<0.01), indicating that the release 
of PGE2 is significantly reduced with oestrogen withdrawal. There was no significant 
difference  between  time  points  (day  2  versus  day  7)  in  cultures  with  applied  PFF. 
However, it was found that under static conditions, PGE2 release in oestrogen deficient 
cells at day 7 was significantly lower compared to day 2 (37.84 ± 27.03 vs. 96.02 ± 
32.68,  p<0.01),  indicating  that  the  release  of  PGE2  is  significantly  reduced  with 
increasing duration of oestrogen deficiency.    
 
Figure  6.9  PGE2  release  in  MC3T3-E1’s  undergoing  oestrogen  deficiency  (E-) 
compared with  continued  oestrogen treatment  (E2), with/without pulsatile fluid  flow 
(PFF). n=6 per group, per loading status, at each time point.  * denotes significantly 
higher  compared  to  static  conditions,  ^  indicates  significantly  lower  compared  to 
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continued oestrogen controls (E2). ** indicates significantly lower compared to the same 
group at two days.   
6.4.  Discussion 
Oestrogen withdrawal has long been associated with rendering bones weak and more 
susceptible to fractures; however, the cellular mechanisms controlling such changes are 
still  being  delineated.  This  study  demonstrates  that  fluid  shear  stress  significantly 
enhances mineral matrix production by osteoblasts in vitro, particularly in cultures pre-
treated  with  oestrogen.  This  study  has  shown  for  the  first  time  that  under  applied 
loading, oestrogen deficiency imposed either by withdrawal of oestrogen or by blocking 
oestrogen receptors, causes significantly lower mineral production in cultures that had 
become  accustomed  to  oestrogen  compared  to  continued  oestrogen  exposure. 
Conversely, in cultures without oestrogen pre-treatment, higher mineral production was 
found when cells were prevented from oestrogen exposure, compared to those treated 
with  oestrogen.  Fulvestrant  reduced  cell viability  of cultures  and orbital  shear stress 
reduced viability in cultures without oestrogen pre-treatment, but it had no affect on the 
viability of those with oestrogen pre-treatment. Most interestingly, significant reductions 
in PGE2 release in response to mechanical loading were observed in oestrogen deficient 
cultures  compared  to  those  with  continued  oestrogen  treatment.  Furthermore,  the 
reductions  in  PGE2  release  as  a result of  oestrogen withdrawal  were amplified with 
increasing  duration  of  oestrogen  deficiency.  Together,  these  findings  support  the 
hypothesis  that  the  anabolic  bone  formation  response  of  bone  cells  to  mechanical 
loading is impaired during oestrogen deficiency. 
There are a number of limitations associated with the current study that should be noted. 
Firstly,  for  orbital  shear  stress  experiments  all  cell  cultures  underwent  shear  stress 
stimulation  on  rocker  platforms,  in  laminar  flow  hoods  at  ambient  temperature  and 
gaseous conditions. Therefore, for the duration of the loading bouts (40 minutes daily) 
the  cells  were  not  cultured  under  conditions  of  37˚C  and  5%  CO2.  However,  static 
cultures were exposed to the same temperature and gaseous conditions, for the same 
durations  as  mechanically  stimulated cultures, therefore, this  limitation  should affect 
both  groups  equally  and  direct  comparisons  between  groups  is  still  valid.  A  further 
limiting factor of this study design is the different means of shear stress application 
employed for the separate studies i.e. the orbital shear stress using the rotational rocker 
for mineralisation  and viability  studies,  and the parallel  plate flow system  for PGE2 
studies. The rocker technique does not apply a uniform laminar stress across the entire          
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monolayer  (Dardik  et  al.,  2005b)  and  although  important  differences  were  indeed 
detected  in  mineral  production,  this  method  was  deemed  unsuitable  for  the  more 
sensitive biochemical studies. In addition, cells were plated at different densities in both 
set-ups, with a lower starting cell density in the longer duration rocker study, whereas, a 
higher cell density was employed for parallel plate experiments to ensure adequate cell 
coverage by two days of oestrogen deficiency. The advantages of employing the rocker 
apparatus initially, was the quick and easy method of attaining important information, 
regarding the mineral production of oestrogen deficient cells under applied loading. It 
permitted investigation of a range of treatment groups and the mechanisms behind the 
results obtained were then investigated using the parallel plate device. A limitation to 
note regarding the laminar flow study was that during the two hour loading sessions 
using the parallel plate device, a circulating volume of 150 mL of media was used, while 
the  non-loaded  static  control  cells  were  kept  in  13  mL  media.  However,  different 
quantities of media between loaded and non loaded cells could not have affected the 
results  obtained  since  both  groups were replenished with  the same quantity of fresh 
media (6 mL) following each loading session and incubated for one hour, after which the 
biochemical release into media was measured.    
In  traditional  parallel  plate  configurations  the  microscope  slide  with  cell  monolayer 
attached, forms the base of the channel, therefore, any flow entrance effects would be 
applied to a portion of the cell monolayer under investigation. The estimated entrance 
length of the flow through the flow chamber was 1.07mm, as calculated using equation 
6.5. However, the entrance length calculated using ANSYS CFX was 20mm (Vaughan, 
2011).  Therefore,  to  ensure  laminar  flow  was  achieved  prior  to  reaching  the  cell 
monolayer,  slides  were  positioned  greater  than  20  mm  beyond  the  entrance  of  the 
chamber.  The  estimated  Reynold’s  number  was  calculated  as  66.74  (Equation  6.4), 
ensuring laminar flow over the cell monolayer. In the parallel plate design presented in 
this chapter, three grooves were machined out of the base plate to accommodate three 
microscope  slides  in  series,  which  lay  flush  with  the  base  of  the  chamber.  The 
advantages of this feature were twofold. Firstly, the entrance and exit flow effects in the 
chamber were eliminated and the flow was  fully  developed before reaching the cell 
monolayer  on  each  of  the  microscope  slides,  thereby,  ensuring  that  Poiseuille  flow 
assumptions were valid over 100% of the length of the slides. Secondly, three slides 
allowed for optimal analysis, which overcame, to a degree, the inherent sample size 
constraints imposed by most parallel plate designs, thereby, reducing the requirement for          
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serial repetitive, experimental runs. The base plate has two entrance channels, which led 
to reservoirs through which media enters and exits the chamber. The reservoirs allowed 
the flow to steady after a change in direction, prior to entering the flow chamber.  
The results of the current study emphasize the importance of mechanical stimulation on 
osteoblastic cell activity. They show that osteoblasts exhibited significantly higher PGE2 
release  in  response  to  applied  shear  stress.  This  finding  is  in  agreement  with  other 
studies  which  have  demonstrated  the  enhancing  effect  of  mechanical  stimulation  on 
PGE2  release  by  osteoblasts  (Bakker  et  al.,  2001;  Nauman  et  al.,  2001;  Reich  and 
Frangos, 1991) and osteocytes (Klein-Nulend et al., 1995b; Reilly et al., 2003). The 
enhancing effect of fluid shear stress on mineralised matrix deposition in this study is 
evident, in particular in cultures that were pre-treated with oestrogen. A previous study 
demonstrated no distinguishable effects of shear stress on mineral production (Nauman 
et al., 2001) however. In that study, cells were cultured statically for 14 days, prior to 
shear stress initiation, therefore, mineral matrix production was already well advanced 
and subsequent differences in mineral production as a consequence of shear stress may 
have  been  undetectable  (Nauman  et  al.,  2001).  Furthermore,  the  height  of  the  cell 
colonies  formed after 21 days  may have been  significant  in  relation  to  the chamber 
height (220µm), in which case the assumptions of Poiseuille flow may no longer have 
been valid (Nauman et al., 2001). The finding of higher mineral production presented in 
this  study,  is  in  agreement  with  studies  that  demonstrated  enhanced  mineral  matrix 
production in 3D scaffolds with increasing fluid shear stress in vitro (Sikavitsas et al., 
2005; Sittichockechaiwut et al., 2009; Van den Dolder et al., 2003). In addition, the 
enhancing effect of mechanical stimulation on in vivo bone formation has been well 
established (Chambers et al., 1993; Forwood et al., 1996; Robling et al., 2000; Turner et 
al., 1996).  
In  this  study,  it  has  been  shown  for  the  first  time,  that  when  cells  are  subjected  to 
mechanical  stimulation,  mineral  production  is  significantly  lower  with  oestrogen 
withdrawal  compared  to  cultures  with  continued  oestrogen  exposure.  The  enhancing 
effect of oestrogen treatment in unison with physiological loading on bone formation has 
been  well  documented:  oestrogen  increases  bone  mineral  density,  trabecular  bone 
volume, bone mass and the degree of bone mineralisation in postmenopausal females, 
(Boivin et al., 2005; Khastgir et al., 2001; Wahab et al., 1997) and also enhances bone 
formation in animal studies (Chow et al., 1992; Edwards et al., 1992). Together, these 
studies demonstrate that oestrogen treatment is capable of exerting an anabolic effect on          
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bone and indicate that oestrogen stimulates osteoblast activity, which is in agreement 
with the findings of the current study. However, altered mineral production as a direct 
consequence of oestrogen withdrawal in vitro has not been demonstrated previously. 
Furthermore, this study has demonstrated that with applied loading, blocking oestrogen 
receptors  with  fulvestrant,  an  oestrogen  antagonist,  also  significantly  reduces 
mineralisation,  in  comparison  to  continued  oestrogen  treatment.  However,  lower 
viability and mineral production with fulvestrant compared to oestrogen withdrawal was 
also  observed,  indicating  that  a  down-regulation  of  oestrogen  receptors  impairs  cell 
activity to a greater degree than simply withholding oestrogen. Similar to Chapter 5, it 
was found that pre-treatment with oestrogen significantly altered cell activity compared 
to untreated cultures. For example, in oestrogen pre-treated cultures under loading, lower 
mineral production was found when oestrogen was withdrawn, compared to continued 
oestrogen  treatment,  whereas,  in  previously  untreated  cells  during  loading,  lower 
mineral  production  was  observed  with  oestrogen  deficiency,  compared  to  oestrogen 
exposure.  
Interestingly, this study highlights the necessity for both mechanical stimulation and 
hormone balance in  unison  to  maintain bone formation.  This  is  evidenced  from our 
studies on pre-treated cultures where oestrogen treatment under applied loading caused 
significantly  higher  mineralisation  compared  to  both  1)  oestrogen  withdrawal  under 
mechanical  loading  and  2)  oestrogen  treatment  of  non-loaded  static  cultures.  The 
requirement for both oestrogen and mechanical stimulation may  explain why female 
amenorrheic (lack of menstrual cycle) runners who place ample mechanical loading on 
their bones, but who lack oestrogen circulation, suffer from bone fragility (Cobb et al., 
2003). On the other hand, this  may also  shed  light  on why  astronauts, with  normal 
hormone circulation and lack of mechanical forces on their bones, suffer from weak 
bones characteristic of osteoporosis (Schneider et al., 1995).  
Most interestingly, this study has shown that the mechano-responsiveness of osteoblasts, 
in terms of PGE2 release, is impaired during oestrogen deficiency. A previous study 
showed that bone cells from osteoporotic donors have reduced PGE2 release, compared 
to those from healthy donors (Sterck et al., 1998). However, as noted by the authors, it 
was ‘unclear whether the abnormal response of the osteoporotic cells was the cause of 
the osteoporotic status, or whether it resulted from the osteoporotic status’. The results 
of the current study have explained, in part, these particular findings by revealing that 
the mechano-sensitivity of osteoblast-like cells became impaired as a direct consequence          
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of oestrogen withdrawal. Furthermore, by showing that increasing duration of oestrogen 
withdrawal exacerbated the impaired response to mechanical loading, this study suggests 
that the abnormal response of osteoporotic cells found by Sterck et al may occur as a 
direct  result  of  being  exposed  to  prolonged  oestrogen  deficiency  and  not  that  the 
abnormal response resulted from the osteoporotic status. It is interesting to speculate on 
the  mechanisms  behind  such  altered  biochemical  responses.  Mechano-sensing  by 
primary cilia, which are solitary organelles that project from the cell surface, is mediated 
by cyclic adenosine monophosphate (cAMP) (Kwon et al., 2010) and they are required 
for flow induced PGE2 release (Malone et al., 2007).  
In addition, PGE2 induces the production of AMP in bone cells (Scutt et al., 1995); 
therefore,  the  up-regulation  of  AMP  with  shear  stress  could  occur  indirectly  via  a 
mechanism involving increased prostaglandin production with shear stress. A reduction 
in PGE2 release by oestrogen deficient cells may therefore represent an impairment of 
this signalling mechanism, or decreased primary cilia numbers. Furthermore, shear stress 
imposed on the cell membrane by fluid flow would confer drag forces to the glycocalyx, 
or  pericellular  matrix,  the  composition  of  which  varies  according  to  cell  function 
(Rambourg and Leblond, 1967). Therefore, it could increase or decrease cell sensitivity 
to  shear  stress.  Indeed,  when  the  glycocalyx  of  osteocytes  was  degraded  with 
hyaluronidase treatment, it was found that the shear stress induced PGE2 release was 
eliminated (Reilly et al., 2003). Is it possible therefore, that oestrogen acts to maintain 
mechano-sensitivity  by  acting  on  the  glycocalyx?  Further  studies  are  required  to 
delineate this question.   
The lower PGE2 release levels under loading found in oestrogen deficient cell cultures in 
the current study is in agreement with the lower mineral production observed during 
mechanical loading in oestrogen deficient cultures. In fact, the lower PGE2 release may 
contribute  to  the  impaired  mineralisation  accompanying  oestrogen  withdrawal  since 
PGE2 has been shown to be a potent stimulator of mineral production in vitro (Kaneki et 
al., 1999; Nagata et al., 1994; Sakamoto et al., 2003; Keila et al., 2001) and in vivo 
(Mori et al., 1992; Weinreb et al., 1997; Keila et al., 2001). Exposure of fetal and adult 
rat calvarial cells, as well as human dental pulp cells to PGE2, evoked a significant 
increase in ALP and mineral production in vitro (Kaneki et al., 1999; Nagata et al., 
1994;  Sakamoto  et  al.,  2003;  Keila  et  al.,  2001).  Similarly,  administration  of  PGE2 
increases bone mass, density and mechanical strength in  young rats (Weinreb et al., 
1997) as well as bone formation and bone area in aged rats (Keila et al., 2001). Most          
 
124 
 
interesting  in  the  context  of  the  current  study,  previous  research  showed  that  PGE2 
administration to ovariectomized rats restored bone area to levels of age matched sham 
operated  animals  as  well  as  increasing  mineral  apposition  and  bone  formation  rates 
(Mori et al.,1992).  
In conclusion, this study has shown that oestrogen withdrawal inhibits the mechano-
responsiveness  of  osteoblasts  by  reducing  biochemical  signalling,  which  may  be 
responsible  for  the  reduced  mineralisation  found  in  oestrogen  deficient  cells  under 
applied loading. This study has also highlighted the synergistic effects of oestrogen and 
mechanical loading on bone cell activity. Impaired capacity of bone cells to respond to 
mechanical stimulation may be the underlying cause of abnormal bone metabolism and 
consequential increased fragility associated with osteoporosis. Therefore, understanding 
the cellular mechanisms involved in impaired mechanically driven bone adaptation, by 
either de-synthesizing bone cells to mechanical loading or inhibiting biochemical signal 
responses  are  vital  for  the  development  of  adequate  therapeutic  interventions.           
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7.  Conclusions 
7.1.  Main Finding of the Thesis 
The research outlined in this thesis has focused on investigating bone tissue mineral 
alterations during osteoporosis by analyzing animal tissue from an ovariectomised model 
and a drug treated cohort over the course of ageing. Static and dynamic in vitro cell 
culture experiments during oestrogen withdrawal were also performed to investigate the 
role of oestrogen deficiency on bone mineral production, apoptosis, proliferation, and 
mechano-biological responsiveness. The primary findings of the thesis are presented in 
this chapter, together with recommendations for future studies.  
1)  The  first  study  of  this  thesis  entailed  investigating  trabecular  bone  mineral 
distribution during oestrogen deficiency in an animal model of osteoporosis. Site 
specific  changes  in  mineral  heterogeneity  occurred  within  trabeculae  as  a 
consequence of oestrogen withdrawal. Furthermore, alterations in tissue mineral 
distribution occurred along the inter-trochanteric fracture line, the most common 
osteoporotic  fracture  site.  This  finding  is  of  immense  importance  since  it 
demonstrates the fact that local factors have a significant impact on bone tissue 
during oestrogen depletion. Therefore, it highlights that those analytical methods, 
which  only  evaluate  the  mean  mineral  content  of  bone  tissue,  cannot  detect 
important tissue level mineral alterations. Furthermore, this study indicates that 
in  addition  to  important  changes  in  bone  mass  and  micro-architecture  during 
osteoporosis,  altered  mineral  distribution  may  be  a  contributing  factor  for 
weakened bone at an increased risk of fracture.  
2)  The  second  study  of  this  thesis  focused  on  evaluating  the  effects  of  ageing, 
prolonged oestrogen withdrawal, and bisphosphonate drug treatment on tissue 
level mineral distribution. This study found that mineralisation is higher with 
increasing age in healthy sheep (12 month CON versus 31 month CON), and that 
long term oestrogen deficiency reduces the calcium concentration of ovine bone 
tissue.  It  was  observed  that  Zoledronic  acid  treatment  during  oestrogen 
deficiency  led  to  a  more  homogeneous  calcium  distribution  both  within 
trabeculae  and between femoral  regions.  It is  proposed that these  changes in 
mineral distribution may contribute to the ability of Zoledronic acid treatment to 
prevent fracture occurrence during oestrogen deficiency. Together, these findings          
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are  of  potential  importance  in  understanding  the  underlying  mechanisms  of 
altered  mechanics  during  osteoporosis  and  the  long-term  efficacy  of  drug 
treatment.  
3)  The third study of the thesis sought to delineate the mechanisms responsible for 
the altered mineral distribution in vivo during oestrogen deficiency detected in 
Chapters 3 and 4. It was observed that oestrogen pre-treatment promoted bone 
cell  mineral  production,  and  that  bone  cells  became  accustomed  to  their 
oestrogen  environment  and  responded  to  oestrogen  withdrawal  by  increasing 
mineral  production.  Furthermore,  the apoptosis  induction  effects  of oestrogen 
withdrawal from osteocytes have been highlighted, which might play a role in 
altered  tissue  mineral  heterogeneity.  The  preventative  effect  of  oestrogen  on 
caspase 3/7 activation by apoptotic stimuli was also reported. Increased apoptosis 
during oestrogen deficiency may have important implications for osteoporotic 
patients,  as  it  may  compromise  the  osteocyte  network,  leading  to  impaired 
mechano-responsiveness and increased fragility.    
4)  The final study in this thesis investigated whether bone cells ability to adaptively 
respond to mechanical stimulation is impaired during oestrogen deficiency. This 
entailed  the  development  of  a  custom  parallel  plate  configuration  to  confer 
mechanical  loading  to  bone  cells  in  vitro.  Under  applied  shear  stress, 
significantly less mineralisation was observed when oestrogen was withdrawn 
from cells, compared to continued oestrogen exposure. Furthermore, this study 
showed  that  the  mechano-responsiveness  of  osteoblasts,  in  terms  of  PGE2 
production, is impaired during oestrogen deficiency. This finding may explain 
the  observed  reduction  in  mineral  production  since  PGE2  is  an  important 
regulator  of  bone  formation.  Together,  these  studies  have  shown  altered 
osteoblast  activity  during  oestrogen  deficiency,  which  may  contribute  to  the 
lower  mineralization  seen  in  the  in  vivo  sheep  study,  and  increase  our 
understanding of the etiology of osteoporosis.    
7.2.  Future Work 
Based on the findings of this thesis the following recommendations are made for future 
research;         
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7.2.1  SEM and CT Scanning of Trabecular Bone Tissue at Early Time Points 
Following Oestrogen Withdrawal 
It was interesting to find that although increased heterogeneity of bone tissue occurred 
12 months post-ovariectomy, no change in mean tissue mineral concentration was found. 
In  contrast,  after  31  months  of  oestrogen  deficiency,  significantly  lower  mean 
mineralisation  was  found.  This  highlights  that  duration  of  oestrogen  deficiency  has 
important  consequences  for  bone  fragility.  A  study  that  would  investigate  this 
observation  further  is  advised.  An  SEM  study,  which  could  track  the  material  level 
mineral changes, paralleled with an investigation into the structural changes in trabecular 
bone tissue using CT scanning, at earlier time points following oestrogen withdrawal is 
advised. This could help to delineate whether altered tissue composition leads to bone 
tissue depletion, or whether altered mineralisation is a compensatory mechanism for the 
compromised trabecular architecture, which is characteristic of osteoporosis.    
7.2.2  Mechanoreceptor Expression during Oestrogen Deficiency: Primary Cilia  
It has been shown that oestrogen withdrawal altered mineralisation in vivo and impaired 
cell responses  to  mechanical  loading; however,  the mechanisms  by which  oestrogen 
deficiency imposes these changes are unknown. Several means of bone cell mechano-
sensing have been explored in previous studies, and as discussed in section 2.4.1.1 and 
2.4.3.1, it is believed that cytoskeleton/integrin/cell processes interactions, in addition to 
the functions of the glcocalyx, are responsible (Pavalko et al.,1998; Reilly et al., 2003; 
Toma et al., 1998;). In addition, it has long been recognised that primary cilia act as 
sensory organelle in kidney cells and sense fluid flow (Liu et al., 2005; Praetorius and 
Spring, 2001), however, it was only recently demonstrated that mechano-responsiveness 
of both osteoblast and osteocyte cells, in terms of PGE2 production, osteopontin mRNA 
levels, and cyclooxygenase 2 (COX2) gene expression, is dependent on the presence of 
primary cilia (Malone et al., 2007). A further study identified a molecular mechanism 
responsible for primary cilium-dependent mechano-sensing involving adenylyl cyclase 6 
(AC6)  and  cAMP  (Kwon  et  al.,  2010).  However,  the  functions  and  physiology  of 
primary cilia in bone diseases have not yet been investigated. There is evidence that 
endometrial cells alter the quantity and length of microvilli and primary cilia according 
to oestrogen concentration or availability (Anderson et al., 1975; Craig and Jollie, 1984; 
Rambo and Szego, 1983). Therefore, oestrogen deficiency might also alter microvilli 
and  primary  cilia  on  bone  cells  and  since  primary  cilia  are  required  for  mechano-
sensation, their down-regulation during oestrogen deficiency might be responsible for          
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the impaired mechano-responsiveness in terms of PGE2 releases and mineral formation 
that was found in Chapter 6. In this way, during osteoporosis bone’s ability to adaptively 
respond  to  biophysical  loads  may  be  impaired,  in  a  manner  similar  to  unloading  or 
disuse.  It  is  therefore  recommended  that  a  thorough  investigation  of  the  effects  of 
oestrogen  deficiency  on  primary  cilia  expression  in  bone  cells  be  performed  and 
compared to the alterations in biochemical responses, as a result of oestrogen deficiency.  
7.2.3  Co-culture of Bone Cells with Loading and Oestrogen Deficiency 
Although important findings of oestrogen deficiency on the apoptosis of osteocytes and 
the bone formation capabilities of osteoblasts in vitro have been demonstrated, bone 
physiology  in  vivo  involves  the  interaction  of  various  cell  types.  Yet  few  studies 
investigate mechanisms of bone loss using a co-culture system, most opt for monolayer 
cultures  of  one  cell  type.  Functional  gap  junctions  between  neighbouring  osteocytes 
were discovered, in addition to gap junctions between osteoblasts and osteocyte cells 
(Yellowley  et  al.,  2000).  Furthermore,  the  ability  of  osteocytes  to  communicate  a 
mechanically  induced  calcium  response  to  osteoblasts  was  demonstrated.  Therefore, 
although the effects of oestrogen deficiency on osteoblast cells under static conditions 
and  with  applied  loading  in  vitro  have  been  determined,  the  vital  interplay  of 
biochemical signalling between cell types is lost in this environment. Therefore, it is 
recommended  to  co-culture  oestrogen  deficient  osteocyte  and  osteoblast  cells  with 
applied  mechanical  loading  in  order  to  further  understand  the  underlying  cellular 
mechanisms of altered tissue mineral distribution during oestrogen deficiency, presented 
in Chapters 3 and 4. 
7.3.  Conclusion  
In conclusion, this thesis has presented experimental work carried out throughout the 
course of the author’s PhD studies in the field of tissue mineralisation and cell mechano-
biology during oestrogen deficiency. A comprehensive literature review of the current 
state of research in this area was firstly presented, together with the rationale for the 
studies performed. The findings of each study and their implications were discussed in 
detail in each chapter.  
These  studies  sought  to  determine  whether  bone  tissue  mineral  was  altered  as  a 
consequence of oestrogen deficiency and found firstly that changes in tissue mineral 
heterogeneity  were  site  specific.  This  coincided  with  important  osteoporotic  fracture 
lines, indicating that altered mineral distribution may contribute to increased fracture          
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risk during osteoporosis. Secondly, it was found that mineral concentration is higher in 
more aged healthy sheep than in younger healthy sheep, but conversely is reduced with 
prolonged  oestrogen  deficiency  which  may  lead  to  diminished  strength  and  fracture 
resistance.  Zoledronic  acid  treatment  of  ovariectomised  animals  significantly 
homogenized  bone  tissue,  both  within  individual  trabeculae  and  between  proximal 
femora  sites,  suggesting  that  altered  mineral  distribution  during  bisphosphonate 
treatment may contribute to reduced risk of fracture associated with its administration.  
In order to understand the tissue level alterations in mineralisation found in Chapters 3 
and 4 of this thesis, cell culture experiments were carried out and presented in Chapters 
5 and 6, in which oestrogen was withdrawn from osteoblast and osteocytes and bone 
formation,  proliferation,  apoptosis,  and  mechano-sensitive  was  assessed.  In  static 
cultures,  oestrogen withdrawal  from  cells  causes  an elevation in  mineral  production, 
however  under  applied  loading  conditions,  oestrogen  withdrawal  reduced  mineral 
production, most likely due to the reduced mechano-responsiveness of bone cells found 
in Chapter 6 of this thesis. Together, these studies have contributed significantly to a 
greater understanding of the etiology of osteoporosis, and have proposed many further 
questions, therefore paving the way for future studies aimed at delineating the cellular 
mechanisms responsible for osteoporosis.           
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8.  Appendices 
 
8.1.  Appendix  1:  Design  Drawings  of  Parallel  Plate  Chamber         
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8.2.  Appendix 2: Estradiol and Progesterone Levels in Sheep 
 
The average, minimum and maximum estradiol and progesterone levels measured in the 
serum of control and ovariectomized animals from the 12 month group are presented in 
Table 8.1. Figures 8.1 and 8.2 show typical estradiol and progesterone cycles for one 
control and one ovariectomised sheep. These measurements were not gathered in the 
course of this PhD and are from the PhD thesis of Dr. Orlaith Brennan, Department of 
Anatomy, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland, who was 
directly  involved  in  the  attainment  of  this  data.  They  are  included  in  this  thesis  as 
requested, to demonstrate the success of the ovariectomy procedure in reducing the level 
of circulating hormones in these sheep. 
 
Table 8.1 Mean, min and max estradiol and progesterone levels in 12 month control and 
OVX animals. 
12 Month 
Post-
OVX 
Estradiol (pg/ml)  Progesterone (mg/ml) 
Mean  Min  Max  Mean  Min  Max 
Control  0.848  0.588  1.351  3.781  1.183  11.429 
OVX  0.351  0.0314  0.760  0.596  0.159  1.114          
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 Figure 8.1: Average estradiol cycles in a 12 month control and ovariectomised animal. 
 
 
Figure  8.2:  Average  progesterone  cycles  in  a  12  month  control  and  ovariectomised 
animal.
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8.3.  Appendix 3: Standard Curves  
 
Figure 8.3 Standard curve of serial dilution of known quantities of DNA content (calf 
thymus) measured on a microplate reader at exitaton 360nm and emission 460nm. 
 
Figure 8.4 Standard curve of known values of pNP per well measured on a microplate 
reader at an absorbance of 405nm. ALP activity (U/ml) is determined as; A/V/T, where 
A is amount of pNP generated by samples (in µmol), V is volume of sample added in the 
assay well (in ml) and T is reaction time (in minutes). 
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Figure 8.5 Alizarin red standard curve created by serial dilutions of a known quantity of 
alizarin red, which were measured on a microplate reader at 550nm. Moles of alizarin 
red were subsequently converted to moles of calcium; one moles of alizarin red binds to 
two moles of calcium (Norgaard et al., 2006). Mineral production was then normalized 
to DNA content and expressed as n moles Ca/pg DNA. 
 
 
Figure 8.6 Relationship between shear stress and flow rate within the parallel plate flow 
system configuration. Flow rate was measured using a Ts410 transit time tubing flow 
meter and flow probe (Transonic Systems). Shear stress was calculated using equation 
6.2. 
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